0001628280-24-046824.txt : 20241112 0001628280-24-046824.hdr.sgml : 20241112 20241112065523 ACCESSION NUMBER: 0001628280-24-046824 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 79 CONFORMED PERIOD OF REPORT: 20240930 FILED AS OF DATE: 20241112 DATE AS OF CHANGE: 20241112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Zai Lab Ltd CENTRAL INDEX KEY: 0001704292 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38205 FILM NUMBER: 241443138 BUSINESS ADDRESS: STREET 1: 4560 JINKE ROAD STREET 2: BLDG. 1, 4F, PUDONG CITY: SHANGHAI STATE: F4 ZIP: 201210 BUSINESS PHONE: 862161632588 MAIL ADDRESS: STREET 1: 4560 JINKE ROAD STREET 2: BLDG. 1, 4F, PUDONG CITY: SHANGHAI STATE: F4 ZIP: 201210 10-Q 1 zlab-20240930.htm 10-Q zlab-20240930
0001704292--12-312024Q3False0P3Yxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureiso4217:CNY00017042922024-01-012024-09-300001704292dei:AdrMember2024-01-012024-09-300001704292us-gaap:CommonStockMember2024-01-012024-09-300001704292us-gaap:CommonStockMember2024-11-060001704292dei:AdrMember2024-11-0600017042922024-09-3000017042922023-12-3100017042922024-07-012024-09-3000017042922023-07-012023-09-3000017042922023-01-012023-09-300001704292us-gaap:CommonStockMember2023-12-310001704292us-gaap:AdditionalPaidInCapitalMember2023-12-310001704292us-gaap:RetainedEarningsMember2023-12-310001704292us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001704292us-gaap:TreasuryStockCommonMember2023-12-310001704292us-gaap:CommonStockMember2024-01-012024-03-310001704292us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-3100017042922024-01-012024-03-310001704292us-gaap:RetainedEarningsMember2024-01-012024-03-310001704292us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001704292us-gaap:CommonStockMember2024-03-310001704292us-gaap:AdditionalPaidInCapitalMember2024-03-310001704292us-gaap:RetainedEarningsMember2024-03-310001704292us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001704292us-gaap:TreasuryStockCommonMember2024-03-3100017042922024-03-310001704292us-gaap:CommonStockMember2024-04-012024-06-300001704292us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-3000017042922024-04-012024-06-300001704292us-gaap:RetainedEarningsMember2024-04-012024-06-300001704292us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001704292us-gaap:CommonStockMember2024-06-300001704292us-gaap:AdditionalPaidInCapitalMember2024-06-300001704292us-gaap:RetainedEarningsMember2024-06-300001704292us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001704292us-gaap:TreasuryStockCommonMember2024-06-3000017042922024-06-300001704292us-gaap:CommonStockMember2024-07-012024-09-300001704292us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001704292us-gaap:RetainedEarningsMember2024-07-012024-09-300001704292us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001704292us-gaap:CommonStockMember2024-09-300001704292us-gaap:AdditionalPaidInCapitalMember2024-09-300001704292us-gaap:RetainedEarningsMember2024-09-300001704292us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001704292us-gaap:TreasuryStockCommonMember2024-09-300001704292us-gaap:CommonStockMember2022-12-310001704292us-gaap:AdditionalPaidInCapitalMember2022-12-310001704292us-gaap:RetainedEarningsMember2022-12-310001704292us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001704292us-gaap:TreasuryStockCommonMember2022-12-3100017042922022-12-310001704292us-gaap:CommonStockMember2023-01-012023-03-310001704292us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-3100017042922023-01-012023-03-310001704292us-gaap:TreasuryStockCommonMember2023-01-012023-03-310001704292us-gaap:RetainedEarningsMember2023-01-012023-03-310001704292us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001704292us-gaap:CommonStockMember2023-03-310001704292us-gaap:AdditionalPaidInCapitalMember2023-03-310001704292us-gaap:RetainedEarningsMember2023-03-310001704292us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001704292us-gaap:TreasuryStockCommonMember2023-03-3100017042922023-03-310001704292us-gaap:CommonStockMember2023-04-012023-06-300001704292us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-3000017042922023-04-012023-06-300001704292us-gaap:TreasuryStockCommonMember2023-04-012023-06-300001704292us-gaap:RetainedEarningsMember2023-04-012023-06-300001704292us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001704292us-gaap:CommonStockMember2023-06-300001704292us-gaap:AdditionalPaidInCapitalMember2023-06-300001704292us-gaap:RetainedEarningsMember2023-06-300001704292us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001704292us-gaap:TreasuryStockCommonMember2023-06-3000017042922023-06-300001704292us-gaap:CommonStockMember2023-07-012023-09-300001704292us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001704292us-gaap:TreasuryStockCommonMember2023-07-012023-09-300001704292us-gaap:RetainedEarningsMember2023-07-012023-09-300001704292us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001704292us-gaap:CommonStockMember2023-09-300001704292us-gaap:AdditionalPaidInCapitalMember2023-09-300001704292us-gaap:RetainedEarningsMember2023-09-300001704292us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001704292us-gaap:TreasuryStockCommonMember2023-09-3000017042922023-09-300001704292us-gaap:FairValueInputsLevel1Member2024-09-300001704292us-gaap:FairValueInputsLevel1Member2023-12-310001704292currency:USD2024-09-300001704292currency:USD2023-12-310001704292currency:CNY2024-09-300001704292currency:CNY2023-12-310001704292currency:HKD2024-09-300001704292currency:HKD2023-12-310001704292currency:AUD2024-09-300001704292currency:AUD2023-12-310001704292currency:TWD2024-09-300001704292currency:TWD2023-12-310001704292us-gaap:OfficeEquipmentMember2024-09-300001704292us-gaap:OfficeEquipmentMember2023-12-310001704292zlab:ElectronicEquipmentMember2024-09-300001704292zlab:ElectronicEquipmentMember2023-12-310001704292us-gaap:VehiclesMember2024-09-300001704292us-gaap:VehiclesMember2023-12-310001704292zlab:LaboratoryEquipmentMember2024-09-300001704292zlab:LaboratoryEquipmentMember2023-12-310001704292zlab:ManufacturingEquipmentMember2024-09-300001704292zlab:ManufacturingEquipmentMember2023-12-310001704292us-gaap:LeaseholdImprovementsMember2024-09-300001704292us-gaap:LeaseholdImprovementsMember2023-12-310001704292us-gaap:ConstructionInProgressMember2024-09-300001704292us-gaap:ConstructionInProgressMember2023-12-310001704292zlab:CommercialProductsIntangibleAssetMember2024-09-300001704292zlab:CommercialProductsIntangibleAssetMember2023-12-310001704292us-gaap:ComputerSoftwareIntangibleAssetMember2024-09-300001704292us-gaap:ComputerSoftwareIntangibleAssetMember2023-12-310001704292zlab:RegulatoryMilestoneFeesMember2024-09-300001704292zlab:CommercialDevelopmentCostMember2024-09-300001704292us-gaap:ComputerSoftwareIntangibleAssetMembersrt:MinimumMember2024-09-300001704292us-gaap:ComputerSoftwareIntangibleAssetMembersrt:MaximumMember2024-09-300001704292zlab:ZejulaMember2024-07-012024-09-300001704292zlab:ZejulaMember2023-07-012023-09-300001704292zlab:ZejulaMember2024-01-012024-09-300001704292zlab:ZejulaMember2023-01-012023-09-300001704292zlab:OptuneMember2024-07-012024-09-300001704292zlab:OptuneMember2023-07-012023-09-300001704292zlab:OptuneMember2024-01-012024-09-300001704292zlab:OptuneMember2023-01-012023-09-300001704292zlab:QinlockMember2024-07-012024-09-300001704292zlab:QinlockMember2023-07-012023-09-300001704292zlab:QinlockMember2024-01-012024-09-300001704292zlab:QinlockMember2023-01-012023-09-300001704292zlab:NuzyraMember2024-07-012024-09-300001704292zlab:NuzyraMember2023-07-012023-09-300001704292zlab:NuzyraMember2024-01-012024-09-300001704292zlab:NuzyraMember2023-01-012023-09-300001704292zlab:VyvgartMember2024-07-012024-09-300001704292zlab:VyvgartMember2023-07-012023-09-300001704292zlab:VyvgartMember2024-01-012024-09-300001704292zlab:VyvgartMember2023-01-012023-09-300001704292us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001704292us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001704292us-gaap:RestrictedStockMember2024-01-012024-09-300001704292us-gaap:RestrictedStockMember2023-01-012023-09-300001704292zlab:BankOfChinaWorkingCapitalLoanFacilityMemberus-gaap:LoansPayableMember2024-09-300001704292zlab:SPDBankWorkingCapitalLoanFacilityMemberus-gaap:LoansPayableMember2024-09-300001704292zlab:ChinaMerchantBankWorkingCapitalLoanFacilityMemberus-gaap:LoansPayableMember2024-09-300001704292zlab:BankOfChinaWorkingCapitalLoanFacilityMemberus-gaap:StandbyLettersOfCreditMember2024-02-050001704292zlab:BankOfChinaWorkingCapitalLoanFacilityMemberus-gaap:StandbyLettersOfCreditMember2024-02-052024-02-050001704292zlab:BankOfChinaWorkingCapitalLoanFacilityMember2024-03-310001704292zlab:BankOfChinaWorkingCapitalLoanFacilityMemberus-gaap:StandbyLettersOfCreditMember2024-02-060001704292zlab:BankOfChinaWorkingCapitalLoanFacilityMemberus-gaap:StandbyLettersOfCreditMember2024-06-200001704292zlab:BankOfChinaWorkingCapitalLoanFacilityMemberzlab:ZaiLabShanghaiCo.Ltd.Memberus-gaap:LoansPayableMember2024-09-300001704292zlab:BankOfChinaWorkingCapitalLoanFacilityMemberzlab:ZaiLabShanghaiCo.Ltd.Memberus-gaap:LoansPayableMember2024-01-012024-09-300001704292zlab:ShanghaiPudongDevelopmentBankCo.Ltd.Member2024-02-060001704292zlab:SPDBankWorkingCapitalLoanFacilityMemberzlab:ZaiLabShanghaiCo.Ltd.Memberus-gaap:LoansPayableMember2024-09-300001704292zlab:SPDBankWorkingCapitalLoanFacilityMemberzlab:ZaiLabShanghaiCo.Ltd.Memberus-gaap:LoansPayableMember2024-01-012024-09-300001704292zlab:NingboBankWorkingCapitalLoanFacilityMemberzlab:ZaiLabSuzhouCompanyLimitedMemberus-gaap:LoansPayableMember2024-02-060001704292zlab:NingboBankWorkingCapitalLoanFacilityMemberus-gaap:LoansPayableMember2024-02-060001704292zlab:ChinaMerchantsBankCo.Ltd.Member2024-07-050001704292zlab:ChinaMerchantBankWorkingCapitalLoanFacilityMemberzlab:ZaiLabShanghaiCo.Ltd.Memberus-gaap:LoansPayableMember2024-07-050001704292zlab:ChinaMerchantBankWorkingCapitalLoanFacilityMemberzlab:ZaiLabShanghaiCo.Ltd.Memberus-gaap:LoansPayableMember2024-07-052024-07-050001704292zlab:ChinaMerchantBankWorkingCapitalLoanFacilityMemberzlab:ZaiLabShanghaiCo.Ltd.Memberus-gaap:LoansPayableMember2024-09-300001704292zlab:ChinaMerchantBankWorkingCapitalLoanFacilityMemberzlab:ZaiLabShanghaiCo.Ltd.Memberus-gaap:LoansPayableMember2024-01-012024-09-300001704292us-gaap:RestrictedStockMember2024-01-012024-09-300001704292us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001704292us-gaap:EmployeeStockOptionMemberzlab:April2023AndLaterMember2024-01-012024-09-300001704292us-gaap:EmployeeStockOptionMemberzlab:PriorToApril2023Member2024-01-012024-09-300001704292us-gaap:EmployeeStockOptionMemberzlab:ShareBasedPaymentArrangementTrancheFourMemberzlab:April2023AndLaterMember2024-01-012024-09-300001704292us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMemberzlab:April2023AndLaterMember2024-01-012024-09-300001704292us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMemberzlab:April2023AndLaterMember2024-01-012024-09-300001704292us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheOneMemberzlab:April2023AndLaterMember2024-01-012024-09-300001704292us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheOneMemberzlab:PriorToApril2023Member2024-01-012024-09-300001704292us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMemberzlab:PriorToApril2023Member2024-01-012024-09-300001704292us-gaap:EmployeeStockOptionMemberzlab:ShareBasedPaymentArrangementTrancheFiveMemberzlab:PriorToApril2023Member2024-01-012024-09-300001704292us-gaap:EmployeeStockOptionMemberzlab:ShareBasedPaymentArrangementTrancheFourMemberzlab:PriorToApril2023Member2024-01-012024-09-300001704292us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMemberzlab:PriorToApril2023Member2024-01-012024-09-300001704292us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-07-012024-09-300001704292us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300001704292us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-09-300001704292us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300001704292us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001704292us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001704292us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001704292us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001704292us-gaap:RestrictedStockMember2024-09-300001704292zlab:InnovivaInc.Memberzlab:SULDURMember2024-04-012024-06-300001704292zlab:InnovivaInc.Memberzlab:SULDURMember2024-09-300001704292zlab:BMSMemberzlab:RepotrectinibMember2024-04-012024-06-300001704292zlab:BMSMemberzlab:RepotrectinibMember2024-09-300001704292zlab:BMSMemberzlab:XanomelineTrospiumChlorideMember2024-07-012024-09-300001704292zlab:BMSMemberzlab:XanomelineTrospiumChlorideMember2024-09-300001704292zlab:OtherCounterpartiesMember2024-07-012024-09-300001704292country:CN2024-01-012024-09-300001704292country:CN2024-07-012024-09-300001704292country:CN2023-07-012023-09-300001704292country:CN2023-01-012023-09-300001704292country:CN2023-12-310001704292country:CN2024-09-300001704292zlab:PropertyAndEquipmentAndCommercialManufacturingDevelopmentActivitiesMember2024-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
____________________
FORM 10-Q
____________________
(Mark One)
xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2024
OR
oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______ to ______
Commission File Number: 001-38205
____________________
Zai Lab logo.jpg
ZAI LAB LIMITED
(Exact Name of Registrant as Specified in its Charter)
____________________
Cayman Islands98-1144595
(State or Other Jurisdiction of
Incorporation or Organization)		(I.R.S. Employer
Identification No.)
4560 Jinke Road
Bldg. 1, Fourth Floor, Pudong
Shanghai
China
201210
314 Main Street
4th Floor, Suite 100
Cambridge, MA, USA		02142
(Address of Principal Executive Offices)(Zip Code)
+86 216163 2588
+1 857 706 2604
(Registrant’s Telephone Number, Including Area Code)
____________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
American Depositary Shares, each representing 10 Ordinary Shares, par value $0.000006 per shareZLABThe Nasdaq Global Market
Ordinary Shares, par value $0.000006 per share*
9688The Stock Exchange of Hong Kong Limited
*Included in connection with the registration of the American Depositary Shares with the Securities and Exchange Commission. The ordinary shares are not registered or listed for trading in the United States but are listed for trading on The Stock Exchange of Hong Kong Limited.
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
x
Accelerated filer
o
Non-accelerated filer
o
Smaller reporting company
o
Emerging growth company
o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of November 6, 2024, 996,087,670 ordinary shares of the registrant, par value $0.000006 per share, were outstanding, of which 762,979,490 ordinary shares were held in the form of American Depositary Shares.

Zai Lab Limited
Quarterly Report on Form 10-Q
For the Third Quarter of 2024

Page


SPECIAL NOTES REGARDING THE COMPANY
Forward-Looking Statements
This report contains certain forward-looking statements, including statements relating to our strategy and plans; potential of and expectations for our business, commercial products, and pipeline programs; the market for our commercial and pipeline products; capital allocation and investment strategy; clinical development programs and related clinical trials; clinical trial data, data readouts, and presentations; risks and uncertainties associated with drug development and commercialization; regulatory discussions, submissions, filings, and approvals and the timing thereof; the potential benefits, safety, and efficacy of our products and product candidates and those of our collaboration partners; the anticipated benefits and potential of investments, collaborations, and business development activities; our profitability and timeline to profitability; and our future financial and operating results. All statements, other than statements of historical fact, included in this report are forward-looking statements, and can be identified by words such as “aim,” “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” or the negative of these terms or similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this report and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. We may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in our forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to the following:
•    Our ability to successfully commercialize and generate revenue from our approved products;
•    Our ability to obtain funding for our operations and business initiatives;
•    The results of our clinical and pre-clinical development of our product candidates;
•    The content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates;
•    Changes in U.S. and China trade policies and relations, as well as relations with other countries, and/or changes in regulations and/or sanctions;
•    Actions the Chinese government may take to intervene in or influence our operations;
•    Economic, political, and social conditions in mainland China, as well as governmental policies;
•    Uncertainties in the Chinese legal system, including with respect to the anti-corruption enforcement efforts in China and the Counter-Espionage Law, the Data Security Law, the Cyber Security Law, the Cybersecurity Review Measures, the Personal Information Protection Law, the Regulation on the Administration of Human Genetic Resources, the Biosecurity Law, the Measures on Security Assessment of Cross-Border Data Transfer (the “Security Assessment Measures”), and other future laws and regulations or amendments to such laws and regulations;
•    Approval, filing, or procedural requirements imposed by the China Securities Regulatory Commission or other Chinese regulatory authorities in connection with issuing securities to foreign investors under Chinese law;
•    Any violation or liability under the U.S. Foreign Corrupt Practices Act (“FCPA”) or Chinese anti-corruption laws;
•    Restrictions on currency exchange;
•    Limitations on the ability of our Chinese subsidiaries to make payments to us;
•    Chinese requirements on the ability of residents in mainland China to establish offshore special purpose companies;
•    Chinese regulations regarding acquisitions of companies based in mainland China by foreign investors;
•    Any issues that our Chinese manufacturing facilities may have with operating in conformity with established Good Manufacturing Practices (“GMPs”) and international best practices, and with passing U.S. Food and Drug Administration (“FDA”), China National Medical Products Administration (“NMPA”), and European Medicines Agency (“EMA”) inspections;


•    Expiration of, or changes to, financial incentives or discretionary policies granted by local governments in mainland China;
•    Restrictions or limitations on the ability of overseas regulators to conduct investigations or collect evidence within mainland China;
•    Business disruptions caused by pandemics such as COVID-19, international war or conflict such as the Russia/Ukraine and Israel/Hamas wars, natural disasters, extreme weather events, and other significant disruptions outside of our control;
•    Unfavorable tax consequences to us and our non-Chinese shareholders or American Depositary Share (“ADS”) holders if we were to be classified as a Chinese resident enterprise for Chinese income tax purposes;
•    Failure to comply with applicable Chinese, U.S., and Hong Kong regulations that could lead to government enforcement actions, fines, other legal or administrative sanctions, and/or harm to our business or reputation;
•    Review by the U.S. Committee on Foreign Investment (“CFIUS”) in our investments or other delays or obstacles for closing transactions;
•    Any inability to renew our current leases on desirable terms or otherwise locate desirable alternatives for our leased properties;
•    Any inability of third parties on whom we rely to conduct our pre-clinical and clinical trials to successfully carry out their contractual duties or meet expected deadlines; and
•    Any inability to obtain or maintain sufficient patent protection for our products and product candidates.
These factors should not be construed as exhaustive and should be read with the other cautionary statements and information in our Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Annual Report”), our Quarterly Reports on Form 10-Q, and our other filings with the U.S. Securities and Exchange Commission. Forward-looking statements are based on our management’s beliefs and assumptions and information currently available to our management. These statements, like all statements in this report, speak only as of their date. We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this report.
Usage of Terms
Unless the context requires otherwise, references in this report to “Greater China” refer to mainland China, Hong Kong Special Administrative Region (“Hong Kong” or “HK”), Macau Special Administrative Region (“Macau”), and Taiwan, collectively; references to “Zai Lab,” the “Company,” “we,” “us,” and “our” refer to Zai Lab Limited, a holding company, and its subsidiaries, on a consolidated basis; and references to “Zai Lab Limited” refer to Zai Lab Limited, a holding company. Zai Lab Limited is the entity in which investors hold their interest.
Our operating subsidiaries consist of Zai Lab (Hong Kong) Limited, domiciled in Hong Kong; Zai Auto Immune (Hong Kong) Limited, domiciled in Hong Kong; Zai Anti Infectives (Hong Kong) Limited, domiciled in Hong Kong; Zai Lab (Shanghai) Co., Ltd., domiciled in mainland China; Zai Lab International Trading (Shanghai) Co., Ltd., domiciled in mainland China; Zai Lab (Suzhou) Co., Ltd., domiciled in mainland China; Zai Biopharmaceutical (Suzhou) Co., Ltd., domiciled in mainland China; Zai Lab Trading (Suzhou) Co., Ltd., domiciled in mainland China; Zai Lab (Taiwan) Limited, domiciled in Taiwan; Zai Lab (AUST) Pty. Ltd., domiciled in Australia; and Zai Lab (US) LLC, domiciled in the United States. As of the date of this report, Zai Anti Infectives (Hong Kong) Limited has non-substantial business operations.
We own various trademarks, including various forms of the Zai Lab brand (in English and Chinese), as well as several domain names that incorporate such trademarks. Trademarks and trade names of other companies appearing in this report are the property of their respective holders. Solely for convenience, some of the trademarks and trade names in this report are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies’ trademarks and trade names to imply a relationship with, or endorsement or sponsorship of, any other company.


PART I – FINANCIAL INFORMATION
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the unaudited condensed consolidated financial statements and the accompanying notes included in this report and the audited consolidated financial information and the accompanying notes included in our 2023 Annual Report.
1

Item 1. Financial Statements.
Zai Lab Limited
Unaudited Condensed Consolidated Balance Sheets
(in thousands of U.S. dollars (“$”), except for number of shares and per share data)
NotesSeptember 30,
2024		December 31,
2023
Assets
Current assets
Cash and cash equivalents3616,086 790,151 
Restricted cash, current100,000 — 
Short-term investments— 16,300 
Accounts receivable (net of allowance for credit losses of $14 and $17 as of September 30, 2024 and December 31, 2023, respectively)
49,970 59,199 
Notes receivable19,278 6,134 
Inventories, net439,548 44,827 
Prepayments and other current assets35,667 22,995 
Total current assets860,549 939,606 
Restricted cash, non-current1,118 1,113 
Long term investments 3,153 9,220 
Prepayments for equipment32 111 
Property and equipment, net550,765 53,734 
Operating lease right-of-use assets12,833 14,844 
Land use rights, net3,012 3,069 
Intangible assets, net651,669 13,389 
Long-term deposits975 1,209 
Value added tax recoverable1,240 — 
Total assets985,346 1,036,295 
Liabilities and shareholders’ equity  
Current liabilities  
Accounts payable120,652 112,991 
Current operating lease liabilities6,585 7,104 
Short-term debt10112,994 — 
Other current liabilities1146,084 82,972 
Total current liabilities286,315 203,067 
Deferred income24,924 28,738 
Non-current operating lease liabilities6,113 8,047 
Other non-current liabilities325 325 
Total liabilities317,677 240,177 
Commitments and contingencies (Note 16)  
Shareholders’ equity  
Ordinary shares (par value of $0.000006 per share; 5,000,000,000 shares authorized; 989,268,370 and 977,151,270 shares issued as of September 30, 2024 and December 31, 2023, respectively; 984,356,170 and 972,239,070 shares outstanding as of September 30, 2024 and December 31, 2023, respectively)
6 6 
Additional paid-in capital3,031,628 2,975,302 
Accumulated deficit(2,371,399)(2,195,980)
Accumulated other comprehensive income28,270 37,626 
Treasury Stock (at cost, 4,912,200 shares as of both September 30, 2024 and December 31, 2023)
(20,836)(20,836)
Total shareholders’ equity667,669 796,118 
Total liabilities and shareholders’ equity985,346 1,036,295 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
2

Zai Lab Limited
Unaudited Condensed Consolidated Statements of Operations
(in thousands of $, except for number of shares and per share data)
Three Months Ended September 30,Nine Months Ended September 30,
Notes2024202320242023
Revenues
Product revenue, net7101,847 69,228 289,102 200,889 
Collaboration revenue7418 — 816 — 
Total revenues102,265 69,228 289,918 200,889 
Expenses
Cost of product revenue(36,569)(25,479)(105,336)(70,579)
Cost of collaboration revenue(348)— (433)— 
Research and development(65,982)(58,767)(182,252)(183,920)
Selling, general, and administrative(67,219)(68,552)(216,123)(198,982)
Gain on sale of intellectual property— — — 10,000 
Loss from operations(67,853)(83,570)(214,226)(242,592)
Interest income9,029 9,172 28,017 29,493 
Interest expense(745)— (1,350)— 
Foreign currency gains (losses)14,457 4,852 8,281 (26,315)
Other income, net143,441 394 3,859 223 
Loss before income tax (41,671)(69,152)(175,419)(239,191)
Income tax expense8— — — — 
Net loss(41,671)(69,152)(175,419)(239,191)
Loss per share - basic and diluted9(0.04)(0.07)(0.18)(0.25)
Weighted-average shares used in calculating net loss per ordinary share - basic and diluted 981,687,390 968,767,730 976,941,030 965,060,570 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
3

Zai Lab Limited
Unaudited Condensed Consolidated Statements of Comprehensive Loss
(in thousands of $)

Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Net loss(41,671)(69,152)(175,419)(239,191)
Other comprehensive income, net of tax of nil:
Foreign currency translation adjustments(14,503)(4,228)(9,356)22,267 
Comprehensive loss(56,174)(73,380)(184,775)(216,924)
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
4

Zai Lab Limited
Unaudited Condensed Consolidated Statements of Shareholders’ Equity
(in thousands of $, except for number of shares)

Ordinary SharesAdditional
paid
in capital		Accumulated
deficit
Accumulated
other
comprehensive
income
Treasury StockTotal
Number
of
Shares		AmountSharesAmount
Balance at December 31, 2023977,151,270 6 2,975,302 (2,195,980)37,626 (4,912,200)(20,836)796,118 
Issuance of ordinary shares upon vesting of restricted shares1,046,440 00— — — — — 
Share-based compensation— — 17,980 — — — — 17,980 
Net loss— — — (53,471)— — — (53,471)
Foreign currency translation— — — — 1,542 — — 1,542 
Balance at March 31, 2024978,197,710 6 2,993,282 (2,249,451)39,168 (4,912,200)(20,836)762,169 
Issuance of ordinary shares upon vesting of restricted shares8,087,630 00— — — — — 
Exercise of share options25,000 044 — — — — 44 
Share-based compensation— — 18,638 — — — — 18,638 
Net loss— — — (80,277)— — — (80,277)
Foreign currency translation— — — — 3,605 — — 3,605 
Balance at June 30, 2024986,310,340 6 3,011,964 (2,329,728)42,773 (4,912,200)(20,836)704,179 
Issuance of ordinary shares upon vesting of restricted shares393,850 0 0 — — — — — 
Exercise of share options2,564,180 0 2,869 — — — — 2,869 
Share-based compensation— — 16,795 — — — — 16,795 
Net loss— — — (41,671)— — — (41,671)
Foreign currency translation— — — — (14,503)— — (14,503)
Balance at September 30, 2024989,268,370 6 3,031,628 (2,371,399)28,270 (4,912,200)(20,836)667,669 


5

Ordinary SharesAdditional
paid
in capital		Accumulated
deficit		Accumulated
other
comprehensive
income (loss)		Treasury StockTotal
Number
of
Shares		AmountSharesAmount
Balance at December 31, 2022962,455,850 6 2,893,120 (1,861,360)25,685 (2,236,280)(11,856)1,045,595 
Issuance of ordinary shares upon vesting of restricted shares732,040 00— — — — — 
Exercise of share options4,009,460 01,673 — — — — 1,673 
Receipt of shares netted to satisfy tax withholding obligations related to share-based compensation— — — — — (1,272,330)(5,130)(5,130)
Share-based compensation— — 16,661 — — — — 16,661 
Net loss— — — (49,144)— — — (49,144)
Foreign currency translation— — — — (8,413)— — (8,413)
Balance at March 31, 2023967,197,350 6 2,911,454 (1,910,504)17,272 (3,508,610)(16,986)1,001,242 
Issuance of ordinary shares upon vesting of restricted shares6,117,040 00— — — — — 
Exercise of share options41,000 088 — — — — 88 
Receipt of shares netted to satisfy tax withholding obligations related to share-based compensation— — — — — (1,280,500)(3,540)(3,540)
Share-based compensation— — 20,511 — — — — 20,511 
Net loss— — — (120,895)— — — (120,895)
Foreign currency translation— — — — 34,908 — — 34,908 
Balance at June 30, 2023973,355,390 6 2,932,053 (2,031,399)52,180 (4,789,110)(20,526)932,314 
Issuance of ordinary shares upon vesting of restricted shares394,890 0 0 — — — — — 
Exercise of share options180,000 0 317 — — — — 317 
Receipt of shares netted to satisfy tax withholding obligations related to share-based compensation— — — — — (104,020)(264)(264)
Share-based compensation— — 21,992 — — — — 21,992 
Net loss— — — (69,152)— — — (69,152)
Foreign currency translation— — — — (4,228)— — (4,228)
Balance at September 30, 2023973,930,280 6 2,954,362 (2,100,551)47,952 (4,893,130)(20,790)880,979 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. “0” in above table means less than 1,000 dollars.
6

Zai Lab Limited
Unaudited Condensed Consolidated Statements of Cash Flows
(in thousands of $)
Nine Months Ended
September 30,
20242023
Cash flows from operating activities
Net loss(175,419)(239,191)
Adjustments to reconcile net loss to net cash used in operating activities:  
Allowance for credit losses(3)1 
Inventory write-down814 746 
Depreciation and amortization expenses8,824 6,570 
Amortization of deferred income(2,518)(2,547)
Share-based compensation53,413 59,164 
Loss from fair value changes of equity investment with readily determinable fair value6,067 1,965 
Losses on disposal of property and equipment451 139 
Gain on disposal of land use right— (408)
Noncash lease expenses6,104 6,630 
Gain from sale of intellectual property— (10,000)
Debt issuance costs700 — 
Foreign currency remeasurement impact(8,281)26,315 
Changes in operating assets and liabilities:  
Accounts receivable9,712 (2,823)
Notes receivable(12,901)(15,563)
Inventories4,403 (14,408)
Prepayments and other current assets(10,767)5,126 
Long-term deposits234 140 
Value added tax recoverable(1,223)— 
Accounts payable6,545 (9,494)
Other current liabilities(36,854)227 
Operating lease liabilities(6,853)(5,794)
Deferred income(1,548)9,619 
Other non-current liabilities— 325 
Net cash used in operating activities(159,100)(183,261)
Cash flows from investing activities  
Purchases of short-term investments— (134,000)
Proceeds from maturity of short-term investment16,300 102,400 
Purchases of property and equipment(3,057)(6,990)
Proceeds from the sale of property and equipment29 122 
Acquisition of intangible assets(40,711)(658)
Proceeds from sale of intellectual property— 10,000 
Proceeds from disposal of land use right— 3,893 
Net cash used in investing activities(27,439)(25,233)
Cash flows from financing activities  
Proceeds from short-term debt111,738 — 
Repayment of short-term bank borrowings (282)— 
Payments of debt issuance costs(700)— 
Proceeds from exercises of stock options1,321 1,899 
Taxes paid related to settlement of equity awards— (8,725)
Net cash provided by (used in) financing activities112,077 (6,826)
Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash402 (3,355)
Net decrease in cash, cash equivalents and restricted cash(74,060)(218,675)
Cash, cash equivalents and restricted cash - beginning of period791,264 1,009,273 
Cash, cash equivalents and restricted cash - end of period717,204 790,598 
Supplemental disclosure on non-cash investing and financing activities  
Payables for purchase of property and equipment2,612 2,625 
Payables for acquisition of intangible assets11,358 98 
Payables for treasury stock— 31 
Right-of-use asset acquired under operating leases3,945 3,296 
Receivables for stock option exercise under equity incentive plans1,593 — 
Supplemental disclosure of cash flow information  
Cash paid for interest1,169 — 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
7

Zai Lab Limited
Notes to the unaudited condensed consolidated financial statements

1. Organization and Principal Activities
Zai Lab Limited was incorporated on March 28, 2013 in the Cayman Islands as an exempted company with limited liability under the Companies Act of the Cayman Islands (as amended). Zai Lab Limited and its subsidiaries (collectively referred to as the “Company”) are focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease.
The Company’s principal operations and geographic markets are in Greater China. The Company has a substantial presence in Greater China and the United States.
2. Basis of Presentation and Consolidation and Significant Accounting Policies
(a) Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), and applicable rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”), regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Annual Report”). The December 31, 2023 condensed consolidated balance sheet data included in this report were derived from the audited financial statements in the 2023 Annual Report.
The accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments that are necessary to present fairly the results for the interim periods presented. Interim results are not necessarily indicative of the results for the year ending December 31, 2024.
(b) Principles of Consolidation
The unaudited condensed consolidated financial statements include the accounts of Zai Lab Limited and its subsidiaries, which are wholly owned. All intercompany transactions and balances are eliminated upon consolidation.
(c) Use of Estimates
The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Areas where management uses subjective judgment include, but are not limited to, accrual of rebates, recognition of research and development expenses, fair value of share-based compensation expenses, and recoverability of deferred tax assets. These estimates, judgments, and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. Actual results could differ from these estimates.
(d) Fair Value Measurements
Equity investments with readily determinable fair value are measured using level 1 inputs and were $3.2 million and $9.2 million as of September 30, 2024 and December 31, 2023, respectively. The unrealized losses from fair value changes are recognized in other income, net in the unaudited condensed consolidated statements of operations.
Financial instruments of the Company primarily include cash and cash equivalents, current restricted cash, short-term investments, accounts receivable, notes receivable, prepayments and other current assets, non-current restricted cash,
8

Zai Lab Limited
Notes to the unaudited condensed consolidated financial statements
accounts payable, short-term debt, and other current liabilities. As of September 30, 2024 and December 31, 2023, the carrying values of cash and cash equivalents, current restricted cash, short-term investments, accounts receivable, prepayments and other current assets, accounts payable, short-term debt, and other current liabilities approximated their fair value due to the short-term maturity of these instruments, and the carrying value of notes receivable and non-current restricted cash approximated their fair value based on the assessment of the ability to recover these amounts.
(e) Recent Accounting Pronouncements
In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures (Topic 280). This ASU requires all public entities, including public entities with a single reportable segment, to disclose the title and position of the Chief Operating Decision Maker (“CODM”) and the significant segment expenses and any additional measures of a segment’s profit or loss used by the CODM to allocate resources and assess performance. This ASU is effective on a retrospective basis for fiscal years beginning after December 15, 2023 and for interim periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this ASU and expects to adopt it for the year ending December 31, 2024.
In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (Topic 740). This ASU requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as additional information on income taxes paid. This ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted. This ASU will result in additional disclosure in the consolidated financial statements, once adopted. The Company is currently evaluating the impact of this ASU and expects to adopt it for the year ending December 31, 2025.
The Company did not adopt any new accounting standards in the nine months ended September 30, 2024 that had a material impact on the consolidated financial statements. For additional information on the Company’s significant accounting policies, refer to the notes to the consolidated financial statements in the 2023 Annual Report.
3. Cash and Cash Equivalents
The following table presents the Company’s cash and cash equivalents ($ in thousands):
September 30, 2024December 31, 2023
Cash 614,937 789,051 
Cash equivalents (i)1,149 1,100 
 616,086 790,151 
Denominated in:  
US$575,116 762,436 
Renminbi (“RMB”) (ii)40,092 25,093 
Hong Kong dollar (“HK$”)53 1,974 
Australian dollar (“A$”)580 587 
Taiwan dollar (“TW$”)245 61 
616,086 790,151 
(i)Cash equivalents represent short-term and highly liquid investments in a money market fund.
(ii)Certain cash and bank balances denominated in RMB were deposited with banks in mainland China. The conversion of these RMB-denominated balances into foreign currencies is subject to the rules and regulations of foreign exchange control promulgated by the Chinese government.
9

Zai Lab Limited
Notes to the unaudited condensed consolidated financial statements
4. Inventories, Net
The following table presents the Company’s inventories, net ($ in thousands):
September 30, 2024December 31, 2023
Finished goods22,460 22,702 
Raw materials15,397 17,655 
Work in progress1,691 4,470 
Inventories, net39,548 44,827 
The Company writes down inventory for any excess or obsolete inventories or when the Company believes that the net realizable value of inventories is less than the carrying value. The Company recorded write-downs in inventory, which were included in cost of product revenue, of an insignificant amount and $0.8 million in the three and nine months ended September 30, 2024, respectively, and $0.1 million and $0.7 million in the three and nine months ended September 30, 2023, respectively.
5. Property and Equipment, Net
The following table presents the components of the Company’s property and equipment, net ($ in thousands):
September 30, 2024December 31, 2023
Office equipment1,059 1,047 
Electronic equipment9,527 9,161 
Vehicle201 199 
Laboratory equipment20,793 20,140 
Manufacturing equipment17,944 17,680 
Leasehold improvements11,544 11,371 
Construction in progress26,050 24,272 
87,118 83,870 
Less: accumulated depreciation(36,353)(30,136)
Property and equipment, net50,765 53,734 
Depreciation expense was $2.1 million and $6.6 million in the three and nine months ended September 30, 2024, respectively, and $1.8 million and $6.1 million in the three and nine months ended September 30, 2023, respectively.
6. Intangible Assets, Net
The following table presents the components of the Company’s intangible assets, net ($ in thousands):
September 30, 2024December 31, 2023
Gross Carrying AmountAccumulated AmortizationNet Carrying ValueGross Carrying AmountAccumulated AmortizationNet Carrying Value
Finite-lived intangible assets
Commercial products (i)52,050 (1,881)50,169 11,351 (186)11,165 
Software4,215 (2,715)1,500 4,340 (2,116)2,224 
Total56,265 (4,596)51,669 15,691 (2,302)13,389 
(i) The increase in the net carrying value is primarily driven by $33.0 million of regulatory milestone fees for repotrectinib and SUL-DUR (see Note 13) and $6.0 million of commercial development costs.
10

Zai Lab Limited
Notes to the unaudited condensed consolidated financial statements
Intangible assets for commercial products include capitalized post-approval milestone fees and commercial manufacturing development costs. The Company is amortizing commercial products as cost of product revenue over the estimated remaining useful life of the related products. Externally purchased software is amortized over three to five years on a straight-line basis.
Amortization expense was $0.7 million and $2.3 million in the three and nine months ended September 30, 2024, respectively, and $0.2 million and $0.5 million in the three and nine months ended September 30, 2023, respectively.
7. Revenues
Product Revenue, Net
The Company’s product revenue is derived from the sales of its commercial products primarily in mainland China. The table below presents the Company’s gross and net product revenue ($ in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Product revenue - gross107,678 74,018 307,401 220,240 
Less: Rebates and sales returns(5,831)(4,790)(18,299)(19,351)
Product revenue - net101,847 69,228 289,102 200,889 
Sales rebates are offered to distributors in mainland China, and the amounts are recorded as a reduction of product revenue. Estimated rebates are determined based on contracted rates, sales volumes, and level of distributor inventories.
The following table presents the Company’s net revenue by product ($ in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
ZEJULA48,227 41,593 138,727 127,230 
OPTUNE7,715 11,562 32,779 38,596 
QINLOCK8,643 5,702 21,774 14,535 
NUZYRA9,997 5,483 32,205 15,588 
VYVGART 27,265 4,888 63,617 4,940 
Product revenue - net101,847 69,228 289,102 200,889 
Collaboration Revenue
Collaboration revenue was $0.4 million and $0.8 million in the three and nine months ended September 30, 2024, respectively, and related to promotional activities in mainland China. We had no such collaboration revenue in the prior year periods.
8. Income Tax
No provision for income taxes has been required to be accrued because the Company is in a cumulative loss position for the periods presented.
The Company recorded a full valuation allowance against deferred tax assets of all its consolidated entities because all entities were in a cumulative loss position as of September 30, 2024 and December 31, 2023. No unrecognized tax benefits and related interest and penalties were recorded in the periods presented.
11

Zai Lab Limited
Notes to the unaudited condensed consolidated financial statements
9. Loss Per Share
The following table presents the computation of the basic and diluted net loss per share ($ in thousands, except share and per share data):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Numerator:
Net loss (41,671)(69,152)(175,419)(239,191)
Denominator:
Weighted average number of ordinary shares - basic and diluted981,687,390 968,767,730 976,941,030 965,060,570 
Net loss per share - basic and diluted(0.04)(0.07)(0.18)(0.25)
As a result of the Company’s net loss in the three and nine months ended September 30, 2024 and 2023, share options and non-vested restricted shares outstanding in the respective periods were excluded from the calculation of diluted loss per share as their inclusion would have been anti-dilutive.
September 30,
20242023
Share options105,188,950 107,249,960 
Non-vested restricted shares32,875,090 32,359,260 
10. Borrowings
The Company has debt arrangements with the Bank of China, SPD Bank, CMB, and Ningbo Bank to support its working capital needs in mainland China. The following table presents the Company’s short-term debt as of September 30, 2024 ($ in thousands):
Weighted average
interest rate per annum		September 30, 2024
Bank of China Working Capital Loans2.86 %70,925 
SPD Bank Working Capital Loans3.45 %14,271 
China Merchant Bank Working Capital Loans3.15 %27,798 
Total short-term debt3.01 %112,994 
Bank of China Working Capital Loan Facility
On February 5, 2024, the Company entered into an uncommitted facility letter with the Bank of China (Hong Kong) Limited (the “BOC HK”) pursuant to which the BOC HK will provide standby letters of credit for loans of up to $100.0 million for a term of one year. In connection with this agreement, the Company paid a one-time, non-refundable fee of $0.7 million in the first quarter of 2024. In accordance with this agreement, the Company also maintained restricted deposits of $100.0 million, which are presented as restricted cash-current on the unaudited condensed consolidated balance sheet, to secure the standby letters of credit. On February 6, 2024 and June 20, 2024, upon the Company’s application, the BOC HK provided standby letters of credit in favor of the Bank of China Pudong Development Zone Branch (the “BOC Pudong Branch”) for $50.0 million and $23.0 million, respectively, which are or may become payable by the Company’s wholly-owned subsidiary, Zai Lab (Shanghai) Co., Ltd. (“Zai Lab Shanghai”). Zai Lab Shanghai entered into working capital loans with the BOC Pudong Branch under this facility in the first half of 2024, and the aggregate principal amount outstanding was RMB497.0 million (approximately $70.9 million) as of September 30, 2024. Each working capital loan has a one-year term and is subject to a floating interest rate, which is subject to adjustment every six months.
12

Zai Lab Limited
Notes to the unaudited condensed consolidated financial statements
SPD Bank Working Capital Loan Facility
On February 6, 2024, the Company entered into a maximum-amount guarantee contract with the Shanghai Pudong Development Bank Co., Ltd. Zhangjiang Hi-Tech Park Sub-branch (the “SPD Bank”) pursuant to which the Company will guarantee working capital loans of up to RMB300.0 million (approximately $42.0 million) from SPD Bank to Zai Lab Shanghai over a three-year period. Zai Lab Shanghai entered into working capital loan contracts with SPD Bank under this debt facility in the first quarter of 2024, and the aggregate principal amount outstanding was RMB100.0 million (approximately $14.3 million) as of September 30, 2024. Each working capital loan has a one-year term and is subject to a fixed interest rate.
Ningbo Bank Working Capital Loan Facility
On February 6, 2024, the Company’s wholly-owned subsidiary, Zai Lab (Suzhou) Co., Ltd. (“Zai Lab Suzhou”), entered into a maximum credit contract with Bank of Ningbo Co., Ltd. Suzhou Sub-branch (“Ningbo Bank”) as well as an Electronic Commercial Draft Discounting Master Agreement and Online Working Capital Loan Master Agreement (collectively, the “Ningbo Bank Agreements”). The Ningbo Bank Agreements permit Zai Lab Suzhou to utilize, including through discounting or working capital loan agreements and subject to the terms and conditions in related master agreements, up to RMB230.3 million (approximately $32.4 million), of which the Company is authorized to utilize up to RMB160.0 million (approximately $22.5 million). In connection with the arrangements described in the Ningbo Bank Agreements, Zai Lab Suzhou agreed to pledge interests in certain real property it owns in Suzhou. As of September 30, 2024, Zai Lab Suzhou has not entered into any discounting arrangements or working capital loans under this Ningbo Bank working capital loan facility.
China Merchants Bank Working Capital Loan Facility
On July 5, 2024, the Company issued a maximum-amount irrevocable letter of guarantee to China Merchants Bank Co., Ltd., Shanghai Branch (“CMB”) pursuant to which the Company will guarantee working capital loans of up to RMB250.0 million (approximately $34.4 million) from CMB to the Company’s wholly-owned subsidiary, Zai Lab Shanghai, and Zai Lab Shanghai entered into a Credit Agreement with CMB with respect to the RMB250.0 million facility. The credit facility will be available for one year. As of September 30, 2024, Zai Lab Shanghai has an aggregate principal amount outstanding of RMB194.8 million (approximately $27.8 million) under this debt facility. Each working capital loan has a one-year term and is subject to a floating interest rate, which is subject to adjustment every three months.
11. Other Current Liabilities
The following table presents the Company’s other current liabilities ($ in thousands):
September 30, 2024December 31, 2023
Accrued payroll24,077 33,711 
Accrued professional service fee3,986 7,520 
Payables for purchase of property and equipment2,612 2,474 
Accrued rebate to distributors8,800 16,926 
Tax payables3,756 16,988 
Other (i)2,853 5,353 
Total46,084 82,972 
(i)Other primarily includes accrued travel and business-related expenses.
13

Zai Lab Limited
Notes to the unaudited condensed consolidated financial statements
12. Share-Based Compensation
During the nine months ended September 30, 2024, the Company granted share options to purchase up to 20,747,480 ordinary shares and restricted shares representing 17,293,410 ordinary shares under its equity incentive plans. The share options granted have a contractual term of ten years. Share options granted since April 2023 generally vest ratably over a four-year period, and share options granted prior to April 2023 generally vest ratably over a five-year period, with 25% or 20% of the awards vesting on each anniversary of the grant date, respectively, subject to continued employment/service with the Company on the vesting date. The restricted shares granted generally vest ratably over a specified period on the anniversary of the grant date, subject to continued employment/service with the Company on the vesting date. For a description of the Company’s equity incentive plans and more details on the terms of the share-based awards, see Note 15 of the 2023 Annual Report.
The following table presents the share-based compensation expense that has been reported in the Company’s unaudited condensed consolidated statements of operations and comprehensive loss as follows ($ in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Selling, general and administrative10,404 14,041 31,861 35,880 
Research and development6,391 7,951 21,552 23,284 
Total16,795 21,992 53,413 59,164 
As of September 30, 2024, there was unrecognized share-based compensation expense related to unvested share options and unvested restricted shares of $80.4 million and $83.3 million, respectively, which the Company expects to recognize over a weighted-average period of 2.83 years and 2.68 years, respectively.
13. License and Collaboration Agreements
The Company has entered into various license and collaboration agreements with third parties to develop and commercialize product candidates.
Significant License and Collaboration Arrangements
For a description of the material terms of the Company’s significant license and collaboration agreements, see Note 16 of the 2023 Annual Report. During the nine months ended September 30, 2024, the Company did not enter into any new significant license or collaboration agreements. The following includes a description of milestone fees incurred in the nine months ended September 30, 2024 under the Company’s significant license and collaboration agreements.
License and Collaboration Agreement with Innoviva (SUL-DUR)
Under the terms of the Company’s license and collaboration agreement with Entasis Therapeutics Holdings Inc., a wholly owned subsidiary of Innoviva, Inc. (“Innoviva”), the Company recorded an $8.0 million regulatory milestone in the second quarter of 2024, which was capitalized as an intangible asset. As of September 30, 2024, the Company may be required to pay an additional aggregate amount of up to $80.6 million in development, regulatory, and sales-based milestones as well as certain royalties at tiered percentage rates ranging from high single digits to low-teens on annual net sales of the licensed products in the licensed territory.
License Agreement with BMS (Repotrectinib)
Under the terms of the Company’s license agreement with Turning Point Therapeutics, Inc., a company later acquired by Bristol Myers Squibb (“BMS”), the Company recorded $25.0 million for regulatory milestones in the second
14

Zai Lab Limited
Notes to the unaudited condensed consolidated financial statements
quarter of 2024, which was capitalized as an intangible asset. As of September 30, 2024, the Company may be required to pay an additional aggregate amount of up to $116.0 million in development, regulatory, and sales-based milestones as well as certain royalties at tiered percentage rates ranging from mid- to high-teens on annual net sales of the licensed products in the licensed territory.
License Agreement with BMS (Xanomeline and Trospium Chloride)
Under the terms of the Company’s license agreement with Karuna Therapeutics, Inc. (a company later acquired by BMS), the Company recorded a $10.0 million development milestone into research and development expenses in the third quarter of 2024. As of September 30, 2024, the Company may be required to pay an additional aggregate amount of up to $132.0 million in development, regulatory, and sales-based milestones as well as certain royalties at tiered percentage rates ranging from low- to high-teens on annual net sales of the licensed products in Greater China.
Other License and Collaboration Arrangements That Are Not Individually Significant
The Company recorded an upfront payment of $12.0 million into research and development expenses in the third quarter of 2024 for a license and collaboration agreement that is not individually significant.
14. Other Income, Net
The following table presents the Company’s other income, net ($ in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Government grants3,861 671 7,186 754 
Loss on equity investments with readily determinable fair value(920)(661)(6,067)(1,965)
Others miscellaneous gain500 384 2,740 1,434 
Total3,441 394 3,859 223 
15. Restricted Net Assets
The Company’s ability to pay dividends may depend on the Company receiving distributions of funds from its Chinese subsidiaries. Relevant Chinese laws and regulations permit payments of dividends by the Company’s Chinese subsidiaries only out of its retained earnings, if any, as determined in accordance with Chinese accounting standards and regulations. The results of operations reflected in the unaudited condensed consolidated financial statements prepared in accordance with U.S. GAAP differ from those reflected in the statutory financial statements of the Company’s Chinese subsidiaries.
In accordance with the Company Law of the People’s Republic of China, a domestic enterprise is required to provide statutory reserves of at least 10% of its annual after-tax profit until such reserve has reached 50% of its respective registered capital based on the enterprise’s Chinese statutory accounts. A domestic enterprise may provide discretionary surplus reserve, at the discretion of the Board of Directors, from the profits determined in accordance with the enterprise’s Chinese statutory accounts. The aforementioned reserves can only be used for specific purposes and are not distributable as cash dividends. The Company’s Chinese subsidiaries were established as domestic enterprises and therefore are subject to the above-mentioned restrictions on distributable profits.
No appropriation to statutory reserves was made in the three and nine months ended September 30, 2024 and 2023 because the Chinese subsidiaries had substantial losses during such periods.
As a result of these Chinese laws and regulations, subject to the limits discussed above that require annual appropriations of 10% of after-tax profit to be set aside, prior to payment of dividends, as a general reserve fund, the Company’s Chinese subsidiaries are restricted in their ability to transfer out a portion of their net assets.
Foreign exchange and other regulation in mainland China may further restrict the Company’s subsidiaries in mainland China from transferring out funds in the form of dividends, loans, and advances. As of September 30, 2024 and December 31, 2023, amounts restricted included the paid-in capital of the Company’s subsidiaries in mainland China and were $506.0 million.
16. Commitments and Contingencies
(a) Purchase Commitments
As of September 30, 2024, the Company’s commitments related to purchase of property and equipment and the commercial manufacturing development activities that are contracted but not yet reflected in the unaudited condensed consolidated financial statements were $8.6 million and were expected to be incurred within one year.
(b) Legal Proceedings
The Company is not currently a party to any material legal proceedings.
(c) Indemnifications
In the normal course of business, the Company enters into agreements that indemnify others for certain liabilities that may arise in connection with a transaction or certain events and activities. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations.
15

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion and analysis of our financial condition and results of operations together with our 2023 Annual Report and our unaudited condensed consolidated financial statements and the accompanying notes for the three and nine months ended September 30, 2024 included in Item 1. Financial Statements.
Overview
We are a patient-focused, innovative, commercial-stage, global biopharmaceutical company with a substantial presence in both Greater China and the United States. We are focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. We intend to leverage our competencies and resources to positively impact human health in Greater China and worldwide. We currently have five commercial products – ZEJULA®, OPTUNE, QINLOCK®, NUZYRA®, and VYVGART® – that have received marketing approval and that we have commercially launched in one or more territories in Greater China. OPTUNE refers to Tumor Treating Fields devices marketed under various brand names, including OPTUNE GIO® for glioblastoma multiforme (“GBM”). We also have three products that have received marketing approval and are moving toward commercial launch for the approved indications – VYVGART Hytrulo (the subcutaneous formulation of efgartigimod), XACDURO® (SUL-DUR), and AUGTYRO® (repotrectinib) – as well as multiple programs in late-stage product development and a number of ongoing pivotal trials across our portfolio.
Since our inception, we have incurred net losses and negative cash flows from our operations. Substantially all of our losses have resulted from funding our research and development programs and selling, general and administrative costs associated with our operations. Developing high quality product candidates requires significant investment in our research and development activities over a prolonged period of time, and a core part of our strategy is to continue making sustained investments in this area. Our ability to generate profits and positive cash flow from operations over the next several years depends upon our ability to successfully market our commercial products and to successfully expand the indications for these products and develop and commercialize our other product candidates. As discussed further below, we expect to continue to incur substantial costs related to our research and development and commercialization activities.
As we pursue our corporate strategic goals, we anticipate that our financial results will fluctuate from quarter to quarter and year to year depending in part on the balance between the success of our commercial products and the level of our research and development expenses. We cannot predict whether or when our product candidates will receive regulatory approval. Further, if we receive such regulatory approval, we cannot predict whether or when we may be able to successfully commercialize such products or whether or when such products may become profitable.
Recent Developments
Commercial Products
Net product revenue was $101.8 million for the third quarter of 2024, an increase of 47% compared to the prior year period, primarily driven by increased sales for VYVGART since its launch in September 2023 and listing on China’s National Reimbursement Drug List (“NRDL”) in January 2024 for the treatment of adult patients with generalized myasthenia gravis (“gMG”) who are anti-acetylcholine receptor (“AChR”) antibody positive and increased sales for ZEJULA and NUZYRA. The NRDL listing for ZEJULA as a maintenance treatment was renewed in the first quarter of 2024, and ZEJULA continues to be the leading PARP inhibitor in hospital sales for ovarian cancer in mainland China. Increased sales for NUZYRA were supported by the inclusion in the NRDL for its intravenous (“IV”) formulation for the treatment of adult patients with community-acquired bacterial pneumonia (“CABP”) and acute bacterial skin and skin structure infections (“ABSSSI”) in the first quarter of 2023 and for its oral formulation for these indications in the first quarter of 2024.
16

Product Candidates
We continued to advance our product candidates through our research and development activities, including the following developments with respect to our clinical trials and regulatory approvals:
Oncology
•Niraparib: In July 2024, data from a Zai-supported study was published in Cell that provides new insights with potential to improve treatment of HRD-positive ovarian cancers, including through neoadjuvant monotherapy with niraparib and a combination of niraparib and ZL-1218, our investigational CCR8 antibody.
•Early-Stage Global Pipeline: In October 2024, we presented data from a Phase I study of ZL-1310, an investigational DLL3-antibody-drug conjugate, in second-line+ extensive stage small cell lung cancer. The data, from the ongoing Part Ia monotherapy dose-escalation portion of the study, included results from 25 patients across four dose cohorts (0.8 mg/kg, 1.6 mg/kg, 2.0 mg/kg, 2.4 mg/kg). Findings from this study suggest that ZL-1310 delivers anti-tumor activity across multiple dose levels with an overall response rate of 74%. It was well tolerated across all dose levels with the majority of treatment emergent adverse events being Grade 1 or 2.
Immunology, Neuroscience, and Infectious Disease
•Efgartigimod: In July 2024, the NMPA approved the Biologics License Application for efgartigimod alfa injection (subcutaneous injection), under the brand name VYVGART Hytrulo, as an add on to standard therapy for the treatment of adult patients with gMG who are AChR antibody positive. In November 2024, the NMPA approved the supplemental Biologics License Application for VYVGART Hytrulo for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy.
•Xanomeline and Trospium Chloride (KarXT):
◦Schizophrenia: In October 2024, we announced positive topline results from the Phase III bridging study evaluating the safety and efficacy of KarXT in schizophrenia in China. The study met its primary endpoint, with KarXT demonstrating a statistically significant and clinically meaningful 9.2-point reduction in the Positive and Negative Syndrome Scale (“PANSS”) total score compared to placebo at Week 5 (-16.9 KarXT vs. -7.7 placebo, p=0.0014). The study also met all secondary efficacy endpoints. We expect to submit a New Drug Application to the NMPA for KarXT for the treatment of patients with schizophrenia in early 2025.

In September 2024, our partner BMS announced that the FDA had approved KarXT, under the brand name COBENFY™, for the treatment of adult patients with schizophrenia. In October 2024, BMS announced new topline results from the Phase III EMERGENT-4 and EMERGENT-5 open-label trials evaluating the long-term efficacy, safety, and tolerability of KarXT in adults with schizophrenia over 52 weeks of treatment. In the analysis, KarXT was associated with continued improvements in symptoms of schizophrenia across all efficacy measures. KarXT continued to see a lack of weight gain, and it was not associated with movement disorders or metabolic changes.
◦ADP: In July 2024, we joined the global Phase III ADEPT-2 study evaluating the safety and efficacy of KarXT for the treatment of psychosis associated with Alzheimer’s disease (“ADP”) in Greater China.
•Early-Stage Global Pipeline: In September 2024, Zai Lab presented pre-clinical data of ZL-1503, an IL-13/IL-31 bi-specific antibody, at the European Academy of Dermatology and Venerology Congress 2024. The presentation discussed the potential of ZL-1503 as a novel treatment for moderate-to-severe atopic dermatitis, as well as other diseases involving the IL-13 and IL-31 pathways.
17

Corporate Updates
We continue to enhance our portfolio through strategic partnerships and to strengthen our organizational structure to support the evolving needs of our business:
•Business Development: In July 2024, we entered into a strategic partnership and global license agreement with MabCare Therapeutics Co., Ltd. Through this collaboration, we expanded our global oncology pipeline with a next generation antibody-drug conjugate targeting ROR1, ZL-6301. ZL-6301 has the potential to be used in the treatment of solid tumors where ROR1 is commonly expressed and in hematological malignancies where ROR1 is a validated target. ZL-6301 has demonstrated an encouraging pre-clinical profile, and it is currently in the IND-enabling stage. We plan to focus on advancing its global development.
•Organizational Update: In September 2024, the Company appointed Prista Charuworn, M.D., as our Vice President, Immunology, Global R&D. Dr. Charuworn is an accomplished gastroenterologist with extensive experience and leadership in clinical development in hepatology and immunology. She reports to Rafael Amado, M.D., our President, Head of Global R&D, and is responsible for leading and advancing the R&D strategy for our immunology therapeutic area as well as our neuroscience and infectious disease assets. She previously held key leadership roles in clinical development at Amgen, AstraZeneca, and Gilead.
Factors Affecting Our Results of Operations
Our Commercial Products
We generate product revenue through the sale of our commercial products in Greater China, net of any related sales returns and rebates to distributors. Our cost of product revenue mainly consists of the costs of manufacturing ZEJULA and NUZYRA, costs of purchasing OPTUNE, QINLOCK, and VYVGART from our collaboration partners, any royalty fees incurred as a result of sales of our commercial products under our license and collaboration agreements, and amortization of any sales-based milestone fees incurred under our license and collaboration agreements. We expect our product revenue to increase in coming years as we continue to focus on increasing patient access to our existing commercial products, such as through NRDL listing or increased supplemental insurance coverage in the private-pay market, and as we launch additional commercial products, if and when we obtain required regulatory approvals. We expect our cost of product revenue to increase as the volume of products sold increases.
Research and Development Expenses
We believe our ability to successfully develop product candidates will be the primary factor affecting our long-term competitiveness, as well as our future growth and development. Developing high quality product candidates requires a significant investment of resources over a prolonged period of time. We are committed to advancing and expanding our pipeline of potential best-in-class and first-in-class products, such as through clinical and pre-clinical trials and business development activities. As a result, we expect to continue making significant investments in research and development, including internal discovery activities.
Elements of research and development expenditures primarily include:
•payroll and other related costs of personnel engaged in research and development activities;
•fees for exclusive development rights of products granted to the Company;
•costs related to pre-clinical testing of the Company’s technologies and clinical trials, such as payments to contract research organizations (“CROs”) and contract manufacturing organizations (“CMOs”), investigators, and clinical trial sites that conduct our clinical studies; and
•costs to produce the product candidates, including raw materials and supplies, product testing, depreciation, and facility-related expenses.
18

Selling, General, and Administrative Expenses
Our selling, general, and administrative expenses consist primarily of personnel compensation and related costs, including share-based compensation for commercial and administrative personnel. Other selling, general, and administrative expenses include product distribution and promotion costs, and professional service fees for legal, intellectual property, consulting, auditing, and tax services as well as other direct and allocated expenses for rent and maintenance of facilities, insurance, and other supplies used in selling, general, and administrative activities. We expect these costs to continue to be significant to support sales of our commercial products and preparation to launch and subsequent sales of additional product candidates if and when approved.
Our Ability to Commercialize Our Product Candidates
We have multiple product candidates in late-stage clinical development and various others in clinical and pre-clinical development in Greater China and the United States. Our ability to generate revenue from our product candidates is dependent on our receipt of regulatory approvals for and successful commercialization of such product candidates, which may not occur. Certain of our product candidates may require additional pre-clinical and/or clinical development, regulatory approvals in multiple jurisdictions, manufacturing supply, and significant marketing efforts before we generate any revenue from product sales.
License and Collaboration Arrangements
Our results of operations have been, and will continue to be, affected by our license and collaboration agreements. In accordance with these agreements, we may be required to make upfront payments and milestone payments upon the achievement of certain development, regulatory, and sales-based milestones for the relevant products as well as certain royalties at tiered percentage rates based on annual net sales of the licensed products in the licensed territories. As of September 30, 2024, we may be required to pay development and regulatory milestone payments of up to an additional aggregate amount of $284.5 million for our current clinical programs and $613.0 million for other programs. Such development and regulatory milestone payments are contingent on the progress of our product candidates prior to commercialization, and we see these payments as favorable because they indicate that product candidates are advancing. As of September 30, 2024, we also may be required to pay sales-based milestone payments of up to an additional aggregate amount of $2,295.0 million as well as certain royalties at tiered percentage rates on annual net sales. Such sales-based milestone and royalty payments are contingent on the performance of our commercial products, and we see these payments as favorable because they signify that a product is achieving higher sales levels.
19

Results of Operations
In this section, we discuss our results of operations for the three and nine months ended September 30, 2024 compared to the same periods in 2023.
The following table presents our results of operations ($ in thousands):
Three Months Ended September 30,ChangeNine Months Ended September 30,Change
20242023$%20242023$%
Revenues
Product revenue, net101,847 69,228 32,619 47 %289,102 200,889 88,213 44 %
Collaboration revenue418 — 418 NM816 — 816 NM
Total revenues102,265 69,228 33,037 48 %289,918 200,889 89,029 44 %
Expenses
Cost of product revenue(36,569)(25,479)(11,090)44 %(105,336)(70,579)(34,757)49 %
Cost of collaboration revenue(348)— (348)NM(433)— (433)NM
Research and development(65,982)(58,767)(7,215)12 %(182,252)(183,920)1,668 (1)%
Selling, general, and administrative(67,219)(68,552)1,333 (2)%(216,123)(198,982)(17,141)9 %
Gain on sale of intellectual property— — — NM— 10,000 (10,000)(100)%
Loss from operations(67,853)(83,570)15,717 (19)%(214,226)(242,592)28,366 (12)%
Interest income9,029 9,172 (143)(2)%28,017 29,493 (1,476)(5)%
Interest expense(745)— (745)NM(1,350)— (1,350)NM
Foreign currency gains (losses)14,457 4,852 9,605 198 %8,281 (26,315)34,596 (131)%
Other income, net3,441 394 3,047 773 %3,859 223 3,636 1630 %
Loss before income tax (41,671)(69,152)27,481 (40)%(175,419)(239,191)63,772 (27)%
Income tax expense— — — — %— — — — %
Net loss(41,671)(69,152)27,481 (40)%(175,419)(239,191)63,772 (27)%
NM - Not Meaningful
Revenues
Product Revenue, Net
The following table presents the components of the Company’s product revenue ($ in thousands):
Three Months Ended September 30,ChangeNine Months Ended September 30,Change
20242023$%20242023$%
Product revenue - gross107,678 74,018 33,660 45 %307,401 220,240 87,161 40 %
Less: Rebates and sales returns(5,831)(4,790)(1,041)22 %(18,299)(19,351)1,052 (5)%
Product revenue - net101,847 69,228 32,619 47 %289,102 200,889 88,213 44 %
Our product revenue is derived from the sales of our commercial products primarily in mainland China, net of sales returns and rebates to distributors with respect to the sales of these products.
Our net product revenue increased by $32.6 million and $88.2 million in the three and nine months ended September 30, 2024, respectively, primarily driven by increased sales for VYVGART since its launch in September 2023 and NRDL listing in January 2024 for the treatment of gMG. Net product revenue growth was also supported by increased sales volumes for ZEJULA and NUZYRA in the three and nine months ended September 30, 2024. ZEJULA sales remained strong as it continued to be the leading PARP inhibitor in hospital sales for ovarian cancer in mainland China. The growth in NUZYRA sales was supported by the inclusion in the NRDL for its IV formulation for the treatment of CABP and ABSSSI in the first quarter of 2023 and for its oral formulation for these indications in the first quarter of 2024.
20

The following table presents net revenue by product ($ in thousands):
Three Months Ended September 30,ChangeNine Months Ended September 30,Change
20242023$%20242023$%
ZEJULA48,227 41,593 6,634 16 %138,727 127,230 11,497 9 %
OPTUNE7,715 11,562 (3,847)(33)%32,779 38,596 (5,817)(15)%
QINLOCK8,643 5,702 2,941 52 %21,774 14,535 7,239 50 %
NUZYRA9,997 5,483 4,514 82 %32,205 15,588 16,617 107 %
VYVGART 27,265 4,888 22,377 458 %63,617 4,940 58,677 1188 %
Total product revenue, net101,847 69,228 32,619 47 %289,102 200,889 88,213 44 %
Cost of Product Revenue
Cost of product revenue increased by $11.1 million and $34.8 million in the three and nine months ended September 30, 2024, respectively, primarily due to increasing sales volumes and shifts in product sales mix.
Collaboration Revenue and Cost of Collaboration Revenue
In the three and nine months ended September 30, 2024, collaboration revenue related to promotional activities in mainland China was $0.4 million and $0.8 million, respectively, and cost of collaboration revenue was $0.3 million and $0.4 million, respectively. We had no such collaboration revenue in the prior year periods.
Research and Development Expenses
The following table presents the components of our research and development expenses ($ in thousands):
Three Months Ended September 30,ChangeNine Months Ended September 30,Change
20242023$%20242023$%
Personnel compensation and related costs23,405 27,933 (4,528)(16)%82,622 85,967 (3,345)(4)%
Licensing fees22,634 9 22,625 NM22,634 19,291 3,343 17 %
CROs/CMOs/Investigators expenses13,004 23,136 (10,132)(44)%57,213 59,201 (1,988)(3)%
Other costs6,939 7,689 (750)(10)%19,783 19,461 322 2 %
Total65,982 58,767 7,215 12 %182,252 183,920 (1,668)(1)%
NM - Not Meaningful
Research and development expenses increased by $7.2 million in the three months ended September 30, 2024, primarily due to:
•an increase of $22.6 million in licensing fees in connection with increased upfront and milestone payments for our license and collaboration agreements; partially offset by
•a decrease of $10.9 million in CROs/CMOs/Investigators expenses and other costs related to ongoing clinical trials; and
•a decrease of $4.5 million in personnel compensation and related costs primarily driven by the Company’s ongoing resource prioritization and efficiency efforts.
21

Research and development expenses decreased by $1.7 million in the nine months ended September 30, 2024, primarily due to:
•a decrease of $3.3 million in personnel compensation and related costs primarily driven by the Company’s ongoing resource prioritization and efficiency efforts; and
•a decrease of $1.7 million in CROs/CMOs/Investigators expenses and other costs related to ongoing clinical trials; partially offset by
•an increase of $3.3 million in licensing fees in connection with increased upfront and milestone payments for our license and collaboration agreements.
The following table presents our research and development expenses by program ($ in thousands):
Three Months Ended September 30,ChangeNine Months Ended September 30,Change
20242023$%20242023$%
Clinical programs23,060 23,243 (183)(1)%63,196 68,232 (5,036)(7)%
Pre-clinical programs14,461 2,013 12,448 618 %19,649 15,252 4,397 29 %
Unallocated research and development expenses28,461 33,511 (5,050)(15)%99,407 100,436 (1,029)(1)%
Total65,982 58,767 7,215 12 %182,252 183,920 (1,668)(1)%
Research and development expenses attributable to pre-clinical programs increased by $12.4 million in the three months ended September 30, 2024 primarily due to an increase in licensing fees.
Research and development expenses attributable to clinical programs decreased by $5.0 million in the nine months ended September 30, 2024 primarily driven by a decrease of $7.3 million in CROs/CMOs/Investigators expenses related to the progress of existing studies, offset by an increase of $2.3 million in licensing fees. Research and development expenses attributable to pre-clinical programs increased by $4.4 million in the nine months ended September 30, 2024 primarily due to an increase of $3.4 million in CROs/CMOs/Investigators expenses related to newly initiated studies and progress of existing studies and an increase of $1.0 million in licensing fees.
Although we manage our external research and development expenses by program, we do not allocate our internal research and development expenses by program because our employees and internal resources may be engaged in projects for multiple programs at any given time.
Selling, General, and Administrative Expenses
The following table presents our selling, general and administrative expenses by program ($ in thousands):
Three Months Ended September 30,ChangeNine Months Ended September 30,Change
20242023$%20242023$%
Personnel compensation and related costs39,984 45,410 (5,426)(12)%134,157 129,198 4,959 4 %
Professional service fees5,863 4,404 1,459 33 %14,917 18,752 (3,835)(20)%
Other costs21,372 18,738 2,634 14 %67,049 51,032 16,017 31 %
Total67,219 68,552 (1,333)(2)%216,123 198,982 17,141 9 %
Selling, general, and administrative expenses decreased by $1.3 million the three months ended September 30, 2024, primarily due to:
•a decrease of $5.4 million in personnel compensation and related costs primarily driven by the Company’s ongoing resource prioritization and efficiency efforts; partially offset by
22

•an increase of $2.6 million in other costs primarily related to higher general selling expenses for VYVGART which was launched in September 2023.
Selling, general, and administrative expenses increased by $17.1 million in the nine months ended September 30, 2024, primarily due to:
•an increase of $16.0 million in other costs primarily related to higher general selling expenses for VYVGART which was launched in September 2023; and
•an increase of $5.0 million in personnel compensation and related costs primarily driven by headcount growth related to support VYVGART; partially offset by
•a decrease of $3.8 million in professional service fees primarily related to decreased finance and human resources administrative expenses.
Gain on Sale of Intellectual Property
We had a gain on sale of intellectual property of $10.0 million in the second quarter of 2023 in connection with our sale of certain patent rights and related know-how to a third party. We had no such gain or loss in the current year periods.
Interest Income
Interest income decreased by $0.1 million and $1.5 million in the three and nine months ended September 30, 2024, respectively, primarily due to decreased cash and cash equivalents.
Interest Expense
Interest expense increased by $0.7 million and $1.4 million in the three and nine months ended September 30, 2024, respectively, primarily due to interest expense on short-term debt we entered into in 2024. We had no such interest expense in the prior year periods.
Foreign Currency Gains (Losses)
Foreign currency gain increased by $9.6 million in the three months ended September 30, 2024, primarily driven by increased remeasurement gain due to appreciation of the RMB against the U.S. dollar.
Foreign currency gain was $8.3 million in the nine months ended September 30, 2024, primarily driven by remeasurement gain due to appreciation of the RMB against the U.S. dollar, compared to foreign currency loss of $26.3 million in the nine months ended September 30, 2023, driven by remeasurement loss due to depreciation of the RMB against the U.S. dollar.
Other Income, Net
Other income, net increased by $3.0 million and $3.6 million in the three and nine months ended September 30, 2024, respectively, primarily due to an increase of $3.2 million and $6.4 million in government grants, respectively, and an increase of $0.1 million and $1.3 million in other miscellaneous gain primarily driven by an increase in sublease rental income, respectively, partially offset by an increase of $0.3 million and $4.1 million in loss of our equity investment in MacroGenics, Inc. as a result of changes in its stock price, respectively.
Income Tax Expense
Income tax expense was nil in both the three and nine months ended September 30, 2024 and 2023.
Net Loss
Net loss was $41.7 million in the three months ended September 30, 2024, or a loss per ordinary share attributable to common stockholders of $0.04 (or loss per ADS of $0.42), compared to a net loss of $69.2 million in the three months ended September 30, 2023, or a loss per ordinary share of $0.07 (or loss per ADS of $0.71).
23

Net loss was $175.4 million in the nine months ended September 30, 2024, or a loss per ordinary share attributable to common stockholders of $0.18 (or loss per ADS of $1.80), compared to a net loss of $239.2 million in the nine months ended September 30, 2023, or a loss per ordinary share of $0.25 (or loss per ADS of $2.48).
Critical Accounting Policies and Significant Judgments and Estimates
We prepare our financial statements in conformity with U.S. GAAP, which requires management to make judgments, estimates, and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures. Some of those judgments can be subjective and complex. Actual results could differ from our estimates.
Our most critical accounting policies and estimates, including those that require the most difficult, subjective, or complex judgments and are the most inherently uncertain, are described below.
Revenue Recognition
We sell our products to distributors (our customers), who ultimately sell the products to healthcare providers, primarily in mainland China. We recognize revenue when the performance obligations are satisfied upon the product’s delivery to distributors.
We offer rebates to our distributors to compensate the distributors consistent with pharmaceutical industry practices. We are required to establish a provision for rebates in the same period the related product sales are recognized. The estimated amount of rebates, if any, is recorded as a reduction of revenue.
Significant judgments are required in making these estimates. In determining the appropriate accrual amount, we consider our contracted rates, sales volumes, levels of distributor inventories, and historical experiences and trends. If actual results vary from our estimates or our expectations change, we will adjust these estimates accordingly, which would affect net product revenue and earnings in the period such variances become expected or known.
Research and Development Expenses
We have a significant amount of research and development expenses, including with respect to pre-clinical and clinical trials for our product candidates. Such costs are expensed as incurred when they have no alternative future uses.
We contract with third parties to perform various pre-clinical and clinical trial activities on our behalf in the ongoing development of our product candidates. Expenses related to pre-clinical and clinical trial activities are accrued based on the Company’s estimates of the actual services performed by the third parties, such as CROs and CMOs.
Significant judgments are required in estimating the actual services performed by the third parties for the respective period and the related expense accruals. In determining the appropriate accrual, we consider a variety of factors, including contractual requirements with respect to services to be provided, related rates, and our assessment of services performed during the period and progress with respect to any contractual milestones when we have not yet been invoiced or otherwise notified by third parties of actual costs. If the actual status and timing of services performed vary from our estimates, our reported expenses and earnings for the corresponding period may be affected.
Share-Based Compensation
We grant share-based awards, including share options and restricted shares, to eligible employees, non-employees, and directors. Such share-based awards are measured at grant date fair value.
Significant assumptions are required in determining the fair value of share options, which we estimate using the Black-Scholes option valuation model. These assumptions include: (i) the expected volatility of our ADS price, (ii) the periods of time over which grantees are expected to hold their options prior to exercise (expected term), (iii) the expected dividend yield on our ADSs, and (iv) risk-free interest rates. Since we do not have sufficient trading history since our September 2017 initial public offering on Nasdaq to cover the expected term of our share options, we estimate expected volatility based on movements in the share price of certain companies we consider comparable over the most recent equivalent historical period. Since we do not have sufficient historical information to develop reasonable expectations
24

about future exercise patterns and post-vesting employment termination behavior, the expected term is derived from the average midpoint between the weighted average vesting and the contractual term, also known as the simplified method. The expected dividend yield is zero as we have never paid dividends and do not currently anticipate paying any in the foreseeable future, and risk-free interest rates are based on quoted U.S. Treasury rates for securities with maturities approximating the expected term. If actual results vary from our estimates or our expectations change, our reported expenses and earnings for the corresponding period may be affected.
Income Taxes
We recognize deferred tax assets and liabilities for temporary differences between the financial statement and income tax bases of assets and liabilities, which are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some or all of a deferred tax asset will not be realized. Significant judgements are required when evaluating tax positions in accordance with ASC 740, Income Taxes.
We recognize in our financial statements the benefit of a tax position if the tax position is “more likely than not” to prevail based on the facts and technical merits of the position. Tax positions that meet the “more likely than not” recognition threshold are measured at the largest amount of tax benefit that has a greater than fifty percent likelihood of being realized upon settlement. We estimate our liability for unrecognized tax benefits which are periodically assessed and may be affected by changing interpretations of laws, rulings by tax authorities, changes and/or developments with respect to tax audits, and the expiration of the applicable statute of limitations. The ultimate outcome for a particular tax position may not be determined with certainty prior to the conclusion of a tax audit and, in some cases, appeal or litigation process.
We consider positive and negative evidence when determining whether some or all of our deferred tax assets will not be realized. This assessment considers various factors, including the nature, frequency, and severity of current and cumulative losses, forecasts of future profitability, the duration of statutory carry-forward periods, our historical results of operations, and our tax planning strategies. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Our estimates may be affected by changing interpretations of laws, rulings by tax authorities, changes and/or developments with respect to tax audits, and expiration of the statute of limitations. If actual benefits vary from our estimates or our expectations change, we will adjust the recognition and measurement estimates accordingly, which would affect reported expenses and earnings in the corresponding period.
Liquidity and Capital Resources
To date, we have financed our activities primarily through private placements, our September 2017 initial public offering and various follow-on offerings on Nasdaq, and our September 2020 secondary listing and initial public offering on the Hong Kong Stock Exchange. In addition, we have raised approximately $164.6 million in private equity financing and approximately $2,462.7 million in net proceeds after deducting underwriting commissions and the offering expenses payable by us in our initial public offering and subsequent follow-on offerings on Nasdaq and our initial public offering on the Hong Kong Stock Exchange. Our operations have consumed substantial amounts of cash since inception. The net cash used in our operating activities was $159.1 million and $183.3 million in the nine months ended 2024 and 2023, respectively. For information on our research and development activities and related expenditures see the Research and Development Expenses, Selling, General, and Administrative Expenses, License and Collaboration Arrangements, and Results of Operations sections above. In addition, as of September 30, 2024, we had commitments for capital expenditures of $8.6 million mainly for the purpose of commercial manufacturing development, plant construction, and installation.
As of September 30, 2024, we had cash and cash equivalents, current restricted cash, and short-term investments of $716.1 million, which we expect will enable us to meet our cash requirements including the funding of operating expenses, capital expenditures, and debt obligations for at least the next 12 months.
Although we believe that we have sufficient capital to fund our operations for at least the next twelve months, we may, from time to time, identify opportunities to access capital through debt arrangements on favorable commercial terms. In the nine months ended September 30, 2024, we entered into four such debt arrangements with Chinese financial
25

institutions that allow certain of our subsidiaries to borrow up to approximately $198.9 million (or RMB1,421.7 million) to support our working capital needs in mainland China. As of September 30, 2024, we had short-term debt of approximately $113.0 million (or RMB791.8 million) pursuant to these debt arrangements. These debt arrangements will provide us with additional capital capacity that gives us enhanced flexibility to execute on our corporate strategic goals. For more information, see Note 10.
We may consider, or we may ultimately need, additional funding sources to bring to fruition our strategic objectives, and there can be no assurances that such funding will be made available to us on acceptable terms or at all.
The following table presents information regarding our cash flows ($ in thousands):
Nine Months Ended
September 30,		Change
20242023$
Net cash used in operating activities(159,100)(183,261)24,161 
Net cash used in investing activities(27,439)(25,233)(2,206)
Net cash provided by (used in) financing activities112,077 (6,826)118,903 
Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash402 (3,355)3,757 
Net decrease in cash, cash equivalents and restricted cash(74,060)(218,675)144,615 
Net Cash Used in Operating Activities
Net cash used in operating activities decreased by $24.2 million in the nine months ended September 30, 2024, primarily due to a decrease of $63.8 million in net loss, partially offset by a decrease of $23.0 million in adjustments to reconcile net loss to net cash used in operating activities and a decrease of $16.6 million in net changes in operating assets and liabilities.
Net Cash Used in Investing Activities
Net cash used in investing activities increased by $2.2 million in the nine months ended September 30, 2024, primarily due to a decrease of $86.1 million in proceeds from the maturity of short-term investments, an increase of $40.1 million from acquisition of intangible assets due to payments for milestone fees, a decrease of $10.0 million in proceeds from sale of intellectual property, and a decrease of $3.9 million in proceeds from land use right, partially offset by a decrease of $134.0 million in purchases of short-term investments, and a decrease of $3.9 million in purchases of property and equipment.
Net Cash Provided by (Used in) Financing Activities
Net cash provided by financing activities was $112.1 million in the nine months ended September 30, 2024, compared to net cash used in financing activities of $6.8 million in the nine months ended September 30, 2023. This shift was primarily due to $111.0 million in short-term debt proceeds net of related issuance costs as we entered into certain debt arrangements in the nine months ended September 30, 2024, and a decrease of $8.7 million in taxes paid related to settlement of equity awards, partially offset by a decrease of $0.6 million in proceeds from exercises of stock options and an increase of $0.3 million in repayment of short-term debt.
Recently Issued Accounting Standards
For more information regarding recently issued accounting standards, see Part II – Item 8. Financial Statements and Supplementary Data – Recent Accounting Pronouncements in our 2023 Annual Report. The Company has not adopted any new accounting standards in the nine months ended September 30, 2024.
26

Item 3. Quantitative and Qualitative Disclosures About Market Risk
We are exposed to market risk including foreign exchange risk and credit risk.
Foreign Exchange Risk
Renminbi, or RMB, is not a freely convertible currency. The State Administration of Foreign Exchange, under the authority of the People’s Bank of China (“PBOC”), controls the conversion of RMB into foreign currencies. The value of RMB is subject to changes in central government policies and to international economic and political developments affecting supply and demand in the China Foreign Exchange Trading System market. The cash and cash equivalents of the Company included aggregated amounts of $40.1 million and $25.1 million, which were denominated in RMB, representing 7% and 3% of the cash and cash equivalents as of September 30, 2024 and December 31, 2023, respectively.
While our financial statements are presented in U.S. dollars, our business mainly operates in mainland China with a significant portion of our transactions settled in RMB, and as such, we do not believe that we currently have significant direct foreign exchange risk and have not used derivative financial instruments to hedge our exposure to such risk. Although, in general, our exposure to foreign exchange risk should be limited, the value of your investment in our ADSs and ordinary shares will be affected by the exchange rate between the U.S. dollar and the RMB and between the HK dollar and the RMB, respectively, because the value of our business is effectively denominated in RMB, while ADSs and ordinary shares are traded in U.S. dollars and HK dollars, respectively.
The value of the RMB against the U.S. dollar and other currencies may fluctuate and is affected by, among other things, changes in Greater China’s political and economic conditions. The conversion of RMB into foreign currencies, including U.S. dollars, has been based on rates set by the PBOC.
The value of our ADSs and our ordinary shares will be affected by the foreign exchange rates between U.S. dollars, HK dollars, and the RMB. For example, to the extent that we need to convert U.S. dollars or HK dollars into RMB for our operations or if any of our arrangements with other parties are denominated in U.S. dollars or HK dollars and need to be converted into RMB, appreciation of the RMB against the U.S. dollar or the HK dollar would have an adverse effect on the RMB amount we receive from the conversion. Conversely, if we decide to convert RMB into U.S. dollars or HK dollars for the purpose of making payments for dividends on ordinary shares or ADSs or for other business purposes, appreciation of the U.S. dollar or the HK dollar against the RMB would have a negative effect on the conversion amounts available to us.
Since 1983, the Hong Kong Monetary Authority (“HKMA”) has pegged the HK dollar to the U.S. dollar at the rate of approximately HK$7.80 to US$1.00. However, there is no assurance that the HK dollar will continue to be pegged to the U.S. dollar or that the HK dollar conversion rate will remain at HK$7.80 to US$1.00. If the HK dollar conversion rate against the U.S. dollar changes and the value of the HK dollar depreciates against the U.S. dollar, our assets denominated in HK dollars will be adversely affected. Additionally, if the HKMA were to repeg the HK dollar to, for example, the RMB rather than the U.S. dollar, or otherwise restrict the conversion of HK dollars into other currencies, then our assets denominated in HK dollars will be adversely affected.
Credit Risk
Financial instruments that are potentially subject to significant concentration of credit risk consist of cash and cash equivalents, short-term investments, accounts receivable, and notes receivable.
The carrying amounts of cash and cash equivalents and short-term investments represent the maximum amount of losses due to credit risk. As of September 30, 2024 and December 31, 2023, we had cash and cash equivalents of $616.1 million and $790.2 million, respectively, and short-term investments of nil and $16.3 million, respectively. As of September 30, 2024 and December 31, 2023, all of our cash and cash equivalents and short-term investments were held by major financial institutions located in mainland China and international financial institutions outside of mainland China which we believe are of high credit quality and for which we monitor continued credit worthiness.
Accounts receivable are typically unsecured and are derived from product revenue and collaborative arrangements. We manage credit risk related to our accounts receivable through ongoing monitoring of outstanding balances and limiting
27

the amount of credit extended based upon payment history and credit worthiness. Historically, we have collected receivables from customers within the credit terms with no significant credit losses incurred. As of September 30, 2024, our two largest customers accounted for approximately 22% of our total accounts receivable collectively.
Certain accounts receivable balances are settled in the form of notes receivable. As of September 30, 2024, such notes receivable included bank acceptance promissory notes that are non-interest bearing and due within six months. These notes receivable were used to collect the receivables based on an administrative convenience, given these notes are readily convertible to known amounts of cash. In accordance with the sales agreements, whether to use cash or bank acceptance promissory notes to settle the receivables is at our discretion, and this selection does not impact the agreed contractual purchase prices.
Item 4. Controls and Procedures
Management’s Evaluation of Our Disclosure Controls and Procedures
Our management, including our Chief Executive Officer and Chief Financial Officer, performed an evaluation of the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e)) as of the end of the period covered by this report. Our disclosure controls and procedures are designed to ensure that the information required to be disclosed in the reports that we file or furnish under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective. Based upon that evaluation, our management has concluded that, as of September 30, 2024, our disclosure controls and procedures were effective.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting (as such item is defined in Rules 13a-15(f)) during the fiscal quarter ended September 30, 2024 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
28

PART II - OTHER INFORMATION
Item 1. Legal Proceedings.
We may be, from time to time, subject to claims and suits arising in the ordinary course of business. We are not currently a party to any material legal or administrative proceedings.
Item 1A. Risk Factors.
We are subject to risks and uncertainties that could, directly or indirectly, adversely affect our business, results of operations, financial condition, liquidity, cash flows, strategies, and/or prospects. There have been no material changes in our risk factors from those disclosed in the “Risk Factors” section of our 2023 Annual Report.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
None.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
None.
Item 5. Other Information.
During the period covered by this report, none of the Company’s directors or executive officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (each as defined in Item 408 of Regulation S-K).
On November 11, 2024, Professor Kai-Xian Chen informed the Company that he has decided to retire and plans to resign from the Board of Directors, effective December 31, 2024. There are no disagreements between Professor Chen and the Company relating to the Company’s operations, policies, or practices that resulted in his decision to retire.
29

Item 6. Exhibits.
Exhibit Index
Exhibit
Number		Exhibit Title
10.1+
10.2+
31.1
31.2
32.1
32.2
101.INS*Inline XBRL Instance Document-the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH*Inline XBRL Taxonomy Extension Schema Document
101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF*Inline XBRL Taxonomy Extension Definitions Linkbase Document
104*Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)


+ Portions of this exhibit have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K
30

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ZAI LAB LIMITED
Dated: November 12, 2024
By:/s/ Yajing Chen
Name:Yajing Chen
Title:Chief Financial Officer
(Principal Financial and Accounting Officer)
31
 EX-31.1 2 zlab-20240930x10qxexx311.htm EX-31.1 Document

Exhibit 31.1
Certification by the Principal Executive Officer
Pursuant to Exchange Act Rule 13a-14(a),
As Adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Samantha (Ying) Du, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 of Zai Lab Limited;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 12, 2024
/s/ Samantha (Ying) Du
Samantha (Ying) Du
Chief Executive Officer
(Principal Executive Officer)

 EX-31.2 3 zlab-20240930x10qxexx312.htm EX-31.2 Document

Exhibit 31.2
Certification by the Principal Financial Officer
Pursuant to Exchange Act Rule 13a-14(a),
As Adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Yajing Chen, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 of Zai Lab Limited;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 12, 2024
/s/ Yajing Chen
Yajing Chen
Chief Financial Officer
(Principal Financial and Accounting Officer)

 EX-32.1 4 zlab-20240930x10qxexx321.htm EX-32.1 Document

Exhibit 32.1
Certification by the Principal Executive Officer
Pursuant to 18 U.S.C. Section 1350,
As Adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 of Zai Lab Limited (the “Company”), as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Samantha (Ying) Du, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 12, 2024
/s/ Samantha (Ying) Du
Samantha (Ying) Du
Chief Executive Officer
(Principal Executive Officer)


 EX-32.2 5 zlab-20240930x10qxexx322.htm EX-32.2 Document

Exhibit 32.2
Certification by the Principal Financial Officer
Pursuant to 18 U.S.C. Section 1350,
As Adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 of Zai Lab Limited (the “Company”), as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Yajing Chen, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 12, 2024
/s/ Yajing Chen
Yajing Chen
Chief Financial Officer
(Principal Financial and Accounting Officer)


 EX-101.SCH 6 zlab-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - Unaudited Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - Unaudited Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - Unaudited Condensed Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - Unaudited Condensed Consolidated Statements of Comprehensive Loss (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - Unaudited Condensed Consolidated Statements of Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 9952157 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - Organization and Principal Activities link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - Basis of Presentation and Consolidation and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - Cash and Cash Equivalents link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - Inventories, Net link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - Property and Equipment, Net link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Intangible Assets, Net link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - Revenues link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - Income Tax link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - Loss Per Share link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - Borrowings link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - License and Collaboration Agreements link:presentationLink link:calculationLink link:definitionLink 9952171 - Disclosure - Other Income, Net link:presentationLink link:calculationLink link:definitionLink 9952172 - Disclosure - Restricted Net Assets link:presentationLink link:calculationLink link:definitionLink 9952173 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Basis of Presentation and Consolidation and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Cash and Cash Equivalents (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Inventories, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Property and Equipment, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Intangible Assets, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Revenues (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Borrowings (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Other Income, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Basis of Presentation and Consolidation and Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Cash and Cash Equivalents (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Inventories, Net - Summary of Inventories, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Inventories, Net - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Property and Equipment, Net - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Intangible Assets, Net - Components of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Intangible Assets, Net - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Revenues - Summary of Product Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Revenues - Disaggregation of Net Revenue by Product (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Revenues - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Income Tax (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Loss Per Share - Summary of Anti-Dilutive Shares Excluded from Calculation of Diluted Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Borrowings - Summary of Short-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Borrowings - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Share-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Share-Based Compensation - Summary of Share-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - License and Collaboration Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Other Income, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Restricted Net Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 zlab-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 zlab-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 zlab-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Ningbo Bank Working Capital Loan Facility Ningbo Bank Working Capital Loan Facility [Member] Ningbo Bank Working Capital Loan Facility Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Statistical Measurement [Domain] Statistical Measurement [Domain] Cover [Abstract] Cover [Abstract] Net decrease in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Accrued rebate to distributors Accrued Rebate To Distributors Current Amount of accrued rebate payable to distributors. Other current liabilities Total Other Liabilities, Current Trading Symbol Trading Symbol All Trading Arrangements All Trading Arrangements [Member] Schedule Of Cash And Cash Equivalents [Table] Cash and Cash Equivalent [Table] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Summary of Basic and Diluted Net Loss Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Accounts receivable, allowance for credit losses Accounts Receivable, Allowance for Credit Loss, Current Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Accounts receivable Increase (Decrease) in Accounts Receivable Payment of upfront fees for license agreement Collaborative Arrangement, Rights and Obligations, Payment Of Upfront Fees For License Agreement Payment of upfront fees for license agreement. Loss from fair value changes of equity investment with readily determinable fair value Loss on equity investments with readily determinable fair value Equity Securities, FV-NI, Gain (Loss) Organization and Principal Activities Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Issuance of ordinary shares upon vesting of restricted shares (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Unrecorded Unconditional Purchase Obligation [Line Items] Unrecorded Unconditional Purchase Obligation [Line Items] Proceeds from exercises of stock options Proceeds from Stock Options Exercised Award Timing Disclosures [Line Items] Payables for purchase of property and equipment Payables For Purchase Of Property And Equipment Current Payables for purchase of property and equipment current. Electronic equipment Electronic Equipment [Member] Electronic equipment. Other Performance Measure, Amount Other Performance Measure, Amount Ordinary shares, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Statutory reserves Statutory Reserves Statutory reserves. Weighted average interest rate per annum Short-Term Debt, Weighted Average Interest Rate, at Point in Time Gain on sale of intellectual property Gain on sale of intellectual property Gain (Loss) on Disposition of Intangible Assets Non-current operating lease liabilities Operating Lease, Liability, Noncurrent Zai Lab Suzhou Zai Lab Suzhou Company Limited [Member] Zai Lab (Suzhou) company limited. Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Loans Payable Loans Payable [Member] Entity Tax Identification Number Entity Tax Identification Number Gross Carrying Amount Finite-Lived Intangible Assets, Gross Intangible Asset, Finite-Lived [Table] Intangible Asset, Finite-Lived [Table] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis] Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis] Selling, general and administrative Selling, General and Administrative Expenses [Member] Noncash lease expenses Non Cash Lease Expenses Non-cash lease expenses. Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Deferred income Deferred Income, Noncurrent Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Treasury Stock Treasury Stock, Common [Member] Tax payables Taxes Payable, Current Xanomeline-Trospium Chloride Xanomeline-Trospium Chloride [Member] Xanomeline-Trospium Chloride Equity Components Equity Components [Axis] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Award Timing Method Award Timing Method [Text Block] Office equipment Office Equipment [Member] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Milestone payment made Collaborative Arrangement, Rights and Obligations, Milestone Payment The amount represents milestone payments. Insider Trading Policies and Procedures [Line Items] Tranche five Share-Based Payment Arrangement, Tranche Five [Member] Share-Based Payment Arrangement, Tranche Five Use of Estimates Use of Estimates, Policy [Policy Text Block] SUL-DUR SUL-DUR [Member] SUL-DUR Restricted Net Assets [Line Items] Restricted Net Assets [Line Items] Restricted net assets. Manufacturing equipment Manufacturing Equipment [Member] Manufacturing equipment. Adjustment to Compensation, Amount Adjustment to Compensation Amount Additional paid-in capital Additional Paid in Capital, Common Stock Compensation Amount Outstanding Recovery Compensation Amount Supplemental disclosure on non-cash investing and financing activities Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Geographical [Axis] Geographical [Axis] Payments of debt issuance costs Payments of Debt Issuance Costs Tabular List, Table Tabular List [Table Text Block] Commercial products Commercial Products, Intangible Asset [Member] Commercial Products, Intangible Asset Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Award Date [Axis] Award Date [Axis] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Antidilutive shares excluded from calculation of diluted loss per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Tranche one Share-Based Payment Arrangement, Tranche One [Member] Schedule of Product Revenue Schedule Of Gross And Net Revenue [Table Text Block] Schedule Of Gross And Net Revenue Credit Facility [Domain] Credit Facility [Domain] Zai Lab Shanghai Zai Lab (Shanghai) Co., Ltd. [Member] Zai Lab (Shanghai) Co., Ltd. Current assets Assets, Current [Abstract] Taxes paid related to settlement of equity awards Payment, Tax Withholding, Share-Based Payment Arrangement Other comprehensive income, net of tax of nil: Other Comprehensive Income (Loss), Net of Tax [Abstract] Inventories, Net Inventory Disclosure [Text Block] Treasury Stock (in shares) Beginning balance (in shares) Ending balance (in shares) Treasury Stock, Common, Shares Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service [Domain] Product and Service [Domain] Share options Share-Based Payment Arrangement, Option [Member] Long-term deposits Increase Decrease In Long Term Deposits Increase decrease in long term deposits. Depreciation expense Depreciation Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Gain on disposal of land use right Gain (Loss) On Disposal Of Land Use Rights Gain (Loss) On Disposal Of Land Use Rights Security Exchange Name Security Exchange Name Award Type [Axis] Award Type [Axis] Prepayments for equipment Prepayments For Equipment Prepayments for equipment. Work in progress Inventory, Work in Process, Net of Reserves Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Total liabilities Liabilities Schedule of Cash and Cash Equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Short-term debt Total short-term debt Short-Term Debt Ordinary shares, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Research and development Research and Development Expense Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Expiration Date Trading Arrangement Expiration Date Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Proceeds from sale of intellectual property Proceeds from Sale of Intangible Assets SPD Bank Shanghai Pudong Development Bank Co., Ltd. [Member] Shanghai Pudong Development Bank Co., Ltd. Other comprehensive income, tax Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent Current operating lease liabilities Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Ordinary shares, shares issued (in shares) Common Stock, Shares, Issued Product revenue - gross Revenue From Contract With Customers, Excluding Assessed Tax, Before Adjustments For Rebates And Sales Returns Amount of revenue from contract with customers excluding assessed tax, before adjustments for rebates and sales return. Entity [Domain] Entity [Domain] Restricted Net Assets [Table] Restricted Net Assets [Table] Restricted net assets . Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Hong Kong dollar (“HK$”) Hong Kong, Dollars Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Cash Cash Other Income, Net Other Nonoperating Income and Expense [Text Block] OPTUNE Optune [Member] Optune Property and equipment, gross Property, Plant and Equipment, Gross Value added tax recoverable Increase (Decrease) In Value Added Taxes Receivable Increase (Decrease) In Value Added Taxes Receivable Exercise of share options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Innoviva Inc. Innoviva Inc. [Member] Innoviva Inc. Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Research and development Research and Development Expense [Member] Ordinary shares, shares authorized (in shares) Common Stock, Shares Authorized Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Weighted-average shares used in calculating net loss per ordinary share - diluted (in shares) Weighted average number of ordinary shares - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Other Counterparties Other Counterparties [Member] Other Counterparties BMS BMS [Member] BMS Total shareholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Cash And Cash Equivalents [Line Items] Cash and Cash Equivalents [Line Items] Interest expense Interest Expense, Nonoperating Property and Equipment, Net Property, Plant and Equipment Disclosure [Text Block] Letters of credit outstanding Letters of Credit Outstanding, Amount Selling, general, and administrative Selling, General and Administrative Expense Entity Address, Country Entity Address, Country Accounts receivable (net of allowance for credit losses of $14 and $17 as of September 30, 2024 and December 31, 2023, respectively) Accounts Receivable, after Allowance for Credit Loss, Current Options granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross SPD Bank Working Capital Loans SPD Bank Working Capital Loan Facility [Member] SPD Bank Working Capital Loan Facility Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Payables for purchase of property and equipment Noncash or Part Noncash Acquisition, Fixed Assets Acquired Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus All Executive Categories All Executive Categories [Member] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Assets Assets [Abstract] Restricted cash, current Restricted Cash, Current Document Type Document Type Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Software Computer Software, Intangible Asset [Member] Payables for treasury stock Non Cash, Payables For Treasury Stock Non cash payables for treasury stock. Cash, cash equivalents and restricted cash - beginning of period Cash, cash equivalents and restricted cash - end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Other Income and Expenses [Abstract] Restricted Net Assets Restricted Assets Disclosure [Text Block] Maximum Maximum [Member] Amortization expense Amortization of Intangible Assets Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Net Carrying Value Finite-Lived Intangible Assets, Net Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accounts payable Accounts Payable, Current Renminbi (“RMB”) China, Yuan Renminbi Summary of significant accounting policies Accounting Policies [Abstract] Revenues Revenues [Abstract] Leasehold improvements Leasehold Improvements [Member] Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Short-term investments Short-Term Investments Statistical Measurement [Axis] Statistical Measurement [Axis] PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Loss before income tax Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Vesting [Axis] Vesting [Axis] Award Type [Domain] Award Type [Domain] Name Outstanding Recovery, Individual Name Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Summary of Anti-Dilutive Shares Excluded from Calculation of Diluted Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Non-PEO NEO Non-PEO NEO [Member] Amortization period Finite-Lived Intangible Asset, Useful Life Additional paid in capital Additional Paid-in Capital [Member] Award Timing Predetermined Award Timing Predetermined [Flag] Restricted cash, non-current Restricted Cash, Noncurrent Short-Term Debt [Line Items] Short-Term Debt [Line Items] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Loss per share - diluted (in dollars per share) Net loss per share - diluted (in dollars per share) Earnings Per Share, Diluted Class of Stock [Axis] Class of Stock [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Denominator: Weighted Average Number Of Share Outstanding Basic And Diluted [Abstract] Weighted average number of share outstanding basic and diluted. Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Vesting percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Foreign currency gains (losses) Gain (Loss), Foreign Currency Transaction, before Tax Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Foreign currency remeasurement impact Unrealized Gain (Loss), Foreign Currency Transaction, before Tax Consolidated balance sheets Statement of Financial Position [Abstract] PRC CHINA Share-based compensation Share-Based Payment Arrangement, Noncash Expense Tranche two Share-Based Payment Arrangement, Tranche Two [Member] Proceeds from the sale of property and equipment Proceeds from Sale of Property, Plant, and Equipment Income tax expense Provision for income taxes Income Tax Expense (Benefit) Supplemental disclosure of cash flow information Supplemental Cash Flow Information [Abstract] Equity investments with readily determinable fair value Equity Securities, FV-NI Recognized over a weighted-average period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Guarantor obligation term Guarantor Obligation, Term Guarantor Obligation, Term Product revenue, net Product revenue - net Product revenue - net Revenue from Contract with Customer, Excluding Assessed Tax Acquisition of intangible assets Payments to Acquire Intangible Assets Payables for acquisition of intangible assets Non Cash, Payables For Intangible Assets Non-cash payables for intangible assets. Other non-current liabilities Increase (Decrease) in Other Noncurrent Liabilities Notes receivable Increase (Decrease) in Notes Receivable, Current Consolidated statements of comprehensive loss Statement of Comprehensive Income [Abstract] Cash equivalents Cash Equivalents, at Carrying Value Inventory write-down Inventory Write-down Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Loss from operations Operating Income (Loss) Operating lease liabilities Increase Decrease In Operating Lease Liabilities Increase (decrease) in operating lease liabilities. Other Current Liabilities Other Current Liabilities Disclosure [Text Block] Other current liabilities disclosure. Total liabilities and shareholders’ equity Liabilities and Equity Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Accrued payroll Employee-related Liabilities, Current Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Prepayments and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Short-Term Debt, Type [Domain] Short-Term Debt, Type [Domain] Maximum guarantor obligation Guarantor Obligations, Maximum Exposure, Undiscounted Schedule of Other Income, Net Schedule of Other Nonoperating Income (Expense) [Table Text Block] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Legal Entity Legal Entity [Axis] Interest income Investment Income, Interest Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] NUZYRA Nuzyra [Member] Nuzyra. Right-of-use asset acquired under operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Underlying Security Market Price Change Underlying Security Market Price Change, Percent Maximum additional milestone payments Collaborative Arrangement, Rights and Obligations, Maximum Additional Milestone Payments The amount represents the additional milestone payments. Individual: Individual [Axis] Receipt of shares netted to satisfy tax withholding obligations related to share-based compensation Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Issuance of ordinary shares upon vesting of restricted shares Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Accumulated other comprehensive income (loss) AOCI Attributable to Parent [Member] Inventories, net Inventories, net Inventory, Net Product and Service [Axis] Product and Service [Axis] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] CMB China Merchants Bank Co., Ltd. [Member] China Merchants Bank Co., Ltd. Schedule of Property and Equipment, Net Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Vesting [Domain] Vesting [Domain] Liabilities and shareholders’ equity Liabilities and Equity [Abstract] License and Collaboration Agreements Licenses And Collaborative Arrangement Disclosure [Text Block] Licenses And Collaborative Arrangement Disclosure Inventory write-down Production Related Impairments or Charges Restricted amount by subsidiaries Amount of Restricted Net Assets for Consolidated and Unconsolidated Subsidiaries Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Unrecorded Unconditional Purchase Obligation [Table] Unrecorded Unconditional Purchase Obligation [Table] Schedule Of Property Plant And Equipment [Table] Property, Plant and Equipment [Table] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Allowance for credit losses Accounts Receivable, Credit Loss Expense (Reversal) Currency [Axis] Currency [Axis] Short-Term Debt, Type [Axis] Short-Term Debt, Type [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Property Plant And Equipment Property, Plant and Equipment [Abstract] Exercise Price Award Exercise Price American Depositary Shares ADR [Member] Loss Per Share Earnings Per Share [Text Block] Arrangement Duration Trading Arrangement Duration Exercise of share options Stock Issued During Period, Value, Stock Options Exercised Expenses Costs and Expenses [Abstract] Shareholders’ equity Equity, Attributable to Parent [Abstract] Long term investments Long-Term Investments Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Value added tax recoverable Value Added Tax Receivable, Noncurrent Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Debt instrument term Debt Instrument, Term All Individuals All Individuals [Member] PEO PEO [Member] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Name Trading Arrangement, Individual Name Other income, net Total Other Nonoperating Income (Expense) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Non-option awards granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Floating interest rate adjustment period Debt Instrument, Variable Interest Rate, Adjustment, Period Debt Instrument, Variable Interest Rate, Adjustment, Period Tranche four Share-Based Payment Arrangement, Tranche Four [Member] Share-Based Payment Arrangement, Tranche Four Unrecognized share-based compensation expense related to unvested restricted shares Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Treasury Stock (at cost, 4,912,200 shares as of both September 30, 2024 and December 31, 2023) Treasury Stock, Common, Value Prior to April 2023 Prior To April 2023 [Member] Prior To April 2023 Cost of collaboration revenue Other Cost of Operating Revenue Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Tranche three Share-Based Payment Arrangement, Tranche Three [Member] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Local Phone Number Local Phone Number Taiwan dollar (“TW$”) Taiwan, New Dollars Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Income Statement Location Statement of Income Location, Balance [Axis] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Debt Disclosure [Abstract] Ordinary Shares Common Stock [Member] Measure: Measure [Axis] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Entity Emerging Growth Company Entity Emerging Growth Company Other Other Sundry Liabilities, Current Receipt of shares netted to satisfy tax withholding obligations related to share-based compensation (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Entity Central Index Key Entity Central Index Key Since April 2023 April 2023 And Later [Member] April 2023 And Later Schedule of Inventories, Net Schedule of Inventory, Current [Table Text Block] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount US$ United States of America, Dollars Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component Equity Component [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Restricted shares Restricted Stock [Member] Entity Shell Company Entity Shell Company Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain] Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Title Trading Arrangement, Individual Title Standby Letters of Credit Standby Letters of Credit [Member] Statement [Table] Statement [Table] Regulatory milestone fees Regulatory Milestone Fees [Member] Regulatory Milestone Fees Counterparty Name [Axis] Counterparty Name [Axis] Basis of Presentation and Consolidation and Significant Accounting Policies Significant Accounting Policies [Text Block] Property and Equipment and Commercial Manufacturing Development Activities Property And Equipment And Commercial Manufacturing Development Activities [Member] Property And Equipment And Commercial Manufacturing Development Activities Unrecognized tax benefits Unrecognized Tax Benefits City Area Code City Area Code China Merchant Bank Working Capital Loans China Merchant Bank Working Capital Loan Facility [Member] China Merchant Bank Working Capital Loan Facility Current liabilities Liabilities, Current [Abstract] Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Purchases of short-term investments Payments to Acquire Short-Term Investments Level 1 Fair Value, Inputs, Level 1 [Member] Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Document Information [Line Items] Document Information [Line Items] Income Tax Income Tax Disclosure [Text Block] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Numerator: Net Income (Loss) Attributable to Parent [Abstract] Equity [Abstract] Land use rights, net Land Use Rights Net Noncurrent Land use rights, net noncurrent. Raw materials Inventory, Raw Materials, Net of Reserves Accumulated deficit Retained Earnings (Accumulated Deficit) Class of Stock [Domain] Class of Stock [Domain] Inventories Increase (Decrease) in Inventories Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Schedule of Short-Term Debt Schedule of Short-Term Debt [Table Text Block] Equity Awards Adjustments Equity Awards Adjustments [Member] Debt instrument fee Debt Instrument, Fee Amount Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Less: Rebates and sales returns Revenue From Contract With Customers, Excluding Assessed Tax, Adjustments For Rebates And Sales Returns Revenue From Contract With Customers, Excluding Assessed Tax, Adjustments For Rebates And Sales Returns Credit Facility [Axis] Credit Facility [Axis] ZEJULA Zejula [Member] Zejula Amendment Flag Amendment Flag Entity Registrant Name Entity Registrant Name Losses on disposal of property and equipment Gain (Loss) on Disposition of Property Plant Equipment Proceeds from disposal of land use right Proceeds From Disposal Of Land Use Rights Proceeds From Disposal Of Land Use Rights Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Depreciation and amortization expenses Depreciation, Depletion and Amortization Intangible Assets, Net Intangible Assets Disclosure [Text Block] Foreign currency translation adjustments Foreign currency translation Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Fair Value as of Grant Date Award Grant Date Fair Value QINLOCK Qinlock [Member] Qinlock Vehicle Vehicles [Member] Borrowings Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Geographical [Domain] Geographical [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Schedule of Disaggregation of Net Revenue Disaggregation of Revenue [Table Text Block] Proceeds from short-term debt Proceeds from Short-Term Debt Entity Address, Postal Zip Code Entity Address, Postal Zip Code Schedule of Share-Based Compensation expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Principles of Consolidation Consolidation, Policy [Policy Text Block] Amortization of deferred income Amortization Of Deferred Income Amortization of deferred income. Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Ordinary shares (par value of $0.000006 per share; 5,000,000,000 shares authorized; 989,268,370 and 977,151,270 shares issued as of September 30, 2024 and December 31, 2023, respectively; 984,356,170 and 972,239,070 shares outstanding as of September 30, 2024 and December 31, 2023, respectively) Common Stock, Value, Issued Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Government grants Government Assistance, Nonoperating Income, Increase (Decrease) Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Other current liabilities Increase (Decrease) in Other Current Liabilities Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Repotrectinib Repotrectinib [Member] Repotrectinib Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations All Currencies [Domain] All Currencies [Domain] Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Loss per share - basic (in dollars per share) Net loss per share - basic (in dollars per share) Earnings Per Share, Basic Schedule of Short-Term Debt [Table] Short-Term Debt [Table] Accounts payable Increase (Decrease) in Accounts Payable Long-term deposits Deposits Assets, Noncurrent Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Other Liabilities Disclosure [Abstract] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Unrecognized share-based compensation expense related to unvested share options granted Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Total assets Assets Cost of product revenue Cost of Goods and Services Sold Cash and cash equivalents Cash and Cash Equivalents [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Other non-current liabilities Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Commitments and contingencies (Note 16) Commitments and Contingencies Receivables for stock option exercise under equity incentive plans Receivables for Stock Option Exercise under Equity Incentive Plans Receivables for Stock Option Exercise under Equity Incentive Plans Termination Date Trading Arrangement Termination Date Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Repayment of short-term bank borrowings Repayments of Short-Term Debt Total revenues Revenues Share-Based Compensation Share-Based Payment Arrangement [Text Block] Laboratory equipment Laboratory Equipment [Member] Laboratory equipment. Entity Address, City or Town Entity Address, City or Town Debt Instrument [Axis] Debt Instrument [Axis] Proceeds from maturity of short-term investment Proceeds from Maturities, Prepayments and Calls of Short-Term Investments Share-based compensation expense Share-Based Payment Arrangement, Expense Net loss Net loss Net Income (Loss) Attributable to Parent Collaboration revenue Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer Trading Arrangement: Trading Arrangement [Axis] VYVGART vyvgart [Member] vyvgart Interest and penalties on unrecognized tax benefits Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Schedule of Components of Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Notes receivable Financing Receivable, Excluding Accrued Interest, after Allowance for Credit Loss, Current Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Purchase obligation to be incurred within one year Unrecorded Unconditional Purchase Obligation, Due in Next Rolling 12 Months Entity File Number Entity File Number Revenues Revenue from Contract with Customer [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Consolidated statements of operations Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Name Forgone Recovery, Individual Name Award Date [Domain] Award Date [Domain] Document Period End Date Document Period End Date Finished goods Inventory, Finished Goods, Net of Reserves Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Deferred income Increase (Decrease) in Deferred Revenue Bank of China Working Capital Loans Bank of China Working Capital Loan Facility [Member] Bank of China Working Capital Loan Facility Insider Trading Arrangements [Line Items] Cash and Cash Equivalents Cash and Cash Equivalents Disclosure [Text Block] Inventories Inventory Disclosure [Abstract] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Adjustment to Compensation: Adjustment to Compensation [Axis] Prepayments and other current assets Prepaid Expense and Other Assets, Current Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Commercial development costs Commercial Development Cost [Member] Commercial Development Cost Accumulated deficit Retained Earnings [Member] Debt issuance costs Amortization of Debt Issuance Costs Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Australian dollar (“A$”) Australia, Dollars Weighted-average shares used in calculating net loss per ordinary share - basic (in shares) Weighted average number of ordinary shares - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Document Information [Table] Document Information [Table] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Accrued professional service fee Accrued Professional Fees, Current Executive Category: Executive Category [Axis] Others miscellaneous gain Other Nonoperating Gains (Losses) Name Awards Close in Time to MNPI Disclosures, Individual Name Construction in progress Construction in Progress [Member] Entity Filer Category Entity Filer Category Schedule of Other Current Liabilities Other Current Liabilities [Table Text Block] Income Statement Location Statement of Income Location, Balance [Domain] Company Selected Measure Name Company Selected Measure Name EX-101.PRE 10 zlab-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 zlab-20240930_g1.jpg begin 644 zlab-20240930_g1.jpg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end XML 13 R1.htm IDEA: XBRL DOCUMENT v3.24.3
Cover Page - shares
 9 Months Ended
Sep. 30, 2024
Nov. 06, 2024
Document Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2024  
Document Transition Report false  
Entity File Number 001-38205  
Entity Registrant Name ZAI LAB LIMITED  
Entity Incorporation, State or Country Code E9  
Entity Tax Identification Number 98-1144595  
Entity Address, Address Line One 4560 Jinke Road  
Entity Address, Address Line Two Bldg. 1, Fourth Floor, Pudong  
Entity Address, City or Town Shanghai  
Entity Address, Country CN  
Entity Address, Postal Zip Code 201210  
City Area Code 86 21  
Local Phone Number 6163 2588  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Emerging Growth Company false  
Entity Small Business false  
Entity Shell Company false  
Entity Central Index Key 0001704292  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q3  
Amendment Flag false  
American Depositary Shares    
Document Information [Line Items]    
Title of 12(b) Security American Depositary Shares, each representing 10 Ordinary Shares, par value $0.000006 per share  
Trading Symbol ZLAB  
Security Exchange Name NASDAQ  
Entity Common Stock, Shares Outstanding   762,979,490
Ordinary Shares    
Document Information [Line Items]    
Title of 12(b) Security Ordinary Shares, par value $0.000006 per share  
Trading Symbol 9688  
Entity Common Stock, Shares Outstanding   996,087,670
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.24.3
Unaudited Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Current assets    
Cash and cash equivalents $ 616,086 $ 790,151
Restricted cash, current 100,000 0
Short-term investments 0 16,300
Accounts receivable (net of allowance for credit losses of $14 and $17 as of September 30, 2024 and December 31, 2023, respectively) 49,970 59,199
Notes receivable 19,278 6,134
Inventories, net 39,548 44,827
Prepayments and other current assets 35,667 22,995
Total current assets 860,549 939,606
Restricted cash, non-current 1,118 1,113
Long term investments 3,153 9,220
Prepayments for equipment 32 111
Property and equipment, net 50,765 53,734
Operating lease right-of-use assets 12,833 14,844
Land use rights, net 3,012 3,069
Intangible assets, net 51,669 13,389
Long-term deposits 975 1,209
Value added tax recoverable 1,240 0
Total assets 985,346 1,036,295
Current liabilities    
Accounts payable 120,652 112,991
Current operating lease liabilities 6,585 7,104
Short-term debt 112,994 0
Other current liabilities 46,084 82,972
Total current liabilities 286,315 203,067
Deferred income 24,924 28,738
Non-current operating lease liabilities 6,113 8,047
Other non-current liabilities 325 325
Total liabilities 317,677 240,177
Commitments and contingencies (Note 16)
Shareholders’ equity    
Ordinary shares (par value of $0.000006 per share; 5,000,000,000 shares authorized; 989,268,370 and 977,151,270 shares issued as of September 30, 2024 and December 31, 2023, respectively; 984,356,170 and 972,239,070 shares outstanding as of September 30, 2024 and December 31, 2023, respectively) 6 6
Additional paid-in capital 3,031,628 2,975,302
Accumulated deficit (2,371,399) (2,195,980)
Accumulated other comprehensive income 28,270 37,626
Treasury Stock (at cost, 4,912,200 shares as of both September 30, 2024 and December 31, 2023) (20,836) (20,836)
Total shareholders’ equity 667,669 796,118
Total liabilities and shareholders’ equity $ 985,346 $ 1,036,295
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.24.3
Unaudited Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Accounts receivable, allowance for credit losses $ 14 $ 17
Ordinary shares, par value (in dollars per share) $ 0.000006 $ 0.000006
Ordinary shares, shares authorized (in shares) 5,000,000,000 5,000,000,000
Ordinary shares, shares issued (in shares) 989,268,370 977,151,270
Ordinary shares, shares outstanding (in shares) 984,356,170 972,239,070
Treasury Stock (in shares) 4,912,200 4,912,200
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.3
Unaudited Condensed Consolidated Statements of Operations - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Revenues        
Product revenue, net $ 101,847,000 $ 69,228,000 $ 289,102,000 $ 200,889,000
Collaboration revenue 418,000 0 816,000 0
Total revenues 102,265,000 69,228,000 289,918,000 200,889,000
Expenses        
Cost of product revenue (36,569,000) (25,479,000) (105,336,000) (70,579,000)
Cost of collaboration revenue (348,000) 0 (433,000) 0
Research and development (65,982,000) (58,767,000) (182,252,000) (183,920,000)
Selling, general, and administrative (67,219,000) (68,552,000) (216,123,000) (198,982,000)
Gain on sale of intellectual property 0 0 0 10,000,000
Loss from operations (67,853,000) (83,570,000) (214,226,000) (242,592,000)
Interest income 9,029,000 9,172,000 28,017,000 29,493,000
Interest expense (745,000) 0 (1,350,000) 0
Foreign currency gains (losses) 14,457,000 4,852,000 8,281,000 (26,315,000)
Other income, net 3,441,000 394,000 3,859,000 223,000
Loss before income tax (41,671,000) (69,152,000) (175,419,000) (239,191,000)
Income tax expense 0 0 0 0
Net loss $ (41,671,000) $ (69,152,000) $ (175,419,000) $ (239,191,000)
Loss per share - basic (in dollars per share) $ (0.04) $ (0.07) $ (0.18) $ (0.25)
Loss per share - diluted (in dollars per share) $ (0.04) $ (0.07) $ (0.18) $ (0.25)
Weighted-average shares used in calculating net loss per ordinary share - basic (in shares) 981,687,390 968,767,730 976,941,030 965,060,570
Weighted-average shares used in calculating net loss per ordinary share - diluted (in shares) 981,687,390 968,767,730 976,941,030 965,060,570
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.24.3
Unaudited Condensed Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Statement of Comprehensive Income [Abstract]        
Net loss $ (41,671) $ (69,152) $ (175,419) $ (239,191)
Other comprehensive income, net of tax of nil:        
Foreign currency translation adjustments (14,503) (4,228) (9,356) 22,267
Comprehensive loss $ (56,174) $ (73,380) $ (184,775) $ (216,924)
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.24.3
Unaudited Condensed Consolidated Statements of Comprehensive Loss (Parenthetical) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Statement of Comprehensive Income [Abstract]        
Other comprehensive income, tax $ 0 $ 0 $ 0 $ 0
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.24.3
Unaudited Condensed Consolidated Statements of Shareholders' Equity - USD ($)
$ in Thousands
Total
Ordinary Shares
Additional paid in capital
Accumulated deficit
Accumulated other comprehensive income (loss)
Treasury Stock
Beginning balance (in shares) at Dec. 31, 2022   962,455,850        
Beginning balance at Dec. 31, 2022 $ 1,045,595 $ 6 $ 2,893,120 $ (1,861,360) $ 25,685 $ (11,856)
Beginning balance (in shares) at Dec. 31, 2022           (2,236,280)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of ordinary shares upon vesting of restricted shares (in shares)   732,040        
Issuance of ordinary shares upon vesting of restricted shares 0 $ 0 0      
Exercise of share options (in shares)   4,009,460        
Exercise of share options 1,673 $ 0 1,673      
Receipt of shares netted to satisfy tax withholding obligations related to share-based compensation (in shares)           (1,272,330)
Receipt of shares netted to satisfy tax withholding obligations related to share-based compensation (5,130)         $ (5,130)
Share-based compensation 16,661   16,661      
Net loss (49,144)     (49,144)    
Foreign currency translation (8,413)       (8,413)  
Ending balance (in shares) at Mar. 31, 2023   967,197,350        
Ending balance at Mar. 31, 2023 1,001,242 $ 6 2,911,454 (1,910,504) 17,272 $ (16,986)
Ending balance (in shares) at Mar. 31, 2023           (3,508,610)
Beginning balance (in shares) at Dec. 31, 2022   962,455,850        
Beginning balance at Dec. 31, 2022 1,045,595 $ 6 2,893,120 (1,861,360) 25,685 $ (11,856)
Beginning balance (in shares) at Dec. 31, 2022           (2,236,280)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss (239,191)          
Foreign currency translation 22,267          
Ending balance (in shares) at Sep. 30, 2023   973,930,280        
Ending balance at Sep. 30, 2023 880,979 $ 6 2,954,362 (2,100,551) 47,952 $ (20,790)
Ending balance (in shares) at Sep. 30, 2023           (4,893,130)
Beginning balance (in shares) at Mar. 31, 2023   967,197,350        
Beginning balance at Mar. 31, 2023 1,001,242 $ 6 2,911,454 (1,910,504) 17,272 $ (16,986)
Beginning balance (in shares) at Mar. 31, 2023           (3,508,610)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of ordinary shares upon vesting of restricted shares (in shares)   6,117,040        
Issuance of ordinary shares upon vesting of restricted shares 0 $ 0 0      
Exercise of share options (in shares)   41,000        
Exercise of share options 88 $ 0 88      
Receipt of shares netted to satisfy tax withholding obligations related to share-based compensation (in shares)           (1,280,500)
Receipt of shares netted to satisfy tax withholding obligations related to share-based compensation (3,540)         $ (3,540)
Share-based compensation 20,511   20,511      
Net loss (120,895)     (120,895)    
Foreign currency translation 34,908       34,908  
Ending balance (in shares) at Jun. 30, 2023   973,355,390        
Ending balance at Jun. 30, 2023 932,314 $ 6 2,932,053 (2,031,399) 52,180 $ (20,526)
Ending balance (in shares) at Jun. 30, 2023           (4,789,110)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of ordinary shares upon vesting of restricted shares (in shares)   394,890        
Issuance of ordinary shares upon vesting of restricted shares 0 $ 0 0      
Exercise of share options (in shares)   180,000        
Exercise of share options 317 $ 0 317      
Receipt of shares netted to satisfy tax withholding obligations related to share-based compensation (in shares)           (104,020)
Receipt of shares netted to satisfy tax withholding obligations related to share-based compensation (264)         $ (264)
Share-based compensation 21,992   21,992      
Net loss (69,152)     (69,152)    
Foreign currency translation (4,228)       (4,228)  
Ending balance (in shares) at Sep. 30, 2023   973,930,280        
Ending balance at Sep. 30, 2023 $ 880,979 $ 6 2,954,362 (2,100,551) 47,952 $ (20,790)
Ending balance (in shares) at Sep. 30, 2023           (4,893,130)
Beginning balance (in shares) at Dec. 31, 2023 972,239,070 977,151,270        
Beginning balance at Dec. 31, 2023 $ 796,118 $ 6 2,975,302 (2,195,980) 37,626 $ (20,836)
Beginning balance (in shares) at Dec. 31, 2023 (4,912,200)         (4,912,200)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of ordinary shares upon vesting of restricted shares (in shares)   1,046,440        
Issuance of ordinary shares upon vesting of restricted shares $ 0 $ 0 0      
Share-based compensation 17,980   17,980      
Net loss (53,471)     (53,471)    
Foreign currency translation 1,542       1,542  
Ending balance (in shares) at Mar. 31, 2024   978,197,710        
Ending balance at Mar. 31, 2024 $ 762,169 $ 6 2,993,282 (2,249,451) 39,168 $ (20,836)
Ending balance (in shares) at Mar. 31, 2024           (4,912,200)
Beginning balance (in shares) at Dec. 31, 2023 972,239,070 977,151,270        
Beginning balance at Dec. 31, 2023 $ 796,118 $ 6 2,975,302 (2,195,980) 37,626 $ (20,836)
Beginning balance (in shares) at Dec. 31, 2023 (4,912,200)         (4,912,200)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss $ (175,419)          
Foreign currency translation $ (9,356)          
Ending balance (in shares) at Sep. 30, 2024 984,356,170 989,268,370        
Ending balance at Sep. 30, 2024 $ 667,669 $ 6 3,031,628 (2,371,399) 28,270 $ (20,836)
Ending balance (in shares) at Sep. 30, 2024 (4,912,200)         (4,912,200)
Beginning balance (in shares) at Mar. 31, 2024   978,197,710        
Beginning balance at Mar. 31, 2024 $ 762,169 $ 6 2,993,282 (2,249,451) 39,168 $ (20,836)
Beginning balance (in shares) at Mar. 31, 2024           (4,912,200)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of ordinary shares upon vesting of restricted shares (in shares)   8,087,630        
Issuance of ordinary shares upon vesting of restricted shares 0 $ 0 0      
Exercise of share options (in shares)   25,000        
Exercise of share options 44 $ 0 44      
Share-based compensation 18,638   18,638      
Net loss (80,277)     (80,277)    
Foreign currency translation 3,605       3,605  
Ending balance (in shares) at Jun. 30, 2024   986,310,340        
Ending balance at Jun. 30, 2024 704,179 $ 6 3,011,964 (2,329,728) 42,773 $ (20,836)
Ending balance (in shares) at Jun. 30, 2024           (4,912,200)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of ordinary shares upon vesting of restricted shares (in shares)   393,850        
Issuance of ordinary shares upon vesting of restricted shares 0 $ 0 0      
Exercise of share options (in shares)   2,564,180        
Exercise of share options 2,869 $ 0 2,869      
Share-based compensation 16,795   16,795      
Net loss (41,671)     (41,671)    
Foreign currency translation $ (14,503)       (14,503)  
Ending balance (in shares) at Sep. 30, 2024 984,356,170 989,268,370        
Ending balance at Sep. 30, 2024 $ 667,669 $ 6 $ 3,031,628 $ (2,371,399) $ 28,270 $ (20,836)
Ending balance (in shares) at Sep. 30, 2024 (4,912,200)         (4,912,200)
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.24.3
Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Cash flows from operating activities    
Net loss $ (175,419) $ (239,191)
Adjustments to reconcile net loss to net cash used in operating activities:    
Allowance for credit losses (3) 1
Inventory write-down 814 746
Depreciation and amortization expenses 8,824 6,570
Amortization of deferred income (2,518) (2,547)
Share-based compensation 53,413 59,164
Loss from fair value changes of equity investment with readily determinable fair value 6,067 1,965
Losses on disposal of property and equipment 451 139
Gain on disposal of land use right 0 (408)
Noncash lease expenses 6,104 6,630
Gain on sale of intellectual property 0 (10,000)
Debt issuance costs 700 0
Foreign currency remeasurement impact (8,281) 26,315
Changes in operating assets and liabilities:    
Accounts receivable 9,712 (2,823)
Notes receivable (12,901) (15,563)
Inventories 4,403 (14,408)
Prepayments and other current assets (10,767) 5,126
Long-term deposits 234 140
Value added tax recoverable (1,223) 0
Accounts payable 6,545 (9,494)
Other current liabilities (36,854) 227
Operating lease liabilities (6,853) (5,794)
Deferred income (1,548) 9,619
Other non-current liabilities 0 325
Net cash used in operating activities (159,100) (183,261)
Cash flows from investing activities    
Purchases of short-term investments 0 (134,000)
Proceeds from maturity of short-term investment 16,300 102,400
Purchases of property and equipment (3,057) (6,990)
Proceeds from the sale of property and equipment 29 122
Acquisition of intangible assets (40,711) (658)
Proceeds from sale of intellectual property 0 10,000
Proceeds from disposal of land use right 0 3,893
Net cash used in investing activities (27,439) (25,233)
Cash flows from financing activities    
Proceeds from short-term debt 111,738 0
Repayment of short-term bank borrowings (282) 0
Payments of debt issuance costs (700) 0
Proceeds from exercises of stock options 1,321 1,899
Taxes paid related to settlement of equity awards 0 (8,725)
Net cash provided by (used in) financing activities 112,077 (6,826)
Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash 402 (3,355)
Net decrease in cash, cash equivalents and restricted cash (74,060) (218,675)
Cash, cash equivalents and restricted cash - beginning of period 791,264 1,009,273
Cash, cash equivalents and restricted cash - end of period 717,204 790,598
Supplemental disclosure on non-cash investing and financing activities    
Payables for purchase of property and equipment 2,612 2,625
Payables for acquisition of intangible assets 11,358 98
Payables for treasury stock 0 31
Right-of-use asset acquired under operating leases 3,945 3,296
Receivables for stock option exercise under equity incentive plans 1,593 0
Supplemental disclosure of cash flow information    
Cash paid for interest $ 1,169 $ 0
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.24.3
Organization and Principal Activities
 9 Months Ended
Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Principal Activities Organization and Principal Activities
Zai Lab Limited was incorporated on March 28, 2013 in the Cayman Islands as an exempted company with limited liability under the Companies Act of the Cayman Islands (as amended). Zai Lab Limited and its subsidiaries (collectively referred to as the “Company”) are focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease.
The Company’s principal operations and geographic markets are in Greater China. The Company has a substantial presence in Greater China and the United States.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.24.3
Basis of Presentation and Consolidation and Significant Accounting Policies
 9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Basis of Presentation and Consolidation and Significant Accounting Policies Basis of Presentation and Consolidation and Significant Accounting Policies
(a) Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), and applicable rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”), regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Annual Report”). The December 31, 2023 condensed consolidated balance sheet data included in this report were derived from the audited financial statements in the 2023 Annual Report.
The accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments that are necessary to present fairly the results for the interim periods presented. Interim results are not necessarily indicative of the results for the year ending December 31, 2024.
(b) Principles of Consolidation
The unaudited condensed consolidated financial statements include the accounts of Zai Lab Limited and its subsidiaries, which are wholly owned. All intercompany transactions and balances are eliminated upon consolidation.
(c) Use of Estimates
The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Areas where management uses subjective judgment include, but are not limited to, accrual of rebates, recognition of research and development expenses, fair value of share-based compensation expenses, and recoverability of deferred tax assets. These estimates, judgments, and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. Actual results could differ from these estimates.
(d) Fair Value Measurements
Equity investments with readily determinable fair value are measured using level 1 inputs and were $3.2 million and $9.2 million as of September 30, 2024 and December 31, 2023, respectively. The unrealized losses from fair value changes are recognized in other income, net in the unaudited condensed consolidated statements of operations.
Financial instruments of the Company primarily include cash and cash equivalents, current restricted cash, short-term investments, accounts receivable, notes receivable, prepayments and other current assets, non-current restricted cash,
accounts payable, short-term debt, and other current liabilities. As of September 30, 2024 and December 31, 2023, the carrying values of cash and cash equivalents, current restricted cash, short-term investments, accounts receivable, prepayments and other current assets, accounts payable, short-term debt, and other current liabilities approximated their fair value due to the short-term maturity of these instruments, and the carrying value of notes receivable and non-current restricted cash approximated their fair value based on the assessment of the ability to recover these amounts.
(e) Recent Accounting Pronouncements
In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures (Topic 280). This ASU requires all public entities, including public entities with a single reportable segment, to disclose the title and position of the Chief Operating Decision Maker (“CODM”) and the significant segment expenses and any additional measures of a segment’s profit or loss used by the CODM to allocate resources and assess performance. This ASU is effective on a retrospective basis for fiscal years beginning after December 15, 2023 and for interim periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this ASU and expects to adopt it for the year ending December 31, 2024.
In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (Topic 740). This ASU requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as additional information on income taxes paid. This ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted. This ASU will result in additional disclosure in the consolidated financial statements, once adopted. The Company is currently evaluating the impact of this ASU and expects to adopt it for the year ending December 31, 2025.
The Company did not adopt any new accounting standards in the nine months ended September 30, 2024 that had a material impact on the consolidated financial statements. For additional information on the Company’s significant accounting policies, refer to the notes to the consolidated financial statements in the 2023 Annual Report.
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.24.3
Cash and Cash Equivalents
 9 Months Ended
Sep. 30, 2024
Cash and Cash Equivalents [Abstract]  
Cash and Cash Equivalents Cash and Cash Equivalents
The following table presents the Company’s cash and cash equivalents ($ in thousands):
September 30, 2024December 31, 2023
Cash 614,937 789,051 
Cash equivalents (i)1,149 1,100 
 616,086 790,151 
Denominated in:  
US$575,116 762,436 
Renminbi (“RMB”) (ii)40,092 25,093 
Hong Kong dollar (“HK$”)53 1,974 
Australian dollar (“A$”)580 587 
Taiwan dollar (“TW$”)245 61 
616,086 790,151 
(i)Cash equivalents represent short-term and highly liquid investments in a money market fund.
(ii)Certain cash and bank balances denominated in RMB were deposited with banks in mainland China. The conversion of these RMB-denominated balances into foreign currencies is subject to the rules and regulations of foreign exchange control promulgated by the Chinese government.
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.24.3
Inventories, Net
 9 Months Ended
Sep. 30, 2024
Inventory Disclosure [Abstract]  
Inventories, Net Inventories, Net
The following table presents the Company’s inventories, net ($ in thousands):
September 30, 2024December 31, 2023
Finished goods22,460 22,702 
Raw materials15,397 17,655 
Work in progress1,691 4,470 
Inventories, net39,548 44,827 
The Company writes down inventory for any excess or obsolete inventories or when the Company believes that the net realizable value of inventories is less than the carrying value. The Company recorded write-downs in inventory, which were included in cost of product revenue, of an insignificant amount and $0.8 million in the three and nine months ended September 30, 2024, respectively, and $0.1 million and $0.7 million in the three and nine months ended September 30, 2023, respectively.
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.24.3
Property and Equipment, Net
 9 Months Ended
Sep. 30, 2024
Property, Plant and Equipment [Abstract]  
Property and Equipment, Net Property and Equipment, Net
The following table presents the components of the Company’s property and equipment, net ($ in thousands):
September 30, 2024December 31, 2023
Office equipment1,059 1,047 
Electronic equipment9,527 9,161 
Vehicle201 199 
Laboratory equipment20,793 20,140 
Manufacturing equipment17,944 17,680 
Leasehold improvements11,544 11,371 
Construction in progress26,050 24,272 
87,118 83,870 
Less: accumulated depreciation(36,353)(30,136)
Property and equipment, net50,765 53,734 
Depreciation expense was $2.1 million and $6.6 million in the three and nine months ended September 30, 2024, respectively, and $1.8 million and $6.1 million in the three and nine months ended September 30, 2023, respectively.
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.24.3
Intangible Assets, Net
 9 Months Ended
Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets, Net Intangible Assets, Net
The following table presents the components of the Company’s intangible assets, net ($ in thousands):
September 30, 2024December 31, 2023
Gross Carrying AmountAccumulated AmortizationNet Carrying ValueGross Carrying AmountAccumulated AmortizationNet Carrying Value
Finite-lived intangible assets
Commercial products (i)52,050 (1,881)50,169 11,351 (186)11,165 
Software4,215 (2,715)1,500 4,340 (2,116)2,224 
Total56,265 (4,596)51,669 15,691 (2,302)13,389 
(i) The increase in the net carrying value is primarily driven by $33.0 million of regulatory milestone fees for repotrectinib and SUL-DUR (see Note 13) and $6.0 million of commercial development costs.
Intangible assets for commercial products include capitalized post-approval milestone fees and commercial manufacturing development costs. The Company is amortizing commercial products as cost of product revenue over the estimated remaining useful life of the related products. Externally purchased software is amortized over three to five years on a straight-line basis.
Amortization expense was $0.7 million and $2.3 million in the three and nine months ended September 30, 2024, respectively, and $0.2 million and $0.5 million in the three and nine months ended September 30, 2023, respectively.
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.24.3
Revenues
 9 Months Ended
Sep. 30, 2024
Revenue from Contract with Customer [Abstract]  
Revenues Revenues
Product Revenue, Net
The Company’s product revenue is derived from the sales of its commercial products primarily in mainland China. The table below presents the Company’s gross and net product revenue ($ in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Product revenue - gross107,678 74,018 307,401 220,240 
Less: Rebates and sales returns(5,831)(4,790)(18,299)(19,351)
Product revenue - net101,847 69,228 289,102 200,889 
Sales rebates are offered to distributors in mainland China, and the amounts are recorded as a reduction of product revenue. Estimated rebates are determined based on contracted rates, sales volumes, and level of distributor inventories.
The following table presents the Company’s net revenue by product ($ in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
ZEJULA48,227 41,593 138,727 127,230 
OPTUNE7,715 11,562 32,779 38,596 
QINLOCK8,643 5,702 21,774 14,535 
NUZYRA9,997 5,483 32,205 15,588 
VYVGART 27,265 4,888 63,617 4,940 
Product revenue - net101,847 69,228 289,102 200,889 
Collaboration Revenue
Collaboration revenue was $0.4 million and $0.8 million in the three and nine months ended September 30, 2024, respectively, and related to promotional activities in mainland China. We had no such collaboration revenue in the prior year periods.
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.24.3
Income Tax
 9 Months Ended
Sep. 30, 2024
Income Tax Disclosure [Abstract]  
Income Tax Income Tax
No provision for income taxes has been required to be accrued because the Company is in a cumulative loss position for the periods presented.
The Company recorded a full valuation allowance against deferred tax assets of all its consolidated entities because all entities were in a cumulative loss position as of September 30, 2024 and December 31, 2023. No unrecognized tax benefits and related interest and penalties were recorded in the periods presented.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.24.3
Loss Per Share
 9 Months Ended
Sep. 30, 2024
Earnings Per Share [Abstract]  
Loss Per Share Loss Per Share
The following table presents the computation of the basic and diluted net loss per share ($ in thousands, except share and per share data):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Numerator:
Net loss (41,671)(69,152)(175,419)(239,191)
Denominator:
Weighted average number of ordinary shares - basic and diluted981,687,390 968,767,730 976,941,030 965,060,570 
Net loss per share - basic and diluted(0.04)(0.07)(0.18)(0.25)
As a result of the Company’s net loss in the three and nine months ended September 30, 2024 and 2023, share options and non-vested restricted shares outstanding in the respective periods were excluded from the calculation of diluted loss per share as their inclusion would have been anti-dilutive.
September 30,
20242023
Share options105,188,950 107,249,960 
Non-vested restricted shares32,875,090 32,359,260 
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.24.3
Borrowings
 9 Months Ended
Sep. 30, 2024
Debt Disclosure [Abstract]  
Borrowings Borrowings
The Company has debt arrangements with the Bank of China, SPD Bank, CMB, and Ningbo Bank to support its working capital needs in mainland China. The following table presents the Company’s short-term debt as of September 30, 2024 ($ in thousands):
Weighted average
interest rate per annum		September 30, 2024
Bank of China Working Capital Loans2.86 %70,925 
SPD Bank Working Capital Loans3.45 %14,271 
China Merchant Bank Working Capital Loans3.15 %27,798 
Total short-term debt3.01 %112,994 
Bank of China Working Capital Loan Facility
On February 5, 2024, the Company entered into an uncommitted facility letter with the Bank of China (Hong Kong) Limited (the “BOC HK”) pursuant to which the BOC HK will provide standby letters of credit for loans of up to $100.0 million for a term of one year. In connection with this agreement, the Company paid a one-time, non-refundable fee of $0.7 million in the first quarter of 2024. In accordance with this agreement, the Company also maintained restricted deposits of $100.0 million, which are presented as restricted cash-current on the unaudited condensed consolidated balance sheet, to secure the standby letters of credit. On February 6, 2024 and June 20, 2024, upon the Company’s application, the BOC HK provided standby letters of credit in favor of the Bank of China Pudong Development Zone Branch (the “BOC Pudong Branch”) for $50.0 million and $23.0 million, respectively, which are or may become payable by the Company’s wholly-owned subsidiary, Zai Lab (Shanghai) Co., Ltd. (“Zai Lab Shanghai”). Zai Lab Shanghai entered into working capital loans with the BOC Pudong Branch under this facility in the first half of 2024, and the aggregate principal amount outstanding was RMB497.0 million (approximately $70.9 million) as of September 30, 2024. Each working capital loan has a one-year term and is subject to a floating interest rate, which is subject to adjustment every six months.
SPD Bank Working Capital Loan Facility
On February 6, 2024, the Company entered into a maximum-amount guarantee contract with the Shanghai Pudong Development Bank Co., Ltd. Zhangjiang Hi-Tech Park Sub-branch (the “SPD Bank”) pursuant to which the Company will guarantee working capital loans of up to RMB300.0 million (approximately $42.0 million) from SPD Bank to Zai Lab Shanghai over a three-year period. Zai Lab Shanghai entered into working capital loan contracts with SPD Bank under this debt facility in the first quarter of 2024, and the aggregate principal amount outstanding was RMB100.0 million (approximately $14.3 million) as of September 30, 2024. Each working capital loan has a one-year term and is subject to a fixed interest rate.
Ningbo Bank Working Capital Loan Facility
On February 6, 2024, the Company’s wholly-owned subsidiary, Zai Lab (Suzhou) Co., Ltd. (“Zai Lab Suzhou”), entered into a maximum credit contract with Bank of Ningbo Co., Ltd. Suzhou Sub-branch (“Ningbo Bank”) as well as an Electronic Commercial Draft Discounting Master Agreement and Online Working Capital Loan Master Agreement (collectively, the “Ningbo Bank Agreements”). The Ningbo Bank Agreements permit Zai Lab Suzhou to utilize, including through discounting or working capital loan agreements and subject to the terms and conditions in related master agreements, up to RMB230.3 million (approximately $32.4 million), of which the Company is authorized to utilize up to RMB160.0 million (approximately $22.5 million). In connection with the arrangements described in the Ningbo Bank Agreements, Zai Lab Suzhou agreed to pledge interests in certain real property it owns in Suzhou. As of September 30, 2024, Zai Lab Suzhou has not entered into any discounting arrangements or working capital loans under this Ningbo Bank working capital loan facility.
China Merchants Bank Working Capital Loan Facility
On July 5, 2024, the Company issued a maximum-amount irrevocable letter of guarantee to China Merchants Bank Co., Ltd., Shanghai Branch (“CMB”) pursuant to which the Company will guarantee working capital loans of up to RMB250.0 million (approximately $34.4 million) from CMB to the Company’s wholly-owned subsidiary, Zai Lab Shanghai, and Zai Lab Shanghai entered into a Credit Agreement with CMB with respect to the RMB250.0 million facility. The credit facility will be available for one year. As of September 30, 2024, Zai Lab Shanghai has an aggregate principal amount outstanding of RMB194.8 million (approximately $27.8 million) under this debt facility. Each working capital loan has a one-year term and is subject to a floating interest rate, which is subject to adjustment every three months.
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.24.3
Other Current Liabilities
 9 Months Ended
Sep. 30, 2024
Other Liabilities Disclosure [Abstract]  
Other Current Liabilities Other Current Liabilities
The following table presents the Company’s other current liabilities ($ in thousands):
September 30, 2024December 31, 2023
Accrued payroll24,077 33,711 
Accrued professional service fee3,986 7,520 
Payables for purchase of property and equipment2,612 2,474 
Accrued rebate to distributors8,800 16,926 
Tax payables3,756 16,988 
Other (i)2,853 5,353 
Total46,084 82,972 
(i)Other primarily includes accrued travel and business-related expenses.
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.24.3
Share-Based Compensation
 9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Share-Based Compensation Share-Based Compensation
During the nine months ended September 30, 2024, the Company granted share options to purchase up to 20,747,480 ordinary shares and restricted shares representing 17,293,410 ordinary shares under its equity incentive plans. The share options granted have a contractual term of ten years. Share options granted since April 2023 generally vest ratably over a four-year period, and share options granted prior to April 2023 generally vest ratably over a five-year period, with 25% or 20% of the awards vesting on each anniversary of the grant date, respectively, subject to continued employment/service with the Company on the vesting date. The restricted shares granted generally vest ratably over a specified period on the anniversary of the grant date, subject to continued employment/service with the Company on the vesting date. For a description of the Company’s equity incentive plans and more details on the terms of the share-based awards, see Note 15 of the 2023 Annual Report.
The following table presents the share-based compensation expense that has been reported in the Company’s unaudited condensed consolidated statements of operations and comprehensive loss as follows ($ in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Selling, general and administrative10,404 14,041 31,861 35,880 
Research and development6,391 7,951 21,552 23,284 
Total16,795 21,992 53,413 59,164 
As of September 30, 2024, there was unrecognized share-based compensation expense related to unvested share options and unvested restricted shares of $80.4 million and $83.3 million, respectively, which the Company expects to recognize over a weighted-average period of 2.83 years and 2.68 years, respectively.
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.24.3
License and Collaboration Agreements
 9 Months Ended
Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
License and Collaboration Agreements License and Collaboration Agreements
The Company has entered into various license and collaboration agreements with third parties to develop and commercialize product candidates.
Significant License and Collaboration Arrangements
For a description of the material terms of the Company’s significant license and collaboration agreements, see Note 16 of the 2023 Annual Report. During the nine months ended September 30, 2024, the Company did not enter into any new significant license or collaboration agreements. The following includes a description of milestone fees incurred in the nine months ended September 30, 2024 under the Company’s significant license and collaboration agreements.
License and Collaboration Agreement with Innoviva (SUL-DUR)
Under the terms of the Company’s license and collaboration agreement with Entasis Therapeutics Holdings Inc., a wholly owned subsidiary of Innoviva, Inc. (“Innoviva”), the Company recorded an $8.0 million regulatory milestone in the second quarter of 2024, which was capitalized as an intangible asset. As of September 30, 2024, the Company may be required to pay an additional aggregate amount of up to $80.6 million in development, regulatory, and sales-based milestones as well as certain royalties at tiered percentage rates ranging from high single digits to low-teens on annual net sales of the licensed products in the licensed territory.
License Agreement with BMS (Repotrectinib)
Under the terms of the Company’s license agreement with Turning Point Therapeutics, Inc., a company later acquired by Bristol Myers Squibb (“BMS”), the Company recorded $25.0 million for regulatory milestones in the second
quarter of 2024, which was capitalized as an intangible asset. As of September 30, 2024, the Company may be required to pay an additional aggregate amount of up to $116.0 million in development, regulatory, and sales-based milestones as well as certain royalties at tiered percentage rates ranging from mid- to high-teens on annual net sales of the licensed products in the licensed territory.
License Agreement with BMS (Xanomeline and Trospium Chloride)
Under the terms of the Company’s license agreement with Karuna Therapeutics, Inc. (a company later acquired by BMS), the Company recorded a $10.0 million development milestone into research and development expenses in the third quarter of 2024. As of September 30, 2024, the Company may be required to pay an additional aggregate amount of up to $132.0 million in development, regulatory, and sales-based milestones as well as certain royalties at tiered percentage rates ranging from low- to high-teens on annual net sales of the licensed products in Greater China.
Other License and Collaboration Arrangements That Are Not Individually Significant
The Company recorded an upfront payment of $12.0 million into research and development expenses in the third quarter of 2024 for a license and collaboration agreement that is not individually significant.
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.24.3
Other Income, Net
 9 Months Ended
Sep. 30, 2024
Other Income and Expenses [Abstract]  
Other Income, Net Other Income, Net
The following table presents the Company’s other income, net ($ in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Government grants3,861 671 7,186 754 
Loss on equity investments with readily determinable fair value(920)(661)(6,067)(1,965)
Others miscellaneous gain500 384 2,740 1,434 
Total3,441 394 3,859 223 
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.24.3
Restricted Net Assets
 9 Months Ended
Sep. 30, 2024
Equity [Abstract]  
Restricted Net Assets Restricted Net Assets
The Company’s ability to pay dividends may depend on the Company receiving distributions of funds from its Chinese subsidiaries. Relevant Chinese laws and regulations permit payments of dividends by the Company’s Chinese subsidiaries only out of its retained earnings, if any, as determined in accordance with Chinese accounting standards and regulations. The results of operations reflected in the unaudited condensed consolidated financial statements prepared in accordance with U.S. GAAP differ from those reflected in the statutory financial statements of the Company’s Chinese subsidiaries.
In accordance with the Company Law of the People’s Republic of China, a domestic enterprise is required to provide statutory reserves of at least 10% of its annual after-tax profit until such reserve has reached 50% of its respective registered capital based on the enterprise’s Chinese statutory accounts. A domestic enterprise may provide discretionary surplus reserve, at the discretion of the Board of Directors, from the profits determined in accordance with the enterprise’s Chinese statutory accounts. The aforementioned reserves can only be used for specific purposes and are not distributable as cash dividends. The Company’s Chinese subsidiaries were established as domestic enterprises and therefore are subject to the above-mentioned restrictions on distributable profits.
No appropriation to statutory reserves was made in the three and nine months ended September 30, 2024 and 2023 because the Chinese subsidiaries had substantial losses during such periods.
As a result of these Chinese laws and regulations, subject to the limits discussed above that require annual appropriations of 10% of after-tax profit to be set aside, prior to payment of dividends, as a general reserve fund, the Company’s Chinese subsidiaries are restricted in their ability to transfer out a portion of their net assets.
Foreign exchange and other regulation in mainland China may further restrict the Company’s subsidiaries in mainland China from transferring out funds in the form of dividends, loans, and advances. As of September 30, 2024 and December 31, 2023, amounts restricted included the paid-in capital of the Company’s subsidiaries in mainland China and were $506.0 million.
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.24.3
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
(a) Purchase Commitments
As of September 30, 2024, the Company’s commitments related to purchase of property and equipment and the commercial manufacturing development activities that are contracted but not yet reflected in the unaudited condensed consolidated financial statements were $8.6 million and were expected to be incurred within one year.
(b) Legal Proceedings
The Company is not currently a party to any material legal proceedings.
(c) Indemnifications
In the normal course of business, the Company enters into agreements that indemnify others for certain liabilities that may arise in connection with a transaction or certain events and activities. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations.
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.24.3
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2024
Sep. 30, 2023
Pay vs Performance Disclosure                
Net loss $ (41,671) $ (80,277) $ (53,471) $ (69,152) $ (120,895) $ (49,144) $ (175,419) $ (239,191)
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.24.3
Insider Trading Arrangements
 3 Months Ended
Sep. 30, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.24.3
Basis of Presentation and Consolidation and Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Basis of Presentation Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), and applicable rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”), regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Annual Report”). The December 31, 2023 condensed consolidated balance sheet data included in this report were derived from the audited financial statements in the 2023 Annual Report.
The accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments that are necessary to present fairly the results for the interim periods presented. Interim results are not necessarily indicative of the results for the year ending December 31, 2024.
Principles of Consolidation Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of Zai Lab Limited and its subsidiaries, which are wholly owned. All intercompany transactions and balances are eliminated upon consolidation.
Use of Estimates Use of Estimates The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Areas where management uses subjective judgment include, but are not limited to, accrual of rebates, recognition of research and development expenses, fair value of share-based compensation expenses, and recoverability of deferred tax assets. These estimates, judgments, and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. Actual results could differ from these estimates.
Fair Value Measurements Fair Value Measurements
Equity investments with readily determinable fair value are measured using level 1 inputs and were $3.2 million and $9.2 million as of September 30, 2024 and December 31, 2023, respectively. The unrealized losses from fair value changes are recognized in other income, net in the unaudited condensed consolidated statements of operations.
Financial instruments of the Company primarily include cash and cash equivalents, current restricted cash, short-term investments, accounts receivable, notes receivable, prepayments and other current assets, non-current restricted cash,
accounts payable, short-term debt, and other current liabilities. As of September 30, 2024 and December 31, 2023, the carrying values of cash and cash equivalents, current restricted cash, short-term investments, accounts receivable, prepayments and other current assets, accounts payable, short-term debt, and other current liabilities approximated their fair value due to the short-term maturity of these instruments, and the carrying value of notes receivable and non-current restricted cash approximated their fair value based on the assessment of the ability to recover these amounts.
Recent Accounting Pronouncements Recent Accounting Pronouncements
In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures (Topic 280). This ASU requires all public entities, including public entities with a single reportable segment, to disclose the title and position of the Chief Operating Decision Maker (“CODM”) and the significant segment expenses and any additional measures of a segment’s profit or loss used by the CODM to allocate resources and assess performance. This ASU is effective on a retrospective basis for fiscal years beginning after December 15, 2023 and for interim periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this ASU and expects to adopt it for the year ending December 31, 2024.
In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (Topic 740). This ASU requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as additional information on income taxes paid. This ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted. This ASU will result in additional disclosure in the consolidated financial statements, once adopted. The Company is currently evaluating the impact of this ASU and expects to adopt it for the year ending December 31, 2025.
The Company did not adopt any new accounting standards in the nine months ended September 30, 2024 that had a material impact on the consolidated financial statements. For additional information on the Company’s significant accounting policies, refer to the notes to the consolidated financial statements in the 2023 Annual Report.
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.24.3
Cash and Cash Equivalents (Tables)
 9 Months Ended
Sep. 30, 2024
Cash and Cash Equivalents [Abstract]  
Schedule of Cash and Cash Equivalents
The following table presents the Company’s cash and cash equivalents ($ in thousands):
September 30, 2024December 31, 2023
Cash 614,937 789,051 
Cash equivalents (i)1,149 1,100 
 616,086 790,151 
Denominated in:  
US$575,116 762,436 
Renminbi (“RMB”) (ii)40,092 25,093 
Hong Kong dollar (“HK$”)53 1,974 
Australian dollar (“A$”)580 587 
Taiwan dollar (“TW$”)245 61 
616,086 790,151 
(i)Cash equivalents represent short-term and highly liquid investments in a money market fund.
(ii)Certain cash and bank balances denominated in RMB were deposited with banks in mainland China. The conversion of these RMB-denominated balances into foreign currencies is subject to the rules and regulations of foreign exchange control promulgated by the Chinese government.
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.24.3
Inventories, Net (Tables)
 9 Months Ended
Sep. 30, 2024
Inventory Disclosure [Abstract]  
Schedule of Inventories, Net
The following table presents the Company’s inventories, net ($ in thousands):
September 30, 2024December 31, 2023
Finished goods22,460 22,702 
Raw materials15,397 17,655 
Work in progress1,691 4,470 
Inventories, net39,548 44,827 
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.24.3
Property and Equipment, Net (Tables)
 9 Months Ended
Sep. 30, 2024
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment, Net
The following table presents the components of the Company’s property and equipment, net ($ in thousands):
September 30, 2024December 31, 2023
Office equipment1,059 1,047 
Electronic equipment9,527 9,161 
Vehicle201 199 
Laboratory equipment20,793 20,140 
Manufacturing equipment17,944 17,680 
Leasehold improvements11,544 11,371 
Construction in progress26,050 24,272 
87,118 83,870 
Less: accumulated depreciation(36,353)(30,136)
Property and equipment, net50,765 53,734 
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.24.3
Intangible Assets, Net (Tables)
 9 Months Ended
Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Components of Intangible Assets
The following table presents the components of the Company’s intangible assets, net ($ in thousands):
September 30, 2024December 31, 2023
Gross Carrying AmountAccumulated AmortizationNet Carrying ValueGross Carrying AmountAccumulated AmortizationNet Carrying Value
Finite-lived intangible assets
Commercial products (i)52,050 (1,881)50,169 11,351 (186)11,165 
Software4,215 (2,715)1,500 4,340 (2,116)2,224 
Total56,265 (4,596)51,669 15,691 (2,302)13,389 
(i) The increase in the net carrying value is primarily driven by $33.0 million of regulatory milestone fees for repotrectinib and SUL-DUR (see Note 13) and $6.0 million of commercial development costs.
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.24.3
Revenues (Tables)
 9 Months Ended
Sep. 30, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of Product Revenue The table below presents the Company’s gross and net product revenue ($ in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Product revenue - gross107,678 74,018 307,401 220,240 
Less: Rebates and sales returns(5,831)(4,790)(18,299)(19,351)
Product revenue - net101,847 69,228 289,102 200,889 
Schedule of Disaggregation of Net Revenue
The following table presents the Company’s net revenue by product ($ in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
ZEJULA48,227 41,593 138,727 127,230 
OPTUNE7,715 11,562 32,779 38,596 
QINLOCK8,643 5,702 21,774 14,535 
NUZYRA9,997 5,483 32,205 15,588 
VYVGART 27,265 4,888 63,617 4,940 
Product revenue - net101,847 69,228 289,102 200,889 
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.24.3
Loss Per Share (Tables)
 9 Months Ended
Sep. 30, 2024
Earnings Per Share [Abstract]  
Summary of Basic and Diluted Net Loss Per Share
The following table presents the computation of the basic and diluted net loss per share ($ in thousands, except share and per share data):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Numerator:
Net loss (41,671)(69,152)(175,419)(239,191)
Denominator:
Weighted average number of ordinary shares - basic and diluted981,687,390 968,767,730 976,941,030 965,060,570 
Net loss per share - basic and diluted(0.04)(0.07)(0.18)(0.25)
Summary of Anti-Dilutive Shares Excluded from Calculation of Diluted Loss Per Share
As a result of the Company’s net loss in the three and nine months ended September 30, 2024 and 2023, share options and non-vested restricted shares outstanding in the respective periods were excluded from the calculation of diluted loss per share as their inclusion would have been anti-dilutive.
September 30,
20242023
Share options105,188,950 107,249,960 
Non-vested restricted shares32,875,090 32,359,260 
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.24.3
Borrowings (Tables)
 9 Months Ended
Sep. 30, 2024
Debt Disclosure [Abstract]  
Schedule of Short-Term Debt The following table presents the Company’s short-term debt as of September 30, 2024 ($ in thousands):
Weighted average
interest rate per annum		September 30, 2024
Bank of China Working Capital Loans2.86 %70,925 
SPD Bank Working Capital Loans3.45 %14,271 
China Merchant Bank Working Capital Loans3.15 %27,798 
Total short-term debt3.01 %112,994 
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.24.3
Other Current Liabilities (Tables)
 9 Months Ended
Sep. 30, 2024
Other Liabilities Disclosure [Abstract]  
Schedule of Other Current Liabilities
The following table presents the Company’s other current liabilities ($ in thousands):
September 30, 2024December 31, 2023
Accrued payroll24,077 33,711 
Accrued professional service fee3,986 7,520 
Payables for purchase of property and equipment2,612 2,474 
Accrued rebate to distributors8,800 16,926 
Tax payables3,756 16,988 
Other (i)2,853 5,353 
Total46,084 82,972 
(i)Other primarily includes accrued travel and business-related expenses.
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.24.3
Share-Based Compensation (Tables)
 9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Share-Based Compensation expense
The following table presents the share-based compensation expense that has been reported in the Company’s unaudited condensed consolidated statements of operations and comprehensive loss as follows ($ in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Selling, general and administrative10,404 14,041 31,861 35,880 
Research and development6,391 7,951 21,552 23,284 
Total16,795 21,992 53,413 59,164 
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.24.3
Other Income, Net (Tables)
 9 Months Ended
Sep. 30, 2024
Other Income and Expenses [Abstract]  
Schedule of Other Income, Net
The following table presents the Company’s other income, net ($ in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Government grants3,861 671 7,186 754 
Loss on equity investments with readily determinable fair value(920)(661)(6,067)(1,965)
Others miscellaneous gain500 384 2,740 1,434 
Total3,441 394 3,859 223 
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.24.3
Basis of Presentation and Consolidation and Significant Accounting Policies (Details) - USD ($)
$ in Millions
Sep. 30, 2024
Dec. 31, 2023
Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity investments with readily determinable fair value $ 3.2 $ 9.2
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.24.3
Cash and Cash Equivalents (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Cash And Cash Equivalents [Line Items]    
Cash $ 614,937 $ 789,051
Cash equivalents 1,149 1,100
Cash and cash equivalents 616,086 790,151
US$    
Cash And Cash Equivalents [Line Items]    
Cash and cash equivalents 575,116 762,436
Renminbi (“RMB”)    
Cash And Cash Equivalents [Line Items]    
Cash and cash equivalents 40,092 25,093
Hong Kong dollar (“HK$”)    
Cash And Cash Equivalents [Line Items]    
Cash and cash equivalents 53 1,974
Australian dollar (“A$”)    
Cash And Cash Equivalents [Line Items]    
Cash and cash equivalents 580 587
Taiwan dollar (“TW$”)    
Cash And Cash Equivalents [Line Items]    
Cash and cash equivalents $ 245 $ 61
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.24.3
Inventories, Net - Summary of Inventories, Net (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Inventory Disclosure [Abstract]    
Finished goods $ 22,460 $ 22,702
Raw materials 15,397 17,655
Work in progress 1,691 4,470
Inventories, net $ 39,548 $ 44,827
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.24.3
Inventories, Net - Additional Information (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Inventory Disclosure [Abstract]        
Inventory write-down $ 0.0 $ 0.1 $ 0.8 $ 0.7
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.24.3
Property and Equipment, Net - Summary of Property and Equipment, Net (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 87,118 $ 83,870
Less: accumulated depreciation (36,353) (30,136)
Property and equipment, net 50,765 53,734
Office equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 1,059 1,047
Electronic equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 9,527 9,161
Vehicle    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 201 199
Laboratory equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 20,793 20,140
Manufacturing equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 17,944 17,680
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 11,544 11,371
Construction in progress    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 26,050 $ 24,272
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.24.3
Property and Equipment, Net - Additional Information (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Property, Plant and Equipment [Abstract]        
Depreciation expense $ 2.1 $ 1.8 $ 6.6 $ 6.1
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.24.3
Intangible Assets, Net - Components of Intangible Assets (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount $ 56,265 $ 15,691
Accumulated Amortization (4,596) (2,302)
Net Carrying Value 51,669 13,389
Commercial products    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 52,050 11,351
Accumulated Amortization (1,881) (186)
Net Carrying Value 50,169 11,165
Regulatory milestone fees    
Finite-Lived Intangible Assets [Line Items]    
Net Carrying Value 33,000  
Commercial development costs    
Finite-Lived Intangible Assets [Line Items]    
Net Carrying Value 6,000  
Software    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 4,215 4,340
Accumulated Amortization (2,715) (2,116)
Net Carrying Value $ 1,500 $ 2,224
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.24.3
Intangible Assets, Net - Additional Information (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Finite-Lived Intangible Assets [Line Items]        
Amortization expense $ 0.7 $ 0.2 $ 2.3 $ 0.5
Software | Minimum        
Finite-Lived Intangible Assets [Line Items]        
Amortization period 3 years   3 years  
Software | Maximum        
Finite-Lived Intangible Assets [Line Items]        
Amortization period 5 years   5 years  
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.24.3
Revenues - Summary of Product Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Revenue from Contract with Customer [Abstract]        
Product revenue - gross $ 107,678 $ 74,018 $ 307,401 $ 220,240
Less: Rebates and sales returns (5,831) (4,790) (18,299) (19,351)
Product revenue - net $ 101,847 $ 69,228 $ 289,102 $ 200,889
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.24.3
Revenues - Disaggregation of Net Revenue by Product (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Disaggregation of Revenue [Line Items]        
Product revenue - net $ 101,847 $ 69,228 $ 289,102 $ 200,889
ZEJULA        
Disaggregation of Revenue [Line Items]        
Product revenue - net 48,227 41,593 138,727 127,230
OPTUNE        
Disaggregation of Revenue [Line Items]        
Product revenue - net 7,715 11,562 32,779 38,596
QINLOCK        
Disaggregation of Revenue [Line Items]        
Product revenue - net 8,643 5,702 21,774 14,535
NUZYRA        
Disaggregation of Revenue [Line Items]        
Product revenue - net 9,997 5,483 32,205 15,588
VYVGART        
Disaggregation of Revenue [Line Items]        
Product revenue - net $ 27,265 $ 4,888 $ 63,617 $ 4,940
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.24.3
Revenues - Additional Information (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Revenue from Contract with Customer [Abstract]        
Collaboration revenue $ 418,000 $ 0 $ 816,000 $ 0
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.24.3
Income Tax (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Income Tax Disclosure [Abstract]          
Provision for income taxes $ 0 $ 0 $ 0 $ 0  
Unrecognized tax benefits 0   0   $ 0
Interest and penalties on unrecognized tax benefits $ 0 $ 0 $ 0 $ 0  
XML 62 R50.htm IDEA: XBRL DOCUMENT v3.24.3
Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2024
Sep. 30, 2023
Numerator:                
Net loss $ (41,671) $ (80,277) $ (53,471) $ (69,152) $ (120,895) $ (49,144) $ (175,419) $ (239,191)
Denominator:                
Weighted average number of ordinary shares - basic (in shares) 981,687,390     968,767,730     976,941,030 965,060,570
Weighted average number of ordinary shares - diluted (in shares) 981,687,390     968,767,730     976,941,030 965,060,570
Net loss per share - basic (in dollars per share) $ (0.04)     $ (0.07)     $ (0.18) $ (0.25)
Net loss per share - diluted (in dollars per share) $ (0.04)     $ (0.07)     $ (0.18) $ (0.25)
XML 63 R51.htm IDEA: XBRL DOCUMENT v3.24.3
Loss Per Share - Summary of Anti-Dilutive Shares Excluded from Calculation of Diluted Loss Per Share (Details) - shares
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Share options    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive shares excluded from calculation of diluted loss per share 105,188,950 107,249,960
Restricted shares    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive shares excluded from calculation of diluted loss per share 32,875,090 32,359,260
XML 64 R52.htm IDEA: XBRL DOCUMENT v3.24.3
Borrowings - Summary of Short-Term Debt (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Short-Term Debt [Line Items]    
Weighted average interest rate per annum 3.01%  
Total short-term debt $ 112,994 $ 0
Loans Payable | Bank of China Working Capital Loans    
Short-Term Debt [Line Items]    
Weighted average interest rate per annum 2.86%  
Total short-term debt $ 70,925  
Loans Payable | SPD Bank Working Capital Loans    
Short-Term Debt [Line Items]    
Weighted average interest rate per annum 3.45%  
Total short-term debt $ 14,271  
Loans Payable | China Merchant Bank Working Capital Loans    
Short-Term Debt [Line Items]    
Weighted average interest rate per annum 3.15%  
Total short-term debt $ 27,798  
XML 65 R53.htm IDEA: XBRL DOCUMENT v3.24.3
Borrowings - Additional Information (Details)
$ in Thousands, ¥ in Millions
 9 Months Ended
Jul. 05, 2024
USD ($)
Feb. 05, 2024
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2024
CNY (¥)
Jul. 05, 2024
CNY (¥)
Jun. 20, 2024
USD ($)
Mar. 31, 2024
USD ($)
Feb. 06, 2024
USD ($)
Feb. 06, 2024
CNY (¥)
Dec. 31, 2023
USD ($)
Short-Term Debt [Line Items]                    
Restricted cash, current     $ 100,000             $ 0
Short-term debt     112,994             $ 0
SPD Bank                    
Short-Term Debt [Line Items]                    
Maximum guarantor obligation               $ 42,000 ¥ 300.0  
Guarantor obligation term               3 years 3 years  
CMB                    
Short-Term Debt [Line Items]                    
Maximum guarantor obligation $ 34,400       ¥ 250.0          
Bank of China Working Capital Loans                    
Short-Term Debt [Line Items]                    
Debt instrument fee             $ 700      
Bank of China Working Capital Loans | Loans Payable                    
Short-Term Debt [Line Items]                    
Short-term debt     $ 70,925              
Bank of China Working Capital Loans | Loans Payable | Zai Lab Shanghai                    
Short-Term Debt [Line Items]                    
Debt instrument term     1 year              
Short-term debt     $ 70,900 ¥ 497.0            
Floating interest rate adjustment period     6 months              
SPD Bank Working Capital Loans | Loans Payable                    
Short-Term Debt [Line Items]                    
Short-term debt     $ 14,271              
SPD Bank Working Capital Loans | Loans Payable | Zai Lab Shanghai                    
Short-Term Debt [Line Items]                    
Debt instrument term     1 year              
Short-term debt     $ 14,300 100.0            
Ningbo Bank Working Capital Loan Facility | Loans Payable                    
Short-Term Debt [Line Items]                    
Maximum borrowing capacity               $ 22,500 ¥ 160.0  
Ningbo Bank Working Capital Loan Facility | Loans Payable | Zai Lab Suzhou                    
Short-Term Debt [Line Items]                    
Maximum borrowing capacity               32,400 ¥ 230.3  
China Merchant Bank Working Capital Loans | Loans Payable                    
Short-Term Debt [Line Items]                    
Short-term debt     $ 27,798              
China Merchant Bank Working Capital Loans | Loans Payable | Zai Lab Shanghai                    
Short-Term Debt [Line Items]                    
Maximum borrowing capacity | ¥         ¥ 250.0          
Debt instrument term 1 year   1 year              
Short-term debt     $ 27,800 ¥ 194.8            
Floating interest rate adjustment period     3 months              
Standby Letters of Credit | Bank of China Working Capital Loans                    
Short-Term Debt [Line Items]                    
Maximum borrowing capacity   $ 100,000                
Debt instrument term   1 year                
Letters of credit outstanding           $ 23,000   $ 50,000    
XML 66 R54.htm IDEA: XBRL DOCUMENT v3.24.3
Other Current Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Other Liabilities Disclosure [Abstract]    
Accrued payroll $ 24,077 $ 33,711
Accrued professional service fee 3,986 7,520
Payables for purchase of property and equipment 2,612 2,474
Accrued rebate to distributors 8,800 16,926
Tax payables 3,756 16,988
Other 2,853 5,353
Total $ 46,084 $ 82,972
XML 67 R55.htm IDEA: XBRL DOCUMENT v3.24.3
Share-Based Compensation - Additional Information (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2024
USD ($)
shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Options granted (in shares) | shares 20,747,480
Unrecognized share-based compensation expense related to unvested share options granted | $ $ 80.4
Restricted shares  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Non-option awards granted (in shares) | shares 17,293,410
Unrecognized share-based compensation expense related to unvested restricted shares | $ $ 83.3
Recognized over a weighted-average period 2 years 8 months 4 days
Share options  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Contractual term 10 years
Recognized over a weighted-average period 2 years 9 months 29 days
Share options | Since April 2023  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Vesting period 4 years
Share options | Prior to April 2023  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Vesting period 5 years
Share options | Tranche one | Since April 2023  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Vesting percentage 25.00%
Share options | Tranche one | Prior to April 2023  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Vesting percentage 20.00%
Share options | Tranche two | Since April 2023  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Vesting percentage 25.00%
Share options | Tranche two | Prior to April 2023  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Vesting percentage 20.00%
Share options | Tranche three | Since April 2023  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Vesting percentage 25.00%
Share options | Tranche three | Prior to April 2023  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Vesting percentage 20.00%
Share options | Tranche four | Since April 2023  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Vesting percentage 25.00%
Share options | Tranche four | Prior to April 2023  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Vesting percentage 20.00%
Share options | Tranche five | Prior to April 2023  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Vesting percentage 20.00%
XML 68 R56.htm IDEA: XBRL DOCUMENT v3.24.3
Share-Based Compensation - Summary of Share-based Compensation Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Share-based compensation expense $ 16,795 $ 21,992 $ 53,413 $ 59,164
Selling, general and administrative        
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Share-based compensation expense 10,404 14,041 31,861 35,880
Research and development        
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Share-based compensation expense $ 6,391 $ 7,951 $ 21,552 $ 23,284
XML 69 R57.htm IDEA: XBRL DOCUMENT v3.24.3
License and Collaboration Agreements (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2024
Jun. 30, 2024
Innoviva Inc. | SUL-DUR    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]    
Milestone payment made   $ 8.0
Maximum additional milestone payments $ 80.6  
BMS | Repotrectinib    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]    
Milestone payment made   $ 25.0
Maximum additional milestone payments 116.0  
BMS | Xanomeline-Trospium Chloride    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]    
Milestone payment made 10.0  
Maximum additional milestone payments 132.0  
Other Counterparties    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]    
Payment of upfront fees for license agreement $ 12.0  
XML 70 R58.htm IDEA: XBRL DOCUMENT v3.24.3
Other Income, Net (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Other Income and Expenses [Abstract]        
Government grants $ 3,861 $ 671 $ 7,186 $ 754
Loss on equity investments with readily determinable fair value (920) (661) (6,067) (1,965)
Others miscellaneous gain 500 384 2,740 1,434
Total $ 3,441 $ 394 $ 3,859 $ 223
XML 71 R59.htm IDEA: XBRL DOCUMENT v3.24.3
Restricted Net Assets (Details) - PRC - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Restricted Net Assets [Line Items]          
Statutory reserves $ 0 $ 0 $ 0 $ 0  
Restricted amount by subsidiaries $ 506,000,000.0   $ 506,000,000.0   $ 506,000,000.0
XML 72 R60.htm IDEA: XBRL DOCUMENT v3.24.3
Commitments and Contingencies (Details)
$ in Millions
Sep. 30, 2024
USD ($)
Property and Equipment and Commercial Manufacturing Development Activities  
Unrecorded Unconditional Purchase Obligation [Line Items]  
Purchase obligation to be incurred within one year $ 8.6
EXCEL 73 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 74 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 75 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 77 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 201 235 1 false 62 0 false 5 false false R1.htm 0000001 - Document - Cover Page Sheet http://zailab.com/role/CoverPage Cover Page Cover 1 false false R2.htm 9952151 - Statement - Unaudited Condensed Consolidated Balance Sheets Sheet http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets Unaudited Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 9952152 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical Unaudited Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 9952153 - Statement - Unaudited Condensed Consolidated Statements of Operations Sheet http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations Unaudited Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 9952154 - Statement - Unaudited Condensed Consolidated Statements of Comprehensive Loss Sheet http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofComprehensiveLoss Unaudited Condensed Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 9952155 - Statement - Unaudited Condensed Consolidated Statements of Comprehensive Loss (Parenthetical) Sheet http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofComprehensiveLossParenthetical Unaudited Condensed Consolidated Statements of Comprehensive Loss (Parenthetical) Statements 6 false false R7.htm 9952156 - Statement - Unaudited Condensed Consolidated Statements of Shareholders' Equity Sheet http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity Unaudited Condensed Consolidated Statements of Shareholders' Equity Statements 7 false false R8.htm 9952157 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows Sheet http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows Unaudited Condensed Consolidated Statements of Cash Flows Statements 8 false false R9.htm 9952158 - Disclosure - Organization and Principal Activities Sheet http://zailab.com/role/OrganizationandPrincipalActivities Organization and Principal Activities Notes 9 false false R10.htm 9952159 - Disclosure - Basis of Presentation and Consolidation and Significant Accounting Policies Sheet http://zailab.com/role/BasisofPresentationandConsolidationandSignificantAccountingPolicies Basis of Presentation and Consolidation and Significant Accounting Policies Notes 10 false false R11.htm 9952160 - Disclosure - Cash and Cash Equivalents Sheet http://zailab.com/role/CashandCashEquivalents Cash and Cash Equivalents Notes 11 false false R12.htm 9952161 - Disclosure - Inventories, Net Sheet http://zailab.com/role/InventoriesNet Inventories, Net Notes 12 false false R13.htm 9952162 - Disclosure - Property and Equipment, Net Sheet http://zailab.com/role/PropertyandEquipmentNet Property and Equipment, Net Notes 13 false false R14.htm 9952163 - Disclosure - Intangible Assets, Net Sheet http://zailab.com/role/IntangibleAssetsNet Intangible Assets, Net Notes 14 false false R15.htm 9952164 - Disclosure - Revenues Sheet http://zailab.com/role/Revenues Revenues Notes 15 false false R16.htm 9952165 - Disclosure - Income Tax Sheet http://zailab.com/role/IncomeTax Income Tax Notes 16 false false R17.htm 9952166 - Disclosure - Loss Per Share Sheet http://zailab.com/role/LossPerShare Loss Per Share Notes 17 false false R18.htm 9952167 - Disclosure - Borrowings Sheet http://zailab.com/role/Borrowings Borrowings Notes 18 false false R19.htm 9952168 - Disclosure - Other Current Liabilities Sheet http://zailab.com/role/OtherCurrentLiabilities Other Current Liabilities Notes 19 false false R20.htm 9952169 - Disclosure - Share-Based Compensation Sheet http://zailab.com/role/ShareBasedCompensation Share-Based Compensation Notes 20 false false R21.htm 9952170 - Disclosure - License and Collaboration Agreements Sheet http://zailab.com/role/LicenseandCollaborationAgreements License and Collaboration Agreements Notes 21 false false R22.htm 9952171 - Disclosure - Other Income, Net Sheet http://zailab.com/role/OtherIncomeNet Other Income, Net Notes 22 false false R23.htm 9952172 - Disclosure - Restricted Net Assets Sheet http://zailab.com/role/RestrictedNetAssets Restricted Net Assets Notes 23 false false R24.htm 9952173 - Disclosure - Commitments and Contingencies Sheet http://zailab.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 24 false false R25.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 25 false false R26.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 26 false false R27.htm 9954471 - Disclosure - Basis of Presentation and Consolidation and Significant Accounting Policies (Policies) Sheet http://zailab.com/role/BasisofPresentationandConsolidationandSignificantAccountingPoliciesPolicies Basis of Presentation and Consolidation and Significant Accounting Policies (Policies) Policies http://zailab.com/role/BasisofPresentationandConsolidationandSignificantAccountingPolicies 27 false false R28.htm 9954472 - Disclosure - Cash and Cash Equivalents (Tables) Sheet http://zailab.com/role/CashandCashEquivalentsTables Cash and Cash Equivalents (Tables) Tables http://zailab.com/role/CashandCashEquivalents 28 false false R29.htm 9954473 - Disclosure - Inventories, Net (Tables) Sheet http://zailab.com/role/InventoriesNetTables Inventories, Net (Tables) Tables http://zailab.com/role/InventoriesNet 29 false false R30.htm 9954474 - Disclosure - Property and Equipment, Net (Tables) Sheet http://zailab.com/role/PropertyandEquipmentNetTables Property and Equipment, Net (Tables) Tables http://zailab.com/role/PropertyandEquipmentNet 30 false false R31.htm 9954475 - Disclosure - Intangible Assets, Net (Tables) Sheet http://zailab.com/role/IntangibleAssetsNetTables Intangible Assets, Net (Tables) Tables http://zailab.com/role/IntangibleAssetsNet 31 false false R32.htm 9954476 - Disclosure - Revenues (Tables) Sheet http://zailab.com/role/RevenuesTables Revenues (Tables) Tables http://zailab.com/role/Revenues 32 false false R33.htm 9954477 - Disclosure - Loss Per Share (Tables) Sheet http://zailab.com/role/LossPerShareTables Loss Per Share (Tables) Tables http://zailab.com/role/LossPerShare 33 false false R34.htm 9954478 - Disclosure - Borrowings (Tables) Sheet http://zailab.com/role/BorrowingsTables Borrowings (Tables) Tables http://zailab.com/role/Borrowings 34 false false R35.htm 9954479 - Disclosure - Other Current Liabilities (Tables) Sheet http://zailab.com/role/OtherCurrentLiabilitiesTables Other Current Liabilities (Tables) Tables http://zailab.com/role/OtherCurrentLiabilities 35 false false R36.htm 9954480 - Disclosure - Share-Based Compensation (Tables) Sheet http://zailab.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://zailab.com/role/ShareBasedCompensation 36 false false R37.htm 9954481 - Disclosure - Other Income, Net (Tables) Sheet http://zailab.com/role/OtherIncomeNetTables Other Income, Net (Tables) Tables http://zailab.com/role/OtherIncomeNet 37 false false R38.htm 9954482 - Disclosure - Basis of Presentation and Consolidation and Significant Accounting Policies (Details) Sheet http://zailab.com/role/BasisofPresentationandConsolidationandSignificantAccountingPoliciesDetails Basis of Presentation and Consolidation and Significant Accounting Policies (Details) Details http://zailab.com/role/BasisofPresentationandConsolidationandSignificantAccountingPoliciesPolicies 38 false false R39.htm 9954483 - Disclosure - Cash and Cash Equivalents (Details) Sheet http://zailab.com/role/CashandCashEquivalentsDetails Cash and Cash Equivalents (Details) Details http://zailab.com/role/CashandCashEquivalentsTables 39 false false R40.htm 9954484 - Disclosure - Inventories, Net - Summary of Inventories, Net (Details) Sheet http://zailab.com/role/InventoriesNetSummaryofInventoriesNetDetails Inventories, Net - Summary of Inventories, Net (Details) Details 40 false false R41.htm 9954485 - Disclosure - Inventories, Net - Additional Information (Details) Sheet http://zailab.com/role/InventoriesNetAdditionalInformationDetails Inventories, Net - Additional Information (Details) Details 41 false false R42.htm 9954486 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment, Net (Details) Sheet http://zailab.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails Property and Equipment, Net - Summary of Property and Equipment, Net (Details) Details 42 false false R43.htm 9954487 - Disclosure - Property and Equipment, Net - Additional Information (Details) Sheet http://zailab.com/role/PropertyandEquipmentNetAdditionalInformationDetails Property and Equipment, Net - Additional Information (Details) Details 43 false false R44.htm 9954488 - Disclosure - Intangible Assets, Net - Components of Intangible Assets (Details) Sheet http://zailab.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsDetails Intangible Assets, Net - Components of Intangible Assets (Details) Details 44 false false R45.htm 9954489 - Disclosure - Intangible Assets, Net - Additional Information (Details) Sheet http://zailab.com/role/IntangibleAssetsNetAdditionalInformationDetails Intangible Assets, Net - Additional Information (Details) Details 45 false false R46.htm 9954490 - Disclosure - Revenues - Summary of Product Revenue (Details) Sheet http://zailab.com/role/RevenuesSummaryofProductRevenueDetails Revenues - Summary of Product Revenue (Details) Details 46 false false R47.htm 9954491 - Disclosure - Revenues - Disaggregation of Net Revenue by Product (Details) Sheet http://zailab.com/role/RevenuesDisaggregationofNetRevenuebyProductDetails Revenues - Disaggregation of Net Revenue by Product (Details) Details 47 false false R48.htm 9954492 - Disclosure - Revenues - Additional Information (Details) Sheet http://zailab.com/role/RevenuesAdditionalInformationDetails Revenues - Additional Information (Details) Details 48 false false R49.htm 9954493 - Disclosure - Income Tax (Details) Sheet http://zailab.com/role/IncomeTaxDetails Income Tax (Details) Details http://zailab.com/role/IncomeTax 49 false false R50.htm 9954494 - Disclosure - Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Details) Sheet http://zailab.com/role/LossPerShareComputationofBasicandDilutedNetLossPerShareDetails Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Details) Details 50 false false R51.htm 9954495 - Disclosure - Loss Per Share - Summary of Anti-Dilutive Shares Excluded from Calculation of Diluted Loss Per Share (Details) Sheet http://zailab.com/role/LossPerShareSummaryofAntiDilutiveSharesExcludedfromCalculationofDilutedLossPerShareDetails Loss Per Share - Summary of Anti-Dilutive Shares Excluded from Calculation of Diluted Loss Per Share (Details) Details 51 false false R52.htm 9954496 - Disclosure - Borrowings - Summary of Short-Term Debt (Details) Sheet http://zailab.com/role/BorrowingsSummaryofShortTermDebtDetails Borrowings - Summary of Short-Term Debt (Details) Details 52 false false R53.htm 9954497 - Disclosure - Borrowings - Additional Information (Details) Sheet http://zailab.com/role/BorrowingsAdditionalInformationDetails Borrowings - Additional Information (Details) Details 53 false false R54.htm 9954498 - Disclosure - Other Current Liabilities (Details) Sheet http://zailab.com/role/OtherCurrentLiabilitiesDetails Other Current Liabilities (Details) Details http://zailab.com/role/OtherCurrentLiabilitiesTables 54 false false R55.htm 9954499 - Disclosure - Share-Based Compensation - Additional Information (Details) Sheet http://zailab.com/role/ShareBasedCompensationAdditionalInformationDetails Share-Based Compensation - Additional Information (Details) Details 55 false false R56.htm 9954500 - Disclosure - Share-Based Compensation - Summary of Share-based Compensation Expense (Details) Sheet http://zailab.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails Share-Based Compensation - Summary of Share-based Compensation Expense (Details) Details 56 false false R57.htm 9954501 - Disclosure - License and Collaboration Agreements (Details) Sheet http://zailab.com/role/LicenseandCollaborationAgreementsDetails License and Collaboration Agreements (Details) Details http://zailab.com/role/LicenseandCollaborationAgreements 57 false false R58.htm 9954502 - Disclosure - Other Income, Net (Details) Sheet http://zailab.com/role/OtherIncomeNetDetails Other Income, Net (Details) Details http://zailab.com/role/OtherIncomeNetTables 58 false false R59.htm 9954503 - Disclosure - Restricted Net Assets (Details) Sheet http://zailab.com/role/RestrictedNetAssetsDetails Restricted Net Assets (Details) Details http://zailab.com/role/RestrictedNetAssets 59 false false R60.htm 9954504 - Disclosure - Commitments and Contingencies (Details) Sheet http://zailab.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://zailab.com/role/CommitmentsandContingencies 60 false false All Reports Book All Reports zlab-20240930.htm zlab-20240930.xsd zlab-20240930_cal.xml zlab-20240930_def.xml zlab-20240930_lab.xml zlab-20240930_pre.xml zlab-20240930_g1.jpg http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 80 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "zlab-20240930.htm": { "nsprefix": "zlab", "nsuri": "http://zailab.com/20240930", "dts": { "inline": { "local": [ "zlab-20240930.htm" ] }, "schema": { "local": [ "zlab-20240930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "zlab-20240930_cal.xml" ] }, "definitionLink": { "local": [ "zlab-20240930_def.xml" ] }, "labelLink": { "local": [ "zlab-20240930_lab.xml" ] }, "presentationLink": { "local": [ "zlab-20240930_pre.xml" ] } }, "keyStandard": 210, "keyCustom": 25, "axisStandard": 20, "axisCustom": 0, "memberStandard": 29, "memberCustom": 30, "hidden": { "total": 7, "http://xbrl.sec.gov/dei/2024": 5, "http://fasb.org/us-gaap/2024": 2 }, "contextCount": 201, "entityCount": 1, "segmentCount": 62, "elementCount": 502, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 675, "http://xbrl.sec.gov/dei/2024": 33, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://zailab.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets", "longName": "9952151 - Statement - Unaudited Condensed Consolidated Balance Sheets", "shortName": "Unaudited Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:ShortTermInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "unique": true } }, "R3": { "role": "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical", "longName": "9952152 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Unaudited Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R4": { "role": "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations", "longName": "9952153 - Statement - Unaudited Condensed Consolidated Statements of Operations", "shortName": "Unaudited Condensed Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "unique": true } }, "R5": { "role": "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofComprehensiveLoss", "longName": "9952154 - Statement - Unaudited Condensed Consolidated Statements of Comprehensive Loss", "shortName": "Unaudited Condensed Consolidated Statements of Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:ComprehensiveIncomeNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "unique": true } }, "R6": { "role": "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofComprehensiveLossParenthetical", "longName": "9952155 - Statement - Unaudited Condensed Consolidated Statements of Comprehensive Loss (Parenthetical)", "shortName": "Unaudited Condensed Consolidated Statements of Comprehensive Loss (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R7": { "role": "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity", "longName": "9952156 - Statement - Unaudited Condensed Consolidated Statements of Shareholders' Equity", "shortName": "Unaudited Condensed Consolidated Statements of Shareholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-47", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-53", "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "unique": true } }, "R8": { "role": "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows", "longName": "9952157 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows", "shortName": "Unaudited Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ProvisionForDoubtfulAccounts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "unique": true } }, "R9": { "role": "http://zailab.com/role/OrganizationandPrincipalActivities", "longName": "9952158 - Disclosure - Organization and Principal Activities", "shortName": "Organization and Principal Activities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://zailab.com/role/BasisofPresentationandConsolidationandSignificantAccountingPolicies", "longName": "9952159 - Disclosure - Basis of Presentation and Consolidation and Significant Accounting Policies", "shortName": "Basis of Presentation and Consolidation and Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://zailab.com/role/CashandCashEquivalents", "longName": "9952160 - Disclosure - Cash and Cash Equivalents", "shortName": "Cash and Cash Equivalents", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://zailab.com/role/InventoriesNet", "longName": "9952161 - Disclosure - Inventories, Net", "shortName": "Inventories, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://zailab.com/role/PropertyandEquipmentNet", "longName": "9952162 - Disclosure - Property and Equipment, Net", "shortName": "Property and Equipment, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://zailab.com/role/IntangibleAssetsNet", "longName": "9952163 - Disclosure - Intangible Assets, Net", "shortName": "Intangible Assets, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://zailab.com/role/Revenues", "longName": "9952164 - Disclosure - Revenues", "shortName": "Revenues", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://zailab.com/role/IncomeTax", "longName": "9952165 - Disclosure - Income Tax", "shortName": "Income Tax", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://zailab.com/role/LossPerShare", "longName": "9952166 - Disclosure - Loss Per Share", "shortName": "Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://zailab.com/role/Borrowings", "longName": "9952167 - Disclosure - Borrowings", "shortName": "Borrowings", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://zailab.com/role/OtherCurrentLiabilities", "longName": "9952168 - Disclosure - Other Current Liabilities", "shortName": "Other Current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "zlab:OtherCurrentLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "zlab:OtherCurrentLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://zailab.com/role/ShareBasedCompensation", "longName": "9952169 - Disclosure - Share-Based Compensation", "shortName": "Share-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://zailab.com/role/LicenseandCollaborationAgreements", "longName": "9952170 - Disclosure - License and Collaboration Agreements", "shortName": "License and Collaboration Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "zlab:LicensesAndCollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "zlab:LicensesAndCollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://zailab.com/role/OtherIncomeNet", "longName": "9952171 - Disclosure - Other Income, Net", "shortName": "Other Income, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://zailab.com/role/RestrictedNetAssets", "longName": "9952172 - Disclosure - Restricted Net Assets", "shortName": "Restricted Net Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestrictedAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestrictedAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://zailab.com/role/CommitmentsandContingencies", "longName": "9952173 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true }, "uniqueAnchor": null }, "R26": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-8", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R27": { "role": "http://zailab.com/role/BasisofPresentationandConsolidationandSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Basis of Presentation and Consolidation and Significant Accounting Policies (Policies)", "shortName": "Basis of Presentation and Consolidation and Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://zailab.com/role/CashandCashEquivalentsTables", "longName": "9954472 - Disclosure - Cash and Cash Equivalents (Tables)", "shortName": "Cash and Cash Equivalents (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R29": { "role": "http://zailab.com/role/InventoriesNetTables", "longName": "9954473 - Disclosure - Inventories, Net (Tables)", "shortName": "Inventories, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://zailab.com/role/PropertyandEquipmentNetTables", "longName": "9954474 - Disclosure - Property and Equipment, Net (Tables)", "shortName": "Property and Equipment, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://zailab.com/role/IntangibleAssetsNetTables", "longName": "9954475 - Disclosure - Intangible Assets, Net (Tables)", "shortName": "Intangible Assets, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://zailab.com/role/RevenuesTables", "longName": "9954476 - Disclosure - Revenues (Tables)", "shortName": "Revenues (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "zlab:ScheduleOfGrossAndNetRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "zlab:ScheduleOfGrossAndNetRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://zailab.com/role/LossPerShareTables", "longName": "9954477 - Disclosure - Loss Per Share (Tables)", "shortName": "Loss Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://zailab.com/role/BorrowingsTables", "longName": "9954478 - Disclosure - Borrowings (Tables)", "shortName": "Borrowings (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R35": { "role": "http://zailab.com/role/OtherCurrentLiabilitiesTables", "longName": "9954479 - Disclosure - Other Current Liabilities (Tables)", "shortName": "Other Current Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R36": { "role": "http://zailab.com/role/ShareBasedCompensationTables", "longName": "9954480 - Disclosure - Share-Based Compensation (Tables)", "shortName": "Share-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R37": { "role": "http://zailab.com/role/OtherIncomeNetTables", "longName": "9954481 - Disclosure - Other Income, Net (Tables)", "shortName": "Other Income, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R38": { "role": "http://zailab.com/role/BasisofPresentationandConsolidationandSignificantAccountingPoliciesDetails", "longName": "9954482 - Disclosure - Basis of Presentation and Consolidation and Significant Accounting Policies (Details)", "shortName": "Basis of Presentation and Consolidation and Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-88", "name": "us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-88", "name": "us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R39": { "role": "http://zailab.com/role/CashandCashEquivalentsDetails", "longName": "9954483 - Disclosure - Cash and Cash Equivalents (Details)", "shortName": "Cash and Cash Equivalents (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:Cash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:Cash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R40": { "role": "http://zailab.com/role/InventoriesNetSummaryofInventoriesNetDetails", "longName": "9954484 - Disclosure - Inventories, Net - Summary of Inventories, Net (Details)", "shortName": "Inventories, Net - Summary of Inventories, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R41": { "role": "http://zailab.com/role/InventoriesNetAdditionalInformationDetails", "longName": "9954485 - Disclosure - Inventories, Net - Additional Information (Details)", "shortName": "Inventories, Net - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:ProductionRelatedImpairmentsOrCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "us-gaap:ProductionRelatedImpairmentsOrCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R42": { "role": "http://zailab.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails", "longName": "9954486 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment, Net (Details)", "shortName": "Property and Equipment, Net - Summary of Property and Equipment, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R43": { "role": "http://zailab.com/role/PropertyandEquipmentNetAdditionalInformationDetails", "longName": "9954487 - Disclosure - Property and Equipment, Net - Additional Information (Details)", "shortName": "Property and Equipment, Net - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R44": { "role": "http://zailab.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsDetails", "longName": "9954488 - Disclosure - Intangible Assets, Net - Components of Intangible Assets (Details)", "shortName": "Intangible Assets, Net - Components of Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R45": { "role": "http://zailab.com/role/IntangibleAssetsNetAdditionalInformationDetails", "longName": "9954489 - Disclosure - Intangible Assets, Net - Additional Information (Details)", "shortName": "Intangible Assets, Net - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R46": { "role": "http://zailab.com/role/RevenuesSummaryofProductRevenueDetails", "longName": "9954490 - Disclosure - Revenues - Summary of Product Revenue (Details)", "shortName": "Revenues - Summary of Product Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-8", "name": "zlab:RevenueFromContractWithCustomersExcludingAssessedTaxBeforeAdjustmentsForRebatesAndSalesReturns", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "zlab:RevenueFromContractWithCustomersExcludingAssessedTaxBeforeAdjustmentsForRebatesAndSalesReturns", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R47": { "role": "http://zailab.com/role/RevenuesDisaggregationofNetRevenuebyProductDetails", "longName": "9954491 - Disclosure - Revenues - Disaggregation of Net Revenue by Product (Details)", "shortName": "Revenues - Disaggregation of Net Revenue by Product (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-122", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "unique": true } }, "R48": { "role": "http://zailab.com/role/RevenuesAdditionalInformationDetails", "longName": "9954492 - Disclosure - Revenues - Additional Information (Details)", "shortName": "Revenues - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true }, "uniqueAnchor": null }, "R49": { "role": "http://zailab.com/role/IncomeTaxDetails", "longName": "9954493 - Disclosure - Income Tax (Details)", "shortName": "Income Tax (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:IncomeTaxExpenseBenefit", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "unique": true } }, "R50": { "role": "http://zailab.com/role/LossPerShareComputationofBasicandDilutedNetLossPerShareDetails", "longName": "9954494 - Disclosure - Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Details)", "shortName": "Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true }, "uniqueAnchor": null }, "R51": { "role": "http://zailab.com/role/LossPerShareSummaryofAntiDilutiveSharesExcludedfromCalculationofDilutedLossPerShareDetails", "longName": "9954495 - Disclosure - Loss Per Share - Summary of Anti-Dilutive Shares Excluded from Calculation of Diluted Loss Per Share (Details)", "shortName": "Loss Per Share - Summary of Anti-Dilutive Shares Excluded from Calculation of Diluted Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-142", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-142", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R52": { "role": "http://zailab.com/role/BorrowingsSummaryofShortTermDebtDetails", "longName": "9954496 - Disclosure - Borrowings - Summary of Short-Term Debt (Details)", "shortName": "Borrowings - Summary of Short-Term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:ShortTermDebtWeightedAverageInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:ShortTermDebtWeightedAverageInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R53": { "role": "http://zailab.com/role/BorrowingsAdditionalInformationDetails", "longName": "9954497 - Disclosure - Borrowings - Additional Information (Details)", "shortName": "Borrowings - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:RestrictedCashCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-156", "name": "us-gaap:GuaranteeObligationsMaximumExposure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "unique": true } }, "R54": { "role": "http://zailab.com/role/OtherCurrentLiabilitiesDetails", "longName": "9954498 - Disclosure - Other Current Liabilities (Details)", "shortName": "Other Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R55": { "role": "http://zailab.com/role/ShareBasedCompensationAdditionalInformationDetails", "longName": "9954499 - Disclosure - Share-Based Compensation - Additional Information (Details)", "shortName": "Share-Based Compensation - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R56": { "role": "http://zailab.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails", "longName": "9954500 - Disclosure - Share-Based Compensation - Summary of Share-based Compensation Expense (Details)", "shortName": "Share-Based Compensation - Summary of Share-based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R57": { "role": "http://zailab.com/role/LicenseandCollaborationAgreementsDetails", "longName": "9954501 - Disclosure - License and Collaboration Agreements (Details)", "shortName": "License and Collaboration Agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-188", "name": "zlab:CollaborativeArrangementRightsAndObligationsMilestonePayment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-188", "name": "zlab:CollaborativeArrangementRightsAndObligationsMilestonePayment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R58": { "role": "http://zailab.com/role/OtherIncomeNetDetails", "longName": "9954502 - Disclosure - Other Income, Net (Details)", "shortName": "Other Income, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:GovernmentAssistanceNonoperatingIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:GovernmentAssistanceNonoperatingIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R59": { "role": "http://zailab.com/role/RestrictedNetAssetsDetails", "longName": "9954503 - Disclosure - Restricted Net Assets (Details)", "shortName": "Restricted Net Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-196", "name": "zlab:StatutoryReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "zlab:StatutoryReserves", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-196", "name": "zlab:StatutoryReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "zlab:StatutoryReserves", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } }, "R60": { "role": "http://zailab.com/role/CommitmentsandContingenciesDetails", "longName": "9954504 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-201", "name": "us-gaap:UnrecordedUnconditionalPurchaseObligationDueInNextRollingTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-201", "name": "us-gaap:UnrecordedUnconditionalPurchaseObligationDueInNextRollingTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "zlab-20240930.htm", "first": true, "unique": true } } }, "tag": { "currency_AUD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2024", "localname": "AUD", "presentation": [ "http://zailab.com/role/CashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Australian dollar (\u201cA$\u201d)", "label": "Australia, Dollars" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Summary of significant accounting policies", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r38", "r660" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable (net of allowance for credit losses of $14 and $17 as of September\u00a030, 2024 and December\u00a031, 2023, respectively)", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r802" ] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://zailab.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://zailab.com/role/OtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued professional service fee", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r41" ] }, "zlab_AccruedRebateToDistributorsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://zailab.com/20240930", "localname": "AccruedRebateToDistributorsCurrent", "crdr": "credit", "calculation": { "http://zailab.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://zailab.com/role/OtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued rebate to distributors", "label": "Accrued Rebate To Distributors Current", "documentation": "Amount of accrued rebate payable to distributors." } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://zailab.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://zailab.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r29", "r119", "r474" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated other comprehensive income", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r14", "r15", "r58", "r126", "r471", "r499", "r500" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income (loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r8", "r15", "r379", "r382", "r419", "r495", "r496", "r780", "r781", "r782", "r791", "r792", "r793", "r794" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r724" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r50" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid in capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r511", "r791", "r792", "r793", "r794", "r859", "r916" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r737" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r737" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r737" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r737" ] }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Receipt of shares netted to satisfy tax withholding obligations related to share-based compensation", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r34", "r35", "r311" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "dei_AdrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdrMember", "presentation": [ "http://zailab.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "American Depositary Shares", "label": "ADR [Member]", "documentation": "American Depositary Receipt (or American Depositary Share, ADS)." } } }, "auth_ref": [ "r690" ] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r770" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r696", "r706", "r716", "r748" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r699", "r709", "r719", "r751" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r771" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r737" ] }, "currency_AllCurrenciesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2024", "localname": "AllCurrenciesDomain", "presentation": [ "http://zailab.com/role/CashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All Currencies [Domain]", "label": "All Currencies [Domain]" } } }, "auth_ref": [] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r744" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r700", "r710", "r720", "r744", "r752", "r756", "r764" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r762" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://zailab.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r340", "r345" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, allowance for credit losses", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r127", "r203", "r207" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://zailab.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "zlab_AmortizationOfDeferredIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://zailab.com/20240930", "localname": "AmortizationOfDeferredIncome", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of deferred income", "label": "Amortization Of Deferred Income", "documentation": "Amortization of deferred income." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Debt issuance costs", "label": "Amortization of Debt Issuance Costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r66", "r279", "r786", "r869" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://zailab.com/role/IntangibleAssetsNetAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization expense", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r6", "r214", "r220", "r630" ] }, "us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries", "crdr": "debit", "presentation": [ "http://zailab.com/role/RestrictedNetAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted amount by subsidiaries", "label": "Amount of Restricted Net Assets for Consolidated and Unconsolidated Subsidiaries", "documentation": "Amount of restricted net assets of consolidated and unconsolidated subsidiaries as of the end of the most recently completed fiscal year." } } }, "auth_ref": [ "r151" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://zailab.com/role/LossPerShareSummaryofAntiDilutiveSharesExcludedfromCalculationofDilutedLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive shares excluded from calculation of diluted loss per share", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r180" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://zailab.com/role/LossPerShareSummaryofAntiDilutiveSharesExcludedfromCalculationofDilutedLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r24" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://zailab.com/role/LossPerShareSummaryofAntiDilutiveSharesExcludedfromCalculationofDilutedLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://zailab.com/role/LossPerShareSummaryofAntiDilutiveSharesExcludedfromCalculationofDilutedLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r24" ] }, "zlab_April2023AndLaterMember": { "xbrltype": "domainItemType", "nsuri": "http://zailab.com/20240930", "localname": "April2023AndLaterMember", "presentation": [ "http://zailab.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Since April 2023", "label": "April 2023 And Later [Member]", "documentation": "April 2023 And Later" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r85", "r97", "r121", "r152", "r184", "r188", "r196", "r197", "r204", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r374", "r376", "r400", "r467", "r550", "r627", "r628", "r660", "r686", "r827", "r828", "r871" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r114", "r129", "r152", "r204", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r374", "r376", "r400", "r660", "r827", "r828", "r871" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AwardDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardDateAxis", "presentation": [ "http://zailab.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Date [Axis]", "label": "Award Date [Axis]", "documentation": "Information by date or year award under share-based payment arrangement is granted." } } }, "auth_ref": [ "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856" ] }, "us-gaap_AwardDateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardDateDomain", "presentation": [ "http://zailab.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Date [Domain]", "label": "Award Date [Domain]", "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "auth_ref": [ "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r759" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r760" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r755" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r755" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r755" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r755" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r755" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r755" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://zailab.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r758" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r757" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r756" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r756" ] }, "zlab_BMSMember": { "xbrltype": "domainItemType", "nsuri": "http://zailab.com/20240930", "localname": "BMSMember", "presentation": [ "http://zailab.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BMS", "label": "BMS [Member]", "documentation": "BMS" } } }, "auth_ref": [] }, "zlab_BankOfChinaWorkingCapitalLoanFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://zailab.com/20240930", "localname": "BankOfChinaWorkingCapitalLoanFacilityMember", "presentation": [ "http://zailab.com/role/BorrowingsAdditionalInformationDetails", "http://zailab.com/role/BorrowingsSummaryofShortTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bank of China Working Capital Loans", "label": "Bank of China Working Capital Loan Facility [Member]", "documentation": "Bank of China Working Capital Loan Facility" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://zailab.com/role/BasisofPresentationandConsolidationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "country_CN": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "CN", "presentation": [ "http://zailab.com/role/RestrictedNetAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PRC", "label": "CHINA" } } }, "auth_ref": [] }, "currency_CNY": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2024", "localname": "CNY", "presentation": [ "http://zailab.com/role/CashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Renminbi (\u201cRMB\u201d)", "label": "China, Yuan Renminbi" } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Cash", "crdr": "debit", "calculation": { "http://zailab.com/role/CashandCashEquivalentsDetails": { "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://zailab.com/role/CashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r99", "r469", "r522", "r545", "r660", "r686", "r776" ] }, "us-gaap_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://zailab.com/role/CashandCashEquivalentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://zailab.com/role/CashandCashEquivalentsDetails", "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r20", "r116", "r615" ] }, "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsDisclosureTextBlock", "presentation": [ "http://zailab.com/role/CashandCashEquivalents" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents Disclosure [Text Block]", "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify." } } }, "auth_ref": [ "r116", "r469" ] }, "us-gaap_CashAndCashEquivalentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsLineItems", "presentation": [ "http://zailab.com/role/CashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash And Cash Equivalents [Line Items]", "label": "Cash and Cash Equivalents [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents and restricted cash - beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash - end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r20", "r72", "r148" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net decrease in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r72" ] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://zailab.com/role/CashandCashEquivalentsDetails": { "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://zailab.com/role/CashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash Equivalents, at Carrying Value", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r776", "r881" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure on non-cash investing and financing activities", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r735" ] }, "zlab_ChinaMerchantBankWorkingCapitalLoanFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://zailab.com/20240930", "localname": "ChinaMerchantBankWorkingCapitalLoanFacilityMember", "presentation": [ "http://zailab.com/role/BorrowingsAdditionalInformationDetails", "http://zailab.com/role/BorrowingsSummaryofShortTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "China Merchant Bank Working Capital Loans", "label": "China Merchant Bank Working Capital Loan Facility [Member]", "documentation": "China Merchant Bank Working Capital Loan Facility" } } }, "auth_ref": [] }, "zlab_ChinaMerchantsBankCo.Ltd.Member": { "xbrltype": "domainItemType", "nsuri": "http://zailab.com/20240930", "localname": "ChinaMerchantsBankCo.Ltd.Member", "presentation": [ "http://zailab.com/role/BorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CMB", "label": "China Merchants Bank Co., Ltd. [Member]", "documentation": "China Merchants Bank Co., Ltd." } } }, "auth_ref": [] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": [ "r732" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r730" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://zailab.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://zailab.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r111", "r123", "r124", "r125", "r152", "r174", "r175", "r177", "r179", "r186", "r187", "r204", "r248", "r250", "r251", "r252", "r255", "r256", "r283", "r284", "r286", "r287", "r288", "r400", "r505", "r506", "r507", "r508", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r523", "r537", "r560", "r579", "r591", "r592", "r593", "r594", "r595", "r774", "r788", "r795" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r736" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r736" ] }, "zlab_CollaborativeArrangementRightsAndObligationsMaximumAdditionalMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://zailab.com/20240930", "localname": "CollaborativeArrangementRightsAndObligationsMaximumAdditionalMilestonePayments", "crdr": "debit", "presentation": [ "http://zailab.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum additional milestone payments", "label": "Collaborative Arrangement, Rights and Obligations, Maximum Additional Milestone Payments", "documentation": "The amount represents the additional milestone payments." } } }, "auth_ref": [] }, "zlab_CollaborativeArrangementRightsAndObligationsMilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://zailab.com/20240930", "localname": "CollaborativeArrangementRightsAndObligationsMilestonePayment", "crdr": "debit", "presentation": [ "http://zailab.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone payment made", "label": "Collaborative Arrangement, Rights and Obligations, Milestone Payment", "documentation": "The amount represents milestone payments." } } }, "auth_ref": [] }, "zlab_CollaborativeArrangementRightsAndObligationsPaymentOfUpfrontFeesForLicenseAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://zailab.com/20240930", "localname": "CollaborativeArrangementRightsAndObligationsPaymentOfUpfrontFeesForLicenseAgreement", "crdr": "debit", "presentation": [ "http://zailab.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment of upfront fees for license agreement", "label": "Collaborative Arrangement, Rights and Obligations, Payment Of Upfront Fees For License Agreement", "documentation": "Payment of upfront fees for license agreement." } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://zailab.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r373" ] }, "zlab_CommercialDevelopmentCostMember": { "xbrltype": "domainItemType", "nsuri": "http://zailab.com/20240930", "localname": "CommercialDevelopmentCostMember", "presentation": [ "http://zailab.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial development costs", "label": "Commercial Development Cost [Member]", "documentation": "Commercial Development Cost" } } }, "auth_ref": [] }, "zlab_CommercialProductsIntangibleAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://zailab.com/20240930", "localname": "CommercialProductsIntangibleAssetMember", "presentation": [ "http://zailab.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial products", "label": "Commercial Products, Intangible Asset [Member]", "documentation": "Commercial Products, Intangible Asset" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 16)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r46", "r88", "r468", "r536" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://zailab.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r80", "r235", "r237", "r597", "r816", "r821" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://zailab.com/role/CoverPage", "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary Shares", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r677", "r678", "r679", "r681", "r682", "r683", "r684", "r791", "r792", "r794", "r859", "r914", "r916" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r49" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r49", "r537" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r49" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical", "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares, shares outstanding (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r9", "r49", "r537", "r556", "r916", "r917" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares (par value of $0.000006 per share; 5,000,000,000 shares authorized; 989,268,370 and 977,151,270 shares issued as of September\u00a030, 2024 and December\u00a031, 2023, respectively; 984,356,170 and 972,239,070 shares outstanding as of September\u00a030, 2024 and December\u00a031, 2023, respectively)", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r49", "r470", "r660" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r741" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r740" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r742" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r739" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r16", "r131", "r133", "r138", "r461", "r479", "r480" ] }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerSoftwareIntangibleAssetMember", "presentation": [ "http://zailab.com/role/IntangibleAssetsNetAdditionalInformationDetails", "http://zailab.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Software", "label": "Computer Software, Intangible Asset [Member]", "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks." } } }, "auth_ref": [ "r610", "r614", "r806", "r807", "r808", "r809", "r810", "r812", "r814", "r815" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://zailab.com/role/BasisofPresentationandConsolidationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r36", "r623" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember", "presentation": [ "http://zailab.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Construction in progress", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cost of product revenue", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r60", "r61", "r428" ] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpensesAbstract", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Expenses", "label": "Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [ "http://zailab.com/role/BorrowingsAdditionalInformationDetails", "http://zailab.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r154", "r155", "r261", "r285", "r420", "r426", "r465", "r620", "r622" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": [ "http://zailab.com/role/BorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r246", "r825" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": [ "http://zailab.com/role/BorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r246", "r825", "r826" ] }, "srt_CurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CurrencyAxis", "presentation": [ "http://zailab.com/role/CashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency [Axis]", "label": "Currency [Axis]" } } }, "auth_ref": [ "r867" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://zailab.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://zailab.com/role/Borrowings" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r81", "r150", "r228", "r229", "r230", "r231", "r232", "r245", "r246", "r257", "r263", "r264", "r265", "r266", "r267", "r268", "r273", "r280", "r281", "r282", "r412" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://zailab.com/role/BorrowingsAdditionalInformationDetails", "http://zailab.com/role/BorrowingsSummaryofShortTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r12", "r40", "r41", "r86", "r87", "r156", "r258", "r259", "r260", "r261", "r262", "r264", "r269", "r270", "r271", "r272", "r274", "r275", "r276", "r277", "r278", "r279", "r631", "r632", "r633", "r634", "r635", "r658", "r789", "r817", "r818", "r819", "r868", "r870" ] }, "us-gaap_DebtInstrumentFeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFeeAmount", "crdr": "debit", "presentation": [ "http://zailab.com/role/BorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument fee", "label": "Debt Instrument, Fee Amount", "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument." } } }, "auth_ref": [ "r43" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://zailab.com/role/BorrowingsAdditionalInformationDetails", "http://zailab.com/role/BorrowingsSummaryofShortTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r12", "r156", "r258", "r259", "r260", "r261", "r262", "r264", "r269", "r270", "r271", "r272", "r274", "r275", "r276", "r277", "r278", "r279", "r631", "r632", "r633", "r634", "r635", "r658", "r789", "r817", "r818", "r819", "r868", "r870" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTerm", "presentation": [ "http://zailab.com/role/BorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument term", "label": "Debt Instrument, Term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "zlab_DebtInstrumentVariableInterestRateAdjustmentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://zailab.com/20240930", "localname": "DebtInstrumentVariableInterestRateAdjustmentPeriod", "presentation": [ "http://zailab.com/role/BorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Floating interest rate adjustment period", "label": "Debt Instrument, Variable Interest Rate, Adjustment, Period", "documentation": "Debt Instrument, Variable Interest Rate, Adjustment, Period" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeNoncurrent", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income", "label": "Deferred Income, Noncurrent", "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r775" ] }, "us-gaap_DepositsAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositsAssetsNoncurrent", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term deposits", "label": "Deposits Assets, Noncurrent", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r777" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://zailab.com/role/PropertyandEquipmentNetAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Depreciation expense", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r6", "r28" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization expenses", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r6", "r184", "r193", "r197", "r627", "r628" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://zailab.com/role/RevenuesDisaggregationofNetRevenuebyProductDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r299", "r637", "r638", "r639", "r640", "r641", "r642", "r643" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://zailab.com/role/RevenuesDisaggregationofNetRevenuebyProductDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r299", "r637", "r638", "r639", "r640", "r641", "r642", "r643" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://zailab.com/role/RevenuesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Disaggregation of Net Revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r830" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://zailab.com/role/ShareBasedCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r309", "r313", "r341", "r342", "r344", "r648" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://zailab.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://zailab.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": [ "http://zailab.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Line Items]", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": [ "http://zailab.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://zailab.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://zailab.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r691" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://zailab.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r723" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://zailab.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": [ "r734" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://zailab.com/role/LossPerShareComputationofBasicandDilutedNetLossPerShareDetails", "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Loss per share - basic (in dollars per share)", "verboseLabel": "Net loss per share - basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r139", "r162", "r163", "r164", "r165", "r166", "r167", "r172", "r174", "r177", "r178", "r179", "r183", "r369", "r372", "r385", "r386", "r462", "r481", "r624" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://zailab.com/role/LossPerShareComputationofBasicandDilutedNetLossPerShareDetails", "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Loss per share - diluted (in dollars per share)", "verboseLabel": "Net loss per share - diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r139", "r162", "r163", "r164", "r165", "r166", "r167", "r174", "r177", "r178", "r179", "r183", "r369", "r372", "r385", "r386", "r462", "r481", "r624" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://zailab.com/role/LossPerShare" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r171", "r180", "r181", "r182" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r866" ] }, "zlab_ElectronicEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://zailab.com/20240930", "localname": "ElectronicEquipmentMember", "presentation": [ "http://zailab.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Electronic equipment", "label": "Electronic Equipment [Member]", "documentation": "Electronic equipment." } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://zailab.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://zailab.com/role/OtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued payroll", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r41" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://zailab.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://zailab.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recognized over a weighted-average period", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r343" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://zailab.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized share-based compensation expense related to unvested restricted shares", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r857" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://zailab.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized share-based compensation expense related to unvested share options granted", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r857" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://zailab.com/role/LossPerShareSummaryofAntiDilutiveSharesExcludedfromCalculationofDilutedLossPerShareDetails", "http://zailab.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share options", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://zailab.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://zailab.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://zailab.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://zailab.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Country", "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://zailab.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://zailab.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r688" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://zailab.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://zailab.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": [ "http://zailab.com/role/BorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://zailab.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r688" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://zailab.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://zailab.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r688" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://zailab.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://zailab.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r773" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://zailab.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r688" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://zailab.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r688" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://zailab.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r688" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://zailab.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r688" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r728" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": [ "r769" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": [ "r769" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r769" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r9", "r112", "r134", "r135", "r136", "r157", "r158", "r159", "r161", "r166", "r168", "r170", "r185", "r205", "r206", "r226", "r289", "r359", "r360", "r366", "r367", "r368", "r370", "r371", "r372", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r405", "r406", "r407", "r408", "r409", "r410", "r413", "r414", "r419", "r478", "r495", "r496", "r497", "r511", "r579" ] }, "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent", "crdr": "debit", "presentation": [ "http://zailab.com/role/BasisofPresentationandConsolidationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity investments with readily determinable fair value", "label": "Equity Securities, FV-NI", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r122", "r388", "r399", "r465", "r466", "r652", "r674", "r676", "r860", "r861", "r862" ] }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiGainLoss", "crdr": "credit", "calculation": { "http://zailab.com/role/OtherIncomeNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 }, "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 23.0 } }, "presentation": [ "http://zailab.com/role/OtherIncomeNetDetails", "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss from fair value changes of equity investment with readily determinable fair value", "terseLabel": "Loss on equity investments with readily determinable fair value", "label": "Equity Securities, FV-NI, Gain (Loss)", "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r482", "r803" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r738" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r696", "r706", "r716", "r748" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r693", "r703", "r713", "r745" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r744" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://zailab.com/role/BasisofPresentationandConsolidationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r388", "r389", "r396", "r652" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://zailab.com/role/BasisofPresentationandConsolidationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r388", "r389", "r396", "r652" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://zailab.com/role/BasisofPresentationandConsolidationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r271", "r302", "r303", "r304", "r305", "r306", "r307", "r387", "r389", "r390", "r391", "r392", "r395", "r396", "r398", "r421", "r422", "r423", "r632", "r633", "r644", "r645", "r646", "r652", "r654" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://zailab.com/role/BasisofPresentationandConsolidationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r271", "r302", "r307", "r389", "r396", "r421", "r644", "r645", "r646", "r652" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://zailab.com/role/BasisofPresentationandConsolidationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://zailab.com/role/BasisofPresentationandConsolidationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r271", "r302", "r303", "r304", "r305", "r306", "r307", "r387", "r389", "r390", "r391", "r392", "r395", "r396", "r398", "r421", "r422", "r423", "r632", "r633", "r644", "r645", "r646", "r652", "r654" ] }, "us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossCurrent", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Notes receivable", "label": "Financing Receivable, Excluding Accrued Interest, after Allowance for Credit Loss, Current", "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease." } } }, "auth_ref": [ "r805" ] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://zailab.com/role/IntangibleAssetsNetAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization period", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://zailab.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://zailab.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r120", "r211", "r219", "r630" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://zailab.com/role/IntangibleAssetsNetAdditionalInformationDetails", "http://zailab.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r213", "r215", "r216", "r217", "r218", "r219", "r221", "r222", "r429", "r430", "r610" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://zailab.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://zailab.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Carrying Amount", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r211", "r219", "r430", "r630" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://zailab.com/role/IntangibleAssetsNetAdditionalInformationDetails", "http://zailab.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r213", "r219", "r221", "r222", "r224", "r429", "r610", "r630" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://zailab.com/role/IntangibleAssetsNetAdditionalInformationDetails", "http://zailab.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r213", "r215", "r216", "r217", "r218", "r219", "r221", "r222", "r610" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://zailab.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://zailab.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net Carrying Value", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r429", "r812" ] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency gains (losses)", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r401", "r402", "r403", "r404", "r576" ] }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossUnrealized", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Foreign currency remeasurement impact", "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r74", "r558", "r685", "r864", "r865", "r915" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r700", "r710", "r720", "r752" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r700", "r710", "r720", "r752" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r700", "r710", "r720", "r752" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r700", "r710", "r720", "r752" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r700", "r710", "r720", "r752" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": [ "r733" ] }, "zlab_GainLossOnDisposalOfLandUseRights": { "xbrltype": "monetaryItemType", "nsuri": "http://zailab.com/20240930", "localname": "GainLossOnDisposalOfLandUseRights", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 18.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gain on disposal of land use right", "label": "Gain (Loss) On Disposal Of Land Use Rights", "documentation": "Gain (Loss) On Disposal Of Land Use Rights" } } }, "auth_ref": [] }, "us-gaap_GainLossOnDispositionOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDispositionOfIntangibleAssets", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 6.0 }, "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows", "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Gain on sale of intellectual property", "negatedTerseLabel": "Gain on sale of intellectual property", "label": "Gain (Loss) on Disposition of Intangible Assets", "documentation": "Amount of gain (loss) on sale or disposal of intangible assets." } } }, "auth_ref": [ "r786" ] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Losses on disposal of property and equipment", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": [ "r6" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GovernmentAssistanceNonoperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GovernmentAssistanceNonoperatingIncome", "crdr": "credit", "calculation": { "http://zailab.com/role/OtherIncomeNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://zailab.com/role/OtherIncomeNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government grants", "label": "Government Assistance, Nonoperating Income, Increase (Decrease)", "documentation": "Amount of increase (decrease) in income from government assistance, classified as nonoperating." } } }, "auth_ref": [ "r411" ] }, "us-gaap_GuaranteeObligationsMaximumExposure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GuaranteeObligationsMaximumExposure", "crdr": "credit", "presentation": [ "http://zailab.com/role/BorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum guarantor obligation", "label": "Guarantor Obligations, Maximum Exposure, Undiscounted", "documentation": "Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions." } } }, "auth_ref": [ "r244" ] }, "zlab_GuarantorObligationTerm": { "xbrltype": "durationItemType", "nsuri": "http://zailab.com/20240930", "localname": "GuarantorObligationTerm", "presentation": [ "http://zailab.com/role/BorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Guarantor obligation term", "label": "Guarantor Obligation, Term", "documentation": "Guarantor Obligation, Term" } } }, "auth_ref": [] }, "currency_HKD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2024", "localname": "HKD", "presentation": [ "http://zailab.com/role/CashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hong Kong dollar (\u201cHK$\u201d)", "label": "Hong Kong, Dollars" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before income tax", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r59", "r92", "r96", "r463", "r476", "r626", "r627", "r797", "r798", "r799", "r800", "r801" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Consolidated statements of operations", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://zailab.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r227", "r233", "r234", "r393", "r394", "r397", "r492", "r494", "r563", "r610", "r653", "r883" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://zailab.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r233", "r234", "r393", "r394", "r397", "r492", "r494", "r563", "r610", "r653", "r883" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://zailab.com/role/IncomeTax" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r153", "r348", "r351", "r352", "r353", "r354", "r357", "r358", "r361", "r363", "r364", "r365", "r510", "r651" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://zailab.com/role/IncomeTaxDetails", "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax expense", "verboseLabel": "Provision for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r98", "r109", "r169", "r170", "r184", "r194", "r197", "r350", "r351", "r362", "r483", "r651" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 20.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDeferredRevenue", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income", "label": "Increase (Decrease) in Deferred Revenue", "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r611" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r5" ] }, "zlab_IncreaseDecreaseInLongTermDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://zailab.com/20240930", "localname": "IncreaseDecreaseInLongTermDeposits", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Long-term deposits", "label": "Increase Decrease In Long Term Deposits", "documentation": "Increase decrease in long term deposits." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInNotesReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInNotesReceivableCurrent", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Notes receivable", "label": "Increase (Decrease) in Notes Receivable, Current", "documentation": "The increase (decrease) during the reporting period of amounts due within one year (or one business cycle) from note holders for outstanding loans." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "zlab_IncreaseDecreaseInOperatingLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://zailab.com/20240930", "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Increase Decrease In Operating Lease Liabilities", "documentation": "Increase (decrease) in operating lease liabilities." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 21.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Increase (Decrease) in Other Current Liabilities", "documentation": "Amount of increase (decrease) in current liabilities classified as other." } } }, "auth_ref": [ "r785" ] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current liabilities", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 22.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepayments and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "zlab_IncreaseDecreaseInValueAddedTaxesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://zailab.com/20240930", "localname": "IncreaseDecreaseInValueAddedTaxesReceivable", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 24.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Value added tax recoverable", "label": "Increase (Decrease) In Value Added Taxes Receivable", "documentation": "Increase (Decrease) In Value Added Taxes Receivable" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r700", "r710", "r720", "r744", "r752", "r756", "r764" ] }, "zlab_InnovivaInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://zailab.com/20240930", "localname": "InnovivaInc.Member", "presentation": [ "http://zailab.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Innoviva Inc.", "label": "Innoviva Inc. [Member]", "documentation": "Innoviva Inc." } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r762" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r692", "r768" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r692", "r768" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r692", "r768" ] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": [ "http://zailab.com/role/IntangibleAssetsNet" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets, Net", "label": "Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": [ "r212", "r223", "r225", "r609", "r610" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r213", "r812", "r813" ] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest expense", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": [ "r192", "r784" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r144", "r146", "r147" ] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://zailab.com/role/InventoriesNet" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories, Net", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r209" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://zailab.com/role/InventoriesNetSummaryofInventoriesNetDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://zailab.com/role/InventoriesNetSummaryofInventoriesNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r77", "r617" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 }, "http://zailab.com/role/InventoriesNetSummaryofInventoriesNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://zailab.com/role/InventoriesNetSummaryofInventoriesNetDetails", "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories, net", "totalLabel": "Inventories, net", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r128", "r616", "r660" ] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://zailab.com/role/InventoriesNetSummaryofInventoriesNetDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://zailab.com/role/InventoriesNetSummaryofInventoriesNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r77", "r619" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://zailab.com/role/InventoriesNetSummaryofInventoriesNetDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://zailab.com/role/InventoriesNetSummaryofInventoriesNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work in progress", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r77", "r618" ] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWriteDown", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory write-down", "label": "Inventory Write-down", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": [ "r210" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r184", "r191", "r197", "r627", "r783" ] }, "zlab_LaboratoryEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://zailab.com/20240930", "localname": "LaboratoryEquipmentMember", "presentation": [ "http://zailab.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Laboratory equipment", "label": "Laboratory Equipment [Member]", "documentation": "Laboratory equipment." } } }, "auth_ref": [] }, "zlab_LandUseRightsNetNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://zailab.com/20240930", "localname": "LandUseRightsNetNoncurrent", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Land use rights, net", "label": "Land Use Rights Net Noncurrent", "documentation": "Land use rights, net noncurrent." } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://zailab.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r79", "r418" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [ "http://zailab.com/role/BorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LettersOfCreditOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LettersOfCreditOutstandingAmount", "crdr": "credit", "presentation": [ "http://zailab.com/role/BorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letters of credit outstanding", "label": "Letters of Credit Outstanding, Amount", "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r12", "r40", "r41", "r42", "r44", "r45", "r46", "r47", "r152", "r204", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r375", "r376", "r377", "r400", "r535", "r625", "r686", "r827", "r871", "r872" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and shareholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r54", "r89", "r473", "r660", "r790", "r804", "r863" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and shareholders\u2019 equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r42", "r115", "r152", "r204", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r375", "r376", "r377", "r400", "r660", "r827", "r871", "r872" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "zlab_LicensesAndCollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://zailab.com/20240930", "localname": "LicensesAndCollaborativeArrangementDisclosureTextBlock", "presentation": [ "http://zailab.com/role/LicenseandCollaborationAgreements" ], "lang": { "en-us": { "role": { "terseLabel": "License and Collaboration Agreements", "label": "Licenses And Collaborative Arrangement Disclosure [Text Block]", "documentation": "Licenses And Collaborative Arrangement Disclosure" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://zailab.com/role/BorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r39", "r43" ] }, "us-gaap_LoansPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansPayableMember", "presentation": [ "http://zailab.com/role/BorrowingsAdditionalInformationDetails", "http://zailab.com/role/BorrowingsSummaryofShortTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loans Payable", "label": "Loans Payable [Member]", "documentation": "Borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://zailab.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermInvestments", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Long term investments", "label": "Long-Term Investments", "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)." } } }, "auth_ref": [ "r117" ] }, "zlab_ManufacturingEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://zailab.com/20240930", "localname": "ManufacturingEquipmentMember", "presentation": [ "http://zailab.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Manufacturing equipment", "label": "Manufacturing Equipment [Member]", "documentation": "Manufacturing equipment." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://zailab.com/role/IntangibleAssetsNetAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r240", "r241", "r242", "r243", "r308", "r346", "r392", "r427", "r491", "r493", "r501", "r527", "r528", "r582", "r584", "r586", "r587", "r589", "r607", "r608", "r629", "r636", "r647", "r654", "r655", "r656", "r657", "r670", "r829", "r873", "r874", "r875", "r876", "r877", "r878" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r736" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r736" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://zailab.com/role/IntangibleAssetsNetAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r240", "r241", "r242", "r243", "r308", "r346", "r392", "r427", "r491", "r493", "r501", "r527", "r528", "r582", "r584", "r586", "r587", "r589", "r607", "r608", "r629", "r636", "r647", "r654", "r655", "r656", "r670", "r829", "r873", "r874", "r875", "r876", "r877", "r878" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r755" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r763" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r737" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r145" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r145" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r72", "r73", "r74" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 19.0 }, "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "http://zailab.com/role/LossPerShareComputationofBasicandDilutedNetLossPerShareDetails", "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows", "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofComprehensiveLoss", "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations", "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r63", "r74", "r93", "r113", "r130", "r132", "r136", "r152", "r160", "r162", "r163", "r164", "r165", "r166", "r169", "r170", "r176", "r204", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r369", "r372", "r386", "r400", "r477", "r559", "r577", "r578", "r685", "r827" ] }, "us-gaap_NetIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAbstract", "presentation": [ "http://zailab.com/role/LossPerShareComputationofBasicandDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Numerator:", "label": "Net Income (Loss) Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://zailab.com/role/BasisofPresentationandConsolidationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "zlab_NingboBankWorkingCapitalLoanFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://zailab.com/20240930", "localname": "NingboBankWorkingCapitalLoanFacilityMember", "presentation": [ "http://zailab.com/role/BorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ningbo Bank Working Capital Loan Facility", "label": "Ningbo Bank Working Capital Loan Facility [Member]", "documentation": "Ningbo Bank Working Capital Loan Facility" } } }, "auth_ref": [] }, "zlab_NonCashLeaseExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://zailab.com/20240930", "localname": "NonCashLeaseExpenses", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Noncash lease expenses", "label": "Non Cash Lease Expenses", "documentation": "Non-cash lease expenses." } } }, "auth_ref": [] }, "zlab_NonCashPayablesForIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://zailab.com/20240930", "localname": "NonCashPayablesForIntangibleAssets", "crdr": "debit", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Payables for acquisition of intangible assets", "label": "Non Cash, Payables For Intangible Assets", "documentation": "Non-cash payables for intangible assets." } } }, "auth_ref": [] }, "zlab_NonCashPayablesForTreasuryStock": { "xbrltype": "monetaryItemType", "nsuri": "http://zailab.com/20240930", "localname": "NonCashPayablesForTreasuryStock", "crdr": "credit", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Payables for treasury stock", "label": "Non Cash, Payables For Treasury Stock", "documentation": "Non cash payables for treasury stock." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r736" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r700", "r710", "r720", "r744", "r752" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r727" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r726" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r744" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r763" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r763" ] }, "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1", "crdr": "debit", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Payables for purchase of property and equipment", "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired", "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r21", "r22", "r23" ] }, "zlab_NuzyraMember": { "xbrltype": "domainItemType", "nsuri": "http://zailab.com/20240930", "localname": "NuzyraMember", "presentation": [ "http://zailab.com/role/RevenuesDisaggregationofNetRevenuebyProductDetails" ], "lang": { "en-us": { "role": { "terseLabel": "NUZYRA", "label": "Nuzyra [Member]", "documentation": "Nuzyra." } } }, "auth_ref": [] }, "us-gaap_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OfficeEquipmentMember", "presentation": [ "http://zailab.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Office equipment", "label": "Office Equipment [Member]", "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r96", "r626", "r797", "r798", "r799", "r800", "r801" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current operating lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r416" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current operating lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r416" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r415" ] }, "zlab_OptuneMember": { "xbrltype": "domainItemType", "nsuri": "http://zailab.com/20240930", "localname": "OptuneMember", "presentation": [ "http://zailab.com/role/RevenuesDisaggregationofNetRevenuebyProductDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OPTUNE", "label": "Optune [Member]", "documentation": "Optune" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://zailab.com/role/OrganizationandPrincipalActivities" ], "lang": { "en-us": { "role": { "terseLabel": "Organization and Principal Activities", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r37", "r83", "r502", "r503" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofComprehensiveLoss", "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments", "verboseLabel": "Foreign currency translation", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": [ "r4", "r8", "r84" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "verboseLabel": "Other comprehensive income, net of tax of nil:", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1", "crdr": "debit", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofComprehensiveLossParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income, tax", "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r4", "r8", "r84" ] }, "us-gaap_OtherCostOfOperatingRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCostOfOperatingRevenue", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cost of collaboration revenue", "label": "Other Cost of Operating Revenue", "documentation": "Other costs incurred during the reporting period related to other revenue generating activities." } } }, "auth_ref": [ "r62" ] }, "zlab_OtherCounterpartiesMember": { "xbrltype": "domainItemType", "nsuri": "http://zailab.com/20240930", "localname": "OtherCounterpartiesMember", "presentation": [ "http://zailab.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Counterparties", "label": "Other Counterparties [Member]", "documentation": "Other Counterparties" } } }, "auth_ref": [] }, "zlab_OtherCurrentLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://zailab.com/20240930", "localname": "OtherCurrentLiabilitiesDisclosureTextBlock", "presentation": [ "http://zailab.com/role/OtherCurrentLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Other Current Liabilities", "label": "Other Current Liabilities Disclosure [Text Block]", "documentation": "Other current liabilities disclosure." } } }, "auth_ref": [] }, "us-gaap_OtherCurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentLiabilitiesTableTextBlock", "presentation": [ "http://zailab.com/role/OtherCurrentLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Current Liabilities", "label": "Other Current Liabilities [Table Text Block]", "documentation": "Tabular disclosure of other current liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndExpensesAbstract", "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 }, "http://zailab.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://zailab.com/role/OtherCurrentLiabilitiesDetails", "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "totalLabel": "Total", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r41", "r660" ] }, "us-gaap_OtherLiabilitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Other Liabilities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r45" ] }, "us-gaap_OtherNonoperatingGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingGainsLosses", "crdr": "credit", "calculation": { "http://zailab.com/role/OtherIncomeNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://zailab.com/role/OtherIncomeNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Others miscellaneous gain", "label": "Other Nonoperating Gains (Losses)", "documentation": "Amount of gain (loss) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r65", "r67" ] }, "us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeAndExpenseTextBlock", "presentation": [ "http://zailab.com/role/OtherIncomeNet" ], "lang": { "en-us": { "role": { "terseLabel": "Other Income, Net", "label": "Other Nonoperating Income and Expense [Text Block]", "documentation": "The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items." } } }, "auth_ref": [ "r141", "r142" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 5.0 }, "http://zailab.com/role/OtherIncomeNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://zailab.com/role/OtherIncomeNetDetails", "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Other income, net", "totalLabel": "Total", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r67" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r736" ] }, "us-gaap_OtherSundryLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherSundryLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://zailab.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://zailab.com/role/OtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Sundry Liabilities, Current", "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date." } } }, "auth_ref": [ "r30", "r41" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r698", "r708", "r718", "r750" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r701", "r711", "r721", "r753" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r701", "r711", "r721", "r753" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r725" ] }, "zlab_PayablesForPurchaseOfPropertyAndEquipmentCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://zailab.com/20240930", "localname": "PayablesForPurchaseOfPropertyAndEquipmentCurrent", "crdr": "credit", "calculation": { "http://zailab.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://zailab.com/role/OtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payables for purchase of property and equipment", "label": "Payables For Purchase Of Property And Equipment Current", "documentation": "Payables for purchase of property and equipment current." } } }, "auth_ref": [] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments of debt issuance costs", "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r19" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Taxes paid related to settlement of equity awards", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r143" ] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisition of intangible assets", "label": "Payments to Acquire Intangible Assets", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r70" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r70" ] }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireShortTermInvestments", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of short-term investments", "label": "Payments to Acquire Short-Term Investments", "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." } } }, "auth_ref": [ "r69" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r735" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r735" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r727" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r744" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r737" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r726" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": [ "r728" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r772" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r727" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Prepayments and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r779" ] }, "zlab_PrepaymentsForEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://zailab.com/20240930", "localname": "PrepaymentsForEquipment", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Prepayments for equipment", "label": "Prepayments For Equipment", "documentation": "Prepayments for equipment." } } }, "auth_ref": [] }, "zlab_PriorToApril2023Member": { "xbrltype": "domainItemType", "nsuri": "http://zailab.com/20240930", "localname": "PriorToApril2023Member", "presentation": [ "http://zailab.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prior to April 2023", "label": "Prior To April 2023 [Member]", "documentation": "Prior To April 2023" } } }, "auth_ref": [] }, "zlab_ProceedsFromDisposalOfLandUseRights": { "xbrltype": "monetaryItemType", "nsuri": "http://zailab.com/20240930", "localname": "ProceedsFromDisposalOfLandUseRights", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from disposal of land use right", "label": "Proceeds From Disposal Of Land Use Rights", "documentation": "Proceeds From Disposal Of Land Use Rights" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from maturity of short-term investment", "label": "Proceeds from Maturities, Prepayments and Calls of Short-Term Investments", "documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." } } }, "auth_ref": [ "r17", "r69" ] }, "us-gaap_ProceedsFromSaleOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfIntangibleAssets", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of intellectual property", "label": "Proceeds from Sale of Intangible Assets", "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r68" ] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from the sale of property and equipment", "label": "Proceeds from Sale of Property, Plant, and Equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r68" ] }, "us-gaap_ProceedsFromShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromShortTermDebt", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from short-term debt", "label": "Proceeds from Short-Term Debt", "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r18" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercises of stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r3", "r11" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://zailab.com/role/LicenseandCollaborationAgreementsDetails", "http://zailab.com/role/RevenuesDisaggregationofNetRevenuebyProductDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r198", "r428", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r612", "r637", "r669", "r670", "r671", "r673", "r675", "r822", "r823", "r830", "r882", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911" ] }, "us-gaap_ProductionRelatedImpairmentsOrCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductionRelatedImpairmentsOrCharges", "crdr": "debit", "presentation": [ "http://zailab.com/role/InventoriesNetAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory write-down", "label": "Production Related Impairments or Charges", "documentation": "Nonrecurring impairment charges related to the write-off of production-related equipment and inventory. This tag is used when an Entity charges this cost to cost of goods sold." } } }, "auth_ref": [ "r60" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://zailab.com/role/LicenseandCollaborationAgreementsDetails", "http://zailab.com/role/RevenuesDisaggregationofNetRevenuebyProductDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r198", "r428", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r612", "r637", "r669", "r670", "r671", "r673", "r675", "r822", "r823", "r830", "r882", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911" ] }, "zlab_PropertyAndEquipmentAndCommercialManufacturingDevelopmentActivitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://zailab.com/20240930", "localname": "PropertyAndEquipmentAndCommercialManufacturingDevelopmentActivitiesMember", "presentation": [ "http://zailab.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment and Commercial Manufacturing Development Activities", "label": "Property And Equipment And Commercial Manufacturing Development Activities [Member]", "documentation": "Property And Equipment And Commercial Manufacturing Development Activities" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Property Plant And Equipment", "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://zailab.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r7", "r418" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://zailab.com/role/PropertyandEquipmentNet" ], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment, Net", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r78", "r104", "r107", "r108" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://zailab.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://zailab.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r79", "r118", "r475" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://zailab.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r418" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 }, "http://zailab.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://zailab.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails", "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r7", "r418", "r464", "r475", "r660" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://zailab.com/role/PropertyandEquipmentNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property and Equipment, Net", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r7" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://zailab.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r79", "r418" ] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for credit losses", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r140", "r208" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r725" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r725" ] }, "zlab_QinlockMember": { "xbrltype": "domainItemType", "nsuri": "http://zailab.com/20240930", "localname": "QinlockMember", "presentation": [ "http://zailab.com/role/RevenuesDisaggregationofNetRevenuebyProductDetails" ], "lang": { "en-us": { "role": { "terseLabel": "QINLOCK", "label": "Qinlock [Member]", "documentation": "Qinlock" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://zailab.com/role/IntangibleAssetsNetAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r240", "r241", "r242", "r243", "r301", "r308", "r336", "r337", "r338", "r346", "r392", "r424", "r425", "r427", "r491", "r493", "r501", "r527", "r528", "r582", "r584", "r586", "r587", "r589", "r607", "r608", "r629", "r636", "r647", "r654", "r655", "r656", "r657", "r670", "r679", "r820", "r829", "r861", "r874", "r875", "r876", "r877", "r878" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://zailab.com/role/IntangibleAssetsNetAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r240", "r241", "r242", "r243", "r301", "r308", "r336", "r337", "r338", "r346", "r392", "r424", "r425", "r427", "r491", "r493", "r501", "r527", "r528", "r582", "r584", "r586", "r587", "r589", "r607", "r608", "r629", "r636", "r647", "r654", "r655", "r656", "r657", "r670", "r679", "r820", "r829", "r861", "r874", "r875", "r876", "r877", "r878" ] }, "zlab_ReceivablesForStockOptionExerciseUnderEquityIncentivePlans": { "xbrltype": "monetaryItemType", "nsuri": "http://zailab.com/20240930", "localname": "ReceivablesForStockOptionExerciseUnderEquityIncentivePlans", "crdr": "debit", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Receivables for stock option exercise under equity incentive plans", "label": "Receivables for Stock Option Exercise under Equity Incentive Plans", "documentation": "Receivables for Stock Option Exercise under Equity Incentive Plans" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r693", "r703", "r713", "r745" ] }, "zlab_RegulatoryMilestoneFeesMember": { "xbrltype": "domainItemType", "nsuri": "http://zailab.com/20240930", "localname": "RegulatoryMilestoneFeesMember", "presentation": [ "http://zailab.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Regulatory milestone fees", "label": "Regulatory Milestone Fees [Member]", "documentation": "Regulatory Milestone Fees" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfShortTermDebt", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayment of short-term bank borrowings", "label": "Repayments of Short-Term Debt", "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r71" ] }, "zlab_RepotrectinibMember": { "xbrltype": "domainItemType", "nsuri": "http://zailab.com/20240930", "localname": "RepotrectinibMember", "presentation": [ "http://zailab.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repotrectinib", "label": "Repotrectinib [Member]", "documentation": "Repotrectinib" } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://zailab.com/role/BorrowingsAdditionalInformationDetails", "http://zailab.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r154", "r155", "r261", "r285", "r420", "r426", "r465", "r621", "r622" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Research and development", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r347", "r610", "r627", "r879" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://zailab.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r694", "r704", "r714", "r746" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r695", "r705", "r715", "r747" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r702", "r712", "r722", "r754" ] }, "us-gaap_RestrictedAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedAssetsDisclosureTextBlock", "presentation": [ "http://zailab.com/role/RestrictedNetAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Net Assets", "label": "Restricted Assets Disclosure [Text Block]", "documentation": "The entire disclosure for assets that are restricted in their use, generally by contractual agreements or regulatory requirements. This would include, but not limited to, a description of the restricted assets and the terms of the restriction." } } }, "auth_ref": [] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashCurrent", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://zailab.com/role/BorrowingsAdditionalInformationDetails", "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash, current", "label": "Restricted Cash, Current", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r776", "r787" ] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash, non-current", "label": "Restricted Cash, Noncurrent", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r101", "r777", "r787" ] }, "zlab_RestrictedNetAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://zailab.com/20240930", "localname": "RestrictedNetAssetsLineItems", "presentation": [ "http://zailab.com/role/RestrictedNetAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Restricted Net Assets [Line Items]", "label": "Restricted Net Assets [Line Items]", "documentation": "Restricted net assets." } } }, "auth_ref": [] }, "zlab_RestrictedNetAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://zailab.com/20240930", "localname": "RestrictedNetAssetsTable", "presentation": [ "http://zailab.com/role/RestrictedNetAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Net Assets [Table]", "label": "Restricted Net Assets [Table]", "documentation": "Restricted net assets ." } } }, "auth_ref": [] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://zailab.com/role/LossPerShareSummaryofAntiDilutiveSharesExcludedfromCalculationofDilutedLossPerShareDetails", "http://zailab.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted shares", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r24" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r51", "r82", "r472", "r498", "r500", "r509", "r538", "r660" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r112", "r157", "r158", "r159", "r161", "r166", "r168", "r170", "r205", "r206", "r226", "r359", "r360", "r366", "r367", "r368", "r370", "r371", "r372", "r378", "r380", "r381", "r383", "r384", "r413", "r414", "r495", "r497", "r511", "r916" ] }, "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://zailab.com/role/RevenuesAdditionalInformationDetails", "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration revenue", "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer", "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606." } } }, "auth_ref": [ "r100", "r858" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 1.0 }, "http://zailab.com/role/RevenuesSummaryofProductRevenueDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://zailab.com/role/RevenuesDisaggregationofNetRevenuebyProductDetails", "http://zailab.com/role/RevenuesSummaryofProductRevenueDetails", "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Product revenue, net", "totalLabel": "Product revenue - net", "verboseLabel": "Product revenue - net", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r94", "r95", "r184", "r189", "r190", "r195", "r197", "r198", "r199", "r201", "r298", "r299", "r428" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://zailab.com/role/Revenues" ], "lang": { "en-us": { "role": { "verboseLabel": "Revenues", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r110", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r300" ] }, "zlab_RevenueFromContractWithCustomersExcludingAssessedTaxAdjustmentsForRebatesAndSalesReturns": { "xbrltype": "monetaryItemType", "nsuri": "http://zailab.com/20240930", "localname": "RevenueFromContractWithCustomersExcludingAssessedTaxAdjustmentsForRebatesAndSalesReturns", "crdr": "debit", "calculation": { "http://zailab.com/role/RevenuesSummaryofProductRevenueDetails": { "parentTag": "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://zailab.com/role/RevenuesSummaryofProductRevenueDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Rebates and sales returns", "label": "Revenue From Contract With Customers, Excluding Assessed Tax, Adjustments For Rebates And Sales Returns", "documentation": "Revenue From Contract With Customers, Excluding Assessed Tax, Adjustments For Rebates And Sales Returns" } } }, "auth_ref": [] }, "zlab_RevenueFromContractWithCustomersExcludingAssessedTaxBeforeAdjustmentsForRebatesAndSalesReturns": { "xbrltype": "monetaryItemType", "nsuri": "http://zailab.com/20240930", "localname": "RevenueFromContractWithCustomersExcludingAssessedTaxBeforeAdjustmentsForRebatesAndSalesReturns", "crdr": "credit", "calculation": { "http://zailab.com/role/RevenuesSummaryofProductRevenueDetails": { "parentTag": "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://zailab.com/role/RevenuesSummaryofProductRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product revenue - gross", "label": "Revenue From Contract With Customers, Excluding Assessed Tax, Before Adjustments For Rebates And Sales Returns", "documentation": "Amount of revenue from contract with customers excluding assessed tax, before adjustments for rebates and sales return." } } }, "auth_ref": [] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total revenues", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r94", "r95", "r137", "r152", "r184", "r189", "r190", "r195", "r197", "r198", "r199", "r201", "r204", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r400", "r463", "r627", "r827" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use asset acquired under operating leases", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r417", "r659" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r763" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r763" ] }, "zlab_SPDBankWorkingCapitalLoanFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://zailab.com/20240930", "localname": "SPDBankWorkingCapitalLoanFacilityMember", "presentation": [ "http://zailab.com/role/BorrowingsAdditionalInformationDetails", "http://zailab.com/role/BorrowingsSummaryofShortTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SPD Bank Working Capital Loans", "label": "SPD Bank Working Capital Loan Facility [Member]", "documentation": "SPD Bank Working Capital Loan Facility" } } }, "auth_ref": [] }, "zlab_SULDURMember": { "xbrltype": "domainItemType", "nsuri": "http://zailab.com/20240930", "localname": "SULDURMember", "presentation": [ "http://zailab.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SUL-DUR", "label": "SUL-DUR [Member]", "documentation": "SUL-DUR" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://zailab.com/role/LossPerShareSummaryofAntiDilutiveSharesExcludedfromCalculationofDilutedLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r24" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://zailab.com/role/LossPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Anti-Dilutive Shares Excluded from Calculation of Diluted Loss Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r24" ] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashAndCashEquivalentsTable", "presentation": [ "http://zailab.com/role/CashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Cash And Cash Equivalents [Table]", "label": "Cash and Cash Equivalent [Table]", "documentation": "Disclosure of information about cash and cash equivalent by type. Excludes restricted cash and cash equivalent." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "presentation": [ "http://zailab.com/role/CashandCashEquivalentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash and Cash Equivalents", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "documentation": "Tabular disclosure of the components of cash and cash equivalents." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://zailab.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r373" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://zailab.com/role/LossPerShareTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Summary of Basic and Diluted Net Loss Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r796" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://zailab.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r33" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://zailab.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-Based Compensation expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r33" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://zailab.com/role/IntangibleAssetsNetAdditionalInformationDetails", "http://zailab.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Asset, Finite-Lived [Table]", "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": [ "r213", "r219", "r221", "r222", "r224", "r429", "r610", "r630" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://zailab.com/role/IntangibleAssetsNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r630", "r811" ] }, "zlab_ScheduleOfGrossAndNetRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://zailab.com/20240930", "localname": "ScheduleOfGrossAndNetRevenueTableTextBlock", "presentation": [ "http://zailab.com/role/RevenuesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Product Revenue", "label": "Schedule Of Gross And Net Revenue [Table Text Block]", "documentation": "Schedule Of Gross And Net Revenue" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://zailab.com/role/InventoriesNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventories, Net", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r13", "r55", "r56", "r57" ] }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "presentation": [ "http://zailab.com/role/OtherIncomeNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Income, Net", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://zailab.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Property Plant And Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r7", "r418" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://zailab.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r310", "r312", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339" ] }, "us-gaap_ScheduleOfShortTermDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShortTermDebtTable", "presentation": [ "http://zailab.com/role/BorrowingsAdditionalInformationDetails", "http://zailab.com/role/BorrowingsSummaryofShortTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Short-Term Debt [Table]", "label": "Short-Term Debt [Table]", "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability." } } }, "auth_ref": [ "r40" ] }, "us-gaap_ScheduleOfShortTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShortTermDebtTextBlock", "presentation": [ "http://zailab.com/role/BorrowingsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Short-Term Debt", "label": "Schedule of Short-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation." } } }, "auth_ref": [ "r40" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://zailab.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r687" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://zailab.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r689" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [ "http://zailab.com/role/RestrictedNetAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r199", "r200", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r524", "r525", "r526", "r583", "r585", "r588", "r590", "r596", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r613", "r638", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r672", "r679", "r830", "r882", "r884", "r885", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Selling, general, and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r64" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://zailab.com/role/ShareBasedCompensationSummaryofSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "zlab_ShanghaiPudongDevelopmentBankCo.Ltd.Member": { "xbrltype": "domainItemType", "nsuri": "http://zailab.com/20240930", "localname": "ShanghaiPudongDevelopmentBankCo.Ltd.Member", "presentation": [ "http://zailab.com/role/BorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SPD Bank", "label": "Shanghai Pudong Development Bank Co., Ltd. [Member]", "documentation": "Shanghai Pudong Development Bank Co., Ltd." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r5" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://zailab.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r648" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://zailab.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r310", "r312", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "presentation": [ "http://zailab.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-option awards granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted", "documentation": "Net number of non-option equity instruments granted to participants." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://zailab.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r321" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://zailab.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339" ] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [ "http://zailab.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche one", "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheThreeMember", "presentation": [ "http://zailab.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche three", "label": "Share-Based Payment Arrangement, Tranche Three [Member]", "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": [ "http://zailab.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche two", "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "zlab_ShareBasedPaymentArrangementTrancheFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://zailab.com/20240930", "localname": "ShareBasedPaymentArrangementTrancheFiveMember", "presentation": [ "http://zailab.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche five", "label": "Share-Based Payment Arrangement, Tranche Five [Member]", "documentation": "Share-Based Payment Arrangement, Tranche Five" } } }, "auth_ref": [] }, "zlab_ShareBasedPaymentArrangementTrancheFourMember": { "xbrltype": "domainItemType", "nsuri": "http://zailab.com/20240930", "localname": "ShareBasedPaymentArrangementTrancheFourMember", "presentation": [ "http://zailab.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche four", "label": "Share-Based Payment Arrangement, Tranche Four [Member]", "documentation": "Share-Based Payment Arrangement, Tranche Four" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://zailab.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting percentage", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r831" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://zailab.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r649" ] }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Receipt of shares netted to satisfy tax withholding obligations related to share-based compensation (in shares)", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermBorrowings", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://zailab.com/role/BorrowingsAdditionalInformationDetails", "http://zailab.com/role/BorrowingsSummaryofShortTermDebtDetails", "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term debt", "verboseLabel": "Total short-term debt", "label": "Short-Term Debt", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r38", "r86", "r660", "r880" ] }, "us-gaap_ShortTermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtLineItems", "presentation": [ "http://zailab.com/role/BorrowingsAdditionalInformationDetails", "http://zailab.com/role/BorrowingsSummaryofShortTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-Term Debt [Line Items]", "label": "Short-Term Debt [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeAxis", "presentation": [ "http://zailab.com/role/BorrowingsAdditionalInformationDetails", "http://zailab.com/role/BorrowingsSummaryofShortTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-Term Debt, Type [Axis]", "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": [ "r40", "r817", "r818", "r819" ] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeDomain", "presentation": [ "http://zailab.com/role/BorrowingsAdditionalInformationDetails", "http://zailab.com/role/BorrowingsSummaryofShortTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-Term Debt, Type [Domain]", "label": "Short-Term Debt, Type [Domain]", "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": [ "r38", "r817", "r818", "r819" ] }, "us-gaap_ShortTermDebtWeightedAverageInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtWeightedAverageInterestRate", "presentation": [ "http://zailab.com/role/BorrowingsSummaryofShortTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average interest rate per annum", "label": "Short-Term Debt, Weighted Average Interest Rate, at Point in Time", "documentation": "Weighted average interest rate of short-term debt outstanding calculated at point in time." } } }, "auth_ref": [ "r39", "r247" ] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestments", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Short-Term Investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": [ "r90", "r91", "r778" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://zailab.com/role/BasisofPresentationandConsolidationandSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation and Consolidation and Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r75", "r149" ] }, "us-gaap_StandbyLettersOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StandbyLettersOfCreditMember", "presentation": [ "http://zailab.com/role/BorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Standby Letters of Credit", "label": "Standby Letters of Credit [Member]", "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation." } } }, "auth_ref": [ "r0", "r824", "r912", "r913" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://zailab.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r111", "r123", "r124", "r125", "r152", "r174", "r175", "r177", "r179", "r186", "r187", "r204", "r248", "r250", "r251", "r252", "r255", "r256", "r283", "r284", "r286", "r287", "r288", "r400", "r505", "r506", "r507", "r508", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r523", "r537", "r560", "r579", "r591", "r592", "r593", "r594", "r595", "r774", "r788", "r795" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r9", "r49", "r52", "r53", "r112", "r134", "r135", "r136", "r157", "r158", "r159", "r161", "r166", "r168", "r170", "r185", "r205", "r206", "r226", "r289", "r359", "r360", "r366", "r367", "r368", "r370", "r371", "r372", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r405", "r406", "r407", "r408", "r409", "r410", "r413", "r414", "r419", "r478", "r495", "r496", "r497", "r511", "r579" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [ "http://zailab.com/role/RestrictedNetAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r199", "r200", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r524", "r525", "r526", "r583", "r585", "r588", "r590", "r596", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r613", "r638", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r672", "r679", "r830", "r882", "r884", "r885", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r157", "r158", "r159", "r185", "r414", "r428", "r504", "r523", "r529", "r530", "r531", "r532", "r533", "r534", "r537", "r540", "r541", "r542", "r543", "r544", "r546", "r547", "r548", "r549", "r551", "r552", "r553", "r554", "r555", "r557", "r561", "r562", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r579", "r680" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Consolidated balance sheets", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Consolidated statements of comprehensive loss", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r157", "r158", "r159", "r185", "r202", "r414", "r428", "r504", "r523", "r529", "r530", "r531", "r532", "r533", "r534", "r537", "r540", "r541", "r542", "r543", "r544", "r546", "r547", "r548", "r549", "r551", "r552", "r553", "r554", "r555", "r557", "r561", "r562", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r579", "r680" ] }, "zlab_StatutoryReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://zailab.com/20240930", "localname": "StatutoryReserves", "crdr": "credit", "presentation": [ "http://zailab.com/role/RestrictedNetAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statutory reserves", "label": "Statutory Reserves", "documentation": "Statutory reserves." } } }, "auth_ref": [] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r697", "r707", "r717", "r749" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of ordinary shares upon vesting of restricted shares (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r9", "r48", "r49", "r82" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of share options (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r9", "r48", "r49", "r82", "r322" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of ordinary shares upon vesting of restricted shares", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r9", "r82" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of share options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r9", "r49", "r52", "r53", "r82" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets", "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total shareholders\u2019 equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r49", "r52", "r53", "r76", "r539", "r556", "r580", "r581", "r660", "r686", "r790", "r804", "r863", "r916" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders\u2019 equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of cash flow information", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "currency_TWD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2024", "localname": "TWD", "presentation": [ "http://zailab.com/role/CashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Taiwan dollar (\u201cTW$\u201d)", "label": "Taiwan, New Dollars" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r743" ] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": { "http://zailab.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://zailab.com/role/OtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax payables", "label": "Taxes Payable, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r40", "r41" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r735" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r742" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r762" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r764" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://zailab.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r765" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r766" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": [ "r766" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r764" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r764" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r767" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r765" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r31" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical", "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock (in shares)", "negatedPeriodStartLabel": "Beginning balance (in shares)", "negatedPeriodEndLabel": "Ending balance (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r31" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "negatedLabel": "Treasury Stock (at cost, 4,912,200 shares as of both September\u00a030, 2024 and December\u00a031, 2023)", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r31", "r32", "r52" ] }, "currency_USD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2024", "localname": "USD", "presentation": [ "http://zailab.com/role/CashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "US$", "label": "United States of America, Dollars" } } }, "auth_ref": [] }, "us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain", "presentation": [ "http://zailab.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain]", "label": "Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain]", "documentation": "General description of the goods or services to be purchased from the counterparty to the unconditional purchase arrangement." } } }, "auth_ref": [ "r235", "r236", "r238", "r239" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r761" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://zailab.com/role/IncomeTaxDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r349", "r356", "r650" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "crdr": "debit", "presentation": [ "http://zailab.com/role/IncomeTaxDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest and penalties on unrecognized tax benefits", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense", "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r355", "r650" ] }, "us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis", "presentation": [ "http://zailab.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]", "label": "Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]", "documentation": "Information by category of product and service for unrecorded unconditional purchase arrangement to acquire product or service or both." } } }, "auth_ref": [ "r235", "r236", "r238" ] }, "us-gaap_UnrecordedUnconditionalPurchaseObligationDueInNextRollingTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecordedUnconditionalPurchaseObligationDueInNextRollingTwelveMonths", "crdr": "credit", "presentation": [ "http://zailab.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase obligation to be incurred within one year", "label": "Unrecorded Unconditional Purchase Obligation, Due in Next Rolling 12 Months", "documentation": "Amount of the fixed and determinable portion of the unrecorded unconditional purchase obligation maturing in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date." } } }, "auth_ref": [] }, "us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecordedUnconditionalPurchaseObligationLineItems", "presentation": [ "http://zailab.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecorded Unconditional Purchase Obligation [Line Items]", "label": "Unrecorded Unconditional Purchase Obligation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r235", "r236", "r238" ] }, "us-gaap_UnrecordedUnconditionalPurchaseObligationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecordedUnconditionalPurchaseObligationTable", "presentation": [ "http://zailab.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecorded Unconditional Purchase Obligation [Table]", "label": "Unrecorded Unconditional Purchase Obligation [Table]", "documentation": "Disclosure of information about unrecorded unconditional purchase obligation arrangement to purchase product and service. Includes, but is not limited to, information about asset pledged to secure payment and payment due in each of next five years and thereafter." } } }, "auth_ref": [ "r235", "r236", "r238" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://zailab.com/role/BasisofPresentationandConsolidationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r25", "r26", "r27", "r102", "r103", "r105", "r106" ] }, "us-gaap_ValueAddedTaxReceivableNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValueAddedTaxReceivableNoncurrent", "crdr": "debit", "calculation": { "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://zailab.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Value added tax recoverable", "label": "Value Added Tax Receivable, Noncurrent", "documentation": "Carrying amount due after one year of the balance sheet date (or one operating cycle), if longer of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities." } } }, "auth_ref": [ "r777" ] }, "us-gaap_VehiclesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VehiclesMember", "presentation": [ "http://zailab.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vehicle", "label": "Vehicles [Member]", "documentation": "Equipment used primarily for road transportation." } } }, "auth_ref": [] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": [ "http://zailab.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting [Axis]", "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": [ "http://zailab.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting [Domain]", "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": [ "r731" ] }, "zlab_VyvgartMember": { "xbrltype": "domainItemType", "nsuri": "http://zailab.com/20240930", "localname": "VyvgartMember", "presentation": [ "http://zailab.com/role/RevenuesDisaggregationofNetRevenuebyProductDetails" ], "lang": { "en-us": { "role": { "terseLabel": "VYVGART", "label": "vyvgart [Member]", "documentation": "vyvgart" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://zailab.com/role/LossPerShareComputationofBasicandDilutedNetLossPerShareDetails", "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average shares used in calculating net loss per ordinary share - diluted (in shares)", "verboseLabel": "Weighted average number of ordinary shares - diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r173", "r179" ] }, "zlab_WeightedAverageNumberOfShareOutstandingBasicAndDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://zailab.com/20240930", "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDilutedAbstract", "presentation": [ "http://zailab.com/role/LossPerShareComputationofBasicandDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Denominator:", "label": "Weighted Average Number Of Share Outstanding Basic And Diluted [Abstract]", "documentation": "Weighted average number of share outstanding basic and diluted." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://zailab.com/role/LossPerShareComputationofBasicandDilutedNetLossPerShareDetails", "http://zailab.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average shares used in calculating net loss per ordinary share - basic (in shares)", "verboseLabel": "Weighted average number of ordinary shares - basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r172", "r179" ] }, "zlab_XanomelineTrospiumChlorideMember": { "xbrltype": "domainItemType", "nsuri": "http://zailab.com/20240930", "localname": "XanomelineTrospiumChlorideMember", "presentation": [ "http://zailab.com/role/LicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Xanomeline-Trospium Chloride", "label": "Xanomeline-Trospium Chloride [Member]", "documentation": "Xanomeline-Trospium Chloride" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r729" ] }, "zlab_ZaiLabShanghaiCo.Ltd.Member": { "xbrltype": "domainItemType", "nsuri": "http://zailab.com/20240930", "localname": "ZaiLabShanghaiCo.Ltd.Member", "presentation": [ "http://zailab.com/role/BorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Zai Lab Shanghai", "label": "Zai Lab (Shanghai) Co., Ltd. [Member]", "documentation": "Zai Lab (Shanghai) Co., Ltd." } } }, "auth_ref": [] }, "zlab_ZaiLabSuzhouCompanyLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://zailab.com/20240930", "localname": "ZaiLabSuzhouCompanyLimitedMember", "presentation": [ "http://zailab.com/role/BorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Zai Lab Suzhou", "label": "Zai Lab Suzhou Company Limited [Member]", "documentation": "Zai Lab (Suzhou) company limited." } } }, "auth_ref": [] }, "zlab_ZejulaMember": { "xbrltype": "domainItemType", "nsuri": "http://zailab.com/20240930", "localname": "ZejulaMember", "presentation": [ "http://zailab.com/role/RevenuesDisaggregationofNetRevenuebyProductDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ZEJULA", "label": "Zejula [Member]", "documentation": "Zejula" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "12", "Subparagraph": "(f)(2)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481410/810-10-15-12" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-10" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479428/808-10-45-3" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(3)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-6" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-7" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/985-20/tableOfContent" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r611": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r612": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r613": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r614": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r615": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r621": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r623": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r625": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r626": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r627": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r632": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r687": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r688": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r689": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d-3" }, "r691": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r692": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r693": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r694": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r774": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "2", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481174/470-10-25-2" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-15" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-16" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 81 0001628280-24-046824-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-24-046824-xbrl.zip M4$L#!!0 ( .@V;%FYZ*LTL T! .-N$ 1 >FQA8BTR,#(T,#DS,"YH M=&WLO6MWX[BQ-OI]_PH>)6>GY[R4F_>+/:-WN=WNB7?;&M^_2F I$19DB5:E A*F)6X;8D7H.JI0E6A4/7S_WT=^<(SCF(O#'[Y MDWPB_4G @1.Z7O#TRY_.'RZNKO[T?WO_]?/_T^W^[Y?[:^%KZ*0C'"3"1811 M@EWAQ4N&0C+$PM_#Z#?O&0EW/DH&833J=K/;+L+Q)/*>AHF@2(I67%9\&YT. MU+Z-%61T-=M$7R+:F.?) ?#JU!JJ,)$OIFJZ,N]I 'G3[ M+K:[4A_^P\BP%*2)[JFJ.I9D&89MN*HFFRJR;%W1D&ZJLJ78KD'?.TQ@SC#O M(#[U7I-?.L,D&9]^_OSR\G+RVH_\DS!Z^NP%OA=@,N?/282"F$P))4"DSS - MJ2LI75GIY ]QL3=]"'U C)V3I_#Y,WQ!+M>*"].X^X30>'KQ ,5]^K;\B[F+ MG3 -DFBR_,GYEW,WP%RZ\/W\YRDL"5:NE!Q>5QE"Q. M"#Z..&(7B/9JE1SR.<(('N@^3L9P MFY/]]4LGP:_)9TK;S[W_^J__^CGQ$A_W"-VZ!9%^_IQ]^//G[-']T)WT?G:] M9R%.)C[^I>-Z\=A'D],@## ,P'L])1?B*/O5[Q MX)>.TP6 !VA$GH2]T\L 7C>Y@-%%R+\*7/SZ%SSI"!ZP?-!5[$Y/ MJ9DJ;8 MRL^?YYY:X247%-?)-R]VD/\/C*++P/T*:K-X#T"CUP5% L+W\9<4*GGVEF_P M23Q]A]SI$1K7]8([N#QTYU^A='I_53_^@G-XNDO?X*.GCI#IIE\ZH,].!]XK M=KL#Y,]KHT=CMOWF]U!!<[W@B>\TNGJQ>C MR?7PZ5T4NBE]RCWVR3IW-1HC+R)CC&^CBR&*GC!,G] #[I**H>F2#L IQE4, M9 TE%.GMV[]Y,')\[3W#>P.0P">O[^/S.,;)CQ@/4O_:&TRIH>M:IW>G_F.! M&)_GI2+" TQT+(Z7"#-1):W M)Z] W<_9^V8OR=\9AVE$_Z*JYI1PA(X[!@H" 8O/1QC%:81[V5_9ES]_GO^N M^)L\8^%YA,-O'Y:K_-,?#U^K/@LP_D &,7TFJ"'/Q>5+*9U1$D8??.W"_>3# MKS@(1UZP[+&;DF;N$9_G1__>K(-TU,?1"HZ,X==*-'2"R4I^7-S\8Y-GY5*2 M/0[T1?$YIHJ[^ OF!7\//!P)%+]XJ?5S87^]N;I".:?/J:ZKO@+%L,H M(>J;ZM.N),/_BOMFWTV'Z98NM;MD@9O_IOB[>,GGN7DO)X.R:S+DL\%/1-5E M?[KPLM>Q[SE>\AT3D BN!]]2AV&JLAX2F!*YY\)'<7P[>$A"Y[?S5P]DG&IX M-\KN_?GSTD=.9S]])D,LB/"1/>\97@1..<&MXP;Z;\#XO'B,:LYI0 MU9^M JVA_<[]AS8ONEM$+-02@[:RBG;N!AW*"LT"LUCT[)J@P\Y=N]:;-0QP M2=FYXWF(-A +C..>\L;12+4F0TGAGG*S].>>2C&!PO,8FY?LQDZJ&UW+_# 0!:N-%V[=L M&P@"U$9[QI)2ZYQ:VWW,O08!&DB75=N^J=I8$* !9FG<^6T#E[CSVU+&<>=W M8P.AKO,X&G=^FZ4_=WX;(CQW?MGA!7=^FZ,]WR;>C.9*??GY6MN]\B86W3KI MWW:G>Z^+;HV$U]ON0#>]Z-;)B[:[R?M>=.ND_:FUG:'-L)N+<$+-V[J6VA [<0VP)H]KN3NYYBZ0A+K7> 6U\BZ0AQK7=<]U? M.9W:#E(8K7=:&RFG4Q_]V^ZH[KF<3GV$;_M^;-/1FCIYT7:W>O_E=.JC_-A*M:8)1;7ZQZC-76=>#%;[[0V$ZVIC?YM=U3W':VIC?"M MW]=M/EI3&R_:[E8W$*VIC?:,E72J\Q2E'7J2NK[5YR0U&*VNC? M=F=YWU&*V@C?=L^8@2A%;;QH^]YR U&*VFC/PE;QCJ;&K!/\#7G1WY"?XB^3 MZ:]_AB>BR!E.KO$S]N?Q-;WH*ABG24ROD-MRL-MBUKUEGPTU]F*SF7->XR@Y MO4BC" ?.)".TD_]U^N/A*_O MIES-!NA:)T89B%S?_: %&F?/O&J%H MG1AESF-[AZ)__DL;]"ASKE@C%*T3H\PY5.]0]/Q'&S#*W(YG(Q2M$Z/,>6?O M4/3Q[VW *'..5B,4K;-_M<2\67R.!GC M>H'T8H":-) M"_4]D .4D:><%3"T6 .1^V%2RH4PKDP_!YKS&* M\3#TW:O1. J?:19'>TP@^3 \W_TSH59):+?_.TM+!2)$J4/2)*\"N/4IPG&+ M1*'=7G"#7*A5%ICUA;]Y@9?@:^\9NU M?"6)NB&US"["N#T*2V'6$V] 8:T=&TDVN(<'YG8W^?,[#'.4CMK#<&:]_K8P M'+VVB^',11@(%7/[^S9ZP-&SYY1CF__$_X8%;L?'CYOI^BLKS 4:6&!&,V?! M986Y> ,+S- V;_90JV0P%V9@@1G5.F_4QPSFH@MKF'$[3M+@,#O%RPIS,046 MF-'4FL%<)($%9C2U9C 72F"!&0VM&2ISD80US/BK%_B[+\[7T**A,N?F,\&- MAE8-M6T^^-YDHXEE0VV;$[XWV6ADW6B;%WZ3_CZ)#C0^I;;-"]\+,YI:-=KF MA>]+,AI9--KFA>]+,AI9,]KFA?]M\OP$I#G01:-M;OA^N-'0JJ&US0_?FVPT ML6QH;?/#]R8;3:P;&G-^^+34*CS!]?PT\9[Q W;2R$L\'%^^.G[J8O=;%(ZR M3 =$@/X>1K\!8_.V -Z?7^ GYEY0JY5,?R+M&_0=P")Z&R+L( M3ZX3]X0;_^] C-GP'8?8OB'&0CA99R[42"O8ARF,,AH##28W:%3>D"V <)>Z M8?!4JC- 8+H9.ABR-7C0CVN"'2XV[8LQX>7F,)L:N@-:^8"P'VEYM67/S[3FSKNTYHWUQ8H[*-CKP1ONBQ1QH!^_* M&\S%C*057#F:XS<&LV'8VCA3[8V$E"5M?3Z./)^D MT)\'[C5\%1TH#)B-@+(!@SN@9?083M%PF"@PF0U0[A\%?X-U&4S#^=W="']! M,7;!@J*69121>M/DUT?X#0CS+4S7*0BNC3; (7-14T9P.#/S"RB2W1>XA9Y; MRP:7(?%Q&.%U)CZ'X@909#::W!XHOH0+NVGBL'X@9 9#; MS(%X5,X*L_'GUN!PYT;BD2"Q;3%GYMQF[YG#<'L8'GZ0?<8CP2'S&YI7 5.. *XP=3(G=>ADR%@'B78]P$ZO^( 1\@'E_+<'7F!%R<1 M(C6H+E\))=0T5M+6:#]RWB74,ZTV(VVMTBWC54F,]B M-D"\$>_N<8Q1Y R!:Z6#LSG+#G258S:2RCS'FEK;F(TY,L^QIE8T9F-SS'.L MJ76L;6&LG6?P[BB!WV(N4+/F;.)5$(3/WC,"R=DZ87Y-:X6'']=??]SO7B5J MFZM$HS8!8RXPN)?_23VZ.P*_7X2C$8X<#_G? M49 .D).DD3=7D?G<2;QG;S=V[O8L_>R]GD8X#F'&.,[^'&+DTO&XWG/O9_A! M.>VIJF-)EF'8AJMJLJDBR]85#>FF*EN*[1K_(CB8W1,G$Q\X/O*"[A![3\/D M5-/'R=F+YR;#4UF2_M_._'4H>H)+DW!\:L!E9'!=+R @.%7,<0(7QV,4]'[N M1Y_A+=GOVG9 K/ ,BJUT$^ E.Z>NRKV>S.Y&R&29 Q\0MWIQ_?0)??5[\ MW+9.;&GY5]*)3#__3)\7%5_FA%6S.;H"S(10YI>.VGDSV7SX<*7@ABDAQA]@ MA&=CY+J UE-)D.$9Q0L^TYDO8^:,26K!I(P(#B;^7,ZEXG(83AB=DA>1=PT M/E5^'A\?SQ\D&81\=;7# PW(?+BQ_W5X]7,-;SFZ_" MY?]>_/G\YM=+X>+V^_>KAX>KVQOVY_#W\X<_7]W\^GA[(PI?+P1%TC6[PJA7 MR??NIJ$MG<:_EORWG9A,D8=ZBN'\ %/5GJ_I6N![.G](Z1P\WS\]-W M%/TFW ;XIS4BUL)%3SFQ[??7O(V73^W$DC=:/E>ME<5JJ(Q?R7I8%G ?#Q9I M$(XW!\3?X<'DX?$J*"CKX"QKA+:5I?JO*;BP./(G9.,J2CK"((Q&* &#[C4Y M'7BOV.TF43H5?*73>UTI]8G;!.DVE*6W!%R0)4K O_XXOW^\O+_^AW!_>7=[ M_RC<_;A_^'%^\R@\W@JP,C^2Y5=6A=M[0=8_N3\)M]^$QS]?"J5%>[I@GU\\ MDJ]E6]6$.1IM;$4QOHZ$D9 ,L?"? D)"YD4(&(;F?F"%N:.W7V:1DGDDNO!) M=P2/&)+;NBZ:="<815T<%,A4P7+"XX0Z2__]!]F0SE1)%(CGL_$JU1K*W]YO MLT9QQ<\5?W;4-*8AC]6:?X#\>*KZM4XO/&35_WA_?O-P114\U_V;ZOYDBJ)" M^0^B<"1DAK20A,*A.$TDD.?%)( H?/- ?8($P$)S6F&5NZ2!.G)S=F\A5SJ) M;\I=U5)(X?6CA+BR/FE0^*L7;*@2[8J_>M)/OGW^*DC(!]4UC^1 M)URCON"'3V'V\9L0F#U^_=#BI4CC5[I"M!:X50%ZCY_H.;4@(9D9!4B-3N^? MYU?"]?D7X?KJ.XFGM0FJ*_SFRU?D) *9IA .A-G$!10+#V/LD/T%5_ "P4MB MX6)(K=QU/G;K9?)0#$AM?;B\QD=]W(+,H;(',VBM5%2T)#-]04X/16! TITR MNFEYD6U/7H3NO!,'(W).L?N$HG$4/N>;F#,'SH1%%DU@_,)5[*/ C>LU-MM. MYT?T>I5O>F;GL^:M"*O3LZTN/%K3[=5FQ-0"91NJUF;ZFZ)- $N4)@T*_Y-& M7NQZ#K5&PP'="YQ#)[TT>D*!]SO]^Z>6(&I#M@LGF\&MKZIR?>ZZ$8[C_)]K>)YHHD*[*T 65;8'IL"%I5UH3O"%S# MAR3".*%KK3932 ^I!Y8)>"[TBPLTZD>>^X1%X?NY*/QX.-^%X3%%7!.0DA19 M4P[.S*13^Y3#G\0([B(O<+PQ\H7+5^RDI):/<#L \PK'!V-,9I,&,1>(G#=K M+GX\4-Z07O@_F^M6LHR?1QC-:5.MT[,,09$7E.G&CR7E._R[81B\"3/+>J=G MR(8J*+IEM9<"1 <@]@(*/:&*V$%'>X0B[PCB-XI3$B)-0>,!9 MK$%6/O5_(LL#V1$[=Y+3U2Q[,]FV!%-5^\22[$K!U-6?:Y)12UA6-D\DJ^K+ M=STHU3K1;6NOL>+=&'Z;V0F/7N+3W1.,G*'@^"B.*]A!&]H$++M)8O^02@!^)2V=GW"K.$VG M >O8R]"#*?+Y^T>5MG AQZ'NN4 R=!>^GCIB44C:WI:5:-(G9YMO!.8.29:$CFG%4R%0DL0^^K/ M(2R2?R$_KKV1EY3,D^IYM3DQND3$::!D+G+2;3!T,I6A_;_\#55H>"(+2&59 M<(#I((]XO'C)D$8[HCRJE>=<9!&0E6;/[+Y2< 4%[HS/LS3;$X' ("P44IP] M 'X(09B4(S)A)/CD=Y>L(B0AF<;/8+SD/3\"@A2!9HK$0C]-Z!.67 _#WQ!V M)^R>#UP.J:O )?D?6.A/!&>(87XC#R1" MOD^LU#!*2!3L/ZE'*)Z$0A_G%\ SIV$PE? B2XW/H5!B\Y2FYTY"OJ:I\2ZM MAD O!4O8P905LB+0DSZQ\ F>1Y@4IV LQ\.0)& 6>>;)$"5OQ_Z"YD=)AIC= MG,_A)Y'"[9.2S;$/!@9\W_\WS(!<3R^%F\@H\N>0HQ)QAA0R2!0G@BT)+IK$ M)Y5SOR_2*(+'9>-,N F%9;JACYS? MGJ(P#=QN#J@!_>]L7_"BX]/.FM-;G=[&\=9VBB2!*J 4M _16M@'M$9A0)9J M?R)@6+8GPA59P9%#-R2_H@1EAQ3>2.SL&>4H]GT*5VJ2GN= IWZFS!^ZC\(G MA*E"&$R65P*G0*%SHN M=,N$#F".!!]F@@7D."!T8.00FP%@&)%59.FG8)L$W:5?Q".05GA+5"A_0.X( MB# 1R:()CX.5AE#M20!7 M3,V OSYXQR\6PS%=>0,4D/*^Q,HF!X_(Q:2TKHLB-Q;(06?/794V MJGY"/[WO'O.8T_'%G.(A]OT"YL(G "^-_&1[<._'57XZ$?X!8^?H68$>$LVM M:D(0;FR\!ACY/(VSA8ARVY![3J.,-^%SJ:*>D174$PLJ?J.!=5!E:>!E-,RV M:3MOZ*IU ,..!]98_$OGZN;;DJVQ<#0BY2-"Y[=LJ_@V3:@:!7TZ3_8@'77= M,.GF#X0U#ZP,>)8T98+9Z=FV(4J6*1KF]%AB,=;>PIYR^';%6)/V(@HO.,)" M.!NA2)Z194]6I(R^5\I8G9YI**)MVJ)F;T 9.D\0 +?83B>O(W-=O<6_66AW M10WW5D1VV:_#7BZH3]D#S#V-,-G8>\8K2^SG[Y9FMZ!^'/IILOJ6C0\@K2[, M7[6+@#GM(C",9N;N$^[V(XQ^ZZ(!C.(4^2]H$A-"[:S5P!)U/!CL++\O&X5+ MVE70W=E36,=Q1*Z"X2!FQB(,(Z+6_K 1&Q^IL(,RN2 :,4CBGS^CI1!9L59: M#)T5*^K/Y2E"[!?HGY9]%K)L%)+_](TH]ZRL.^.C+ZI//@Z]R!7RN1 H9>5^ MWQO]9KJI(N3:L6Z=2'JU4W&KGF3))X9BUO(HXT12WM]%W##:5F_@A/FB"Y3] M=ZATT&B'D6-K".JZQJI!C*W?G]HW!ULF0QVV\P=5<6 MP#(R-66-O#^6:GS[=G5S?G-Q=7XM@!MV>__]G)1[WA<7M]]AJW7B@?#&Z/1(TSQ!/AB=N!&9]J03*XZE&M^^37ZF M!T]94;IU1;?)J:(52K=D2(&VO1WC[#6S(X:/\!9,)7_O.JS.Z=_ +:V>@/ ] MI&?8+K-F=FV>RG19;/4LA+EED:^$K5D)"?-6\8JOA >^$NH;KH0DQ2K"0[B. M'&&^#N/#6A'UMJ^(^N&LB/I!K(CZLA51X$MB.Y9$X)[&E\3C7!*M#9=$FE Y M#'UX19S7#!2@ED:K[4NC=3A+HW402Z/%G<7VKHS /)VOC$>Y,JKR MILXBBFFKI9>#D:>O*CQ]M?FQ5&3< M=Q2@)ZH+ISWWOGJQD]("X]0>.@^0/XD]ZE7,5"C1L5DQ$'+-/8Y3_VV^!M>M M[9%?V>#:E4WNJ':N756N79L?2T7&_944-/(26E6 *DKXP"_^)GK6#^.4-FWH MAVF2]^H1[KWX-ZX\VR.>RI8^*%>>N^*.IN3*4^/*L_FQ5&0<*7H1 6^HXKR+ M0@>[1%=RS=@>V5,.SVD_D&/XFEZG\)OH5($YBGV MP2G%0^&.Q0_BM]-+Y)-K3V:Y8_+=['9J3V#<5SQ -,TG'9/NUSCPPJBD-;F&;(\, M<@W)*G<,B6]9MU)#$L9]AWO KAQ@,"=+Z3U<,[9']KAF9)8[:JX9=:X9FQ]+ M1<;=TF9^5T'6C0L>Q75B>Z2.ZT1FN5-DAQM<)S8_EHJ,NWP=>GV/'T)LD["I M$CNJD M:9I,HKD!8E],#%AV1N]X?%N6A^3#0)=]5W^]L<92M0&1S:'?<" MK3R'%O2J?+B[I&VN;FX?+Q^$^\M?S^^_7MW\*CS^^5*XN/U^=W[SCXUZ^-I[ M:$V]LOWC"XK<[G48_@8J::[BP4;C7H7-/>H%U8:)/ Z]6(BR!IRD+S3R@EAP M0)'"+Z2R$9VEG\\RGLY2%+S \5-W_E,A$VOX+ F%,"42 ?H&/TWHAN_8AW&> M">.0M%HE9YS# ?T1Z&;.N3M]'G> M&),)D8^?(C2"9Y,Z%:/LD%_QH-+M;V^BSSH3'#3V$O*U[X<.FIZY]H)G'"=D M7M-IP+5P+UEB!!<_8S\#=\=F;#P07)4BD/^$6Y))6 MWOFT8/F$IV;T.!,B+_XM>W(:Y'S)MM#C.(19D5>]>,E0<*/T:6Y4Y);9Y+W? MZ0//2(_Q%$881A/!G1Y$AU?':7_D%7\,/)]D>&8#0F.8X#/*#PH1$B?>B#)Y MB",<#C*RS]C:QP$>>&0Z,8W49D_!@P',WID0KA.^%/3/YTS_ %8$+JTF4KPK MS)($,D;Z/NKG"QAICYX$.,IY3DZ!.MZ84J-X??;@,MAF'*6P*CTNGVD!NGDZ M.K!0T0VXLV+@\'C4!Q(E&;"!'!FF /5SWY[1K\E-@Y2814#7XGP__2([R@^4 MC++S_2?"N>_/25E(PSK)D"J&,\6\+GPV7 MT2>!!0)F[/2]G%^"G[!PUH W^!D$$@P&4''P=@_S[*"*:&Y!+ M=<:)\$"04@(I\!(8E(#%]@[^J.ZBB 7%C5% OLW>)]Q%WC-<5DX;NH9_GC+Y MO\/QKG?\?%O(AZRWXO"2FY&IX'2ICPG"@2 M+R#:%?3/G-H7L_4@%UM0"T\P=J"?XT5..H+1TR," 0 E5>1A-&=;]8&,9$I^WM4]K\4U@,4K?"&^\*;FYER5--5X8X!V MB7O0@ 6J@P5*U8YQ]M]_D UIR<];X'^QV,+L@C"SUH M0A<7RP5H5_Q,5%?)JT IZ,9\P8:/01EF%N[L@JD_<4RDO9@MUC].'DXH>2_ M]$'@#Q**CD,?S&A< 8IGGV8>7^8;@&D<@$>)LZ7P,\AXR2S( MJ5[(.OD6II@MLP=(X_/<@"#0)+0ER_T3*/THH)),EO,$_88S\PK669&T8""3Q1 5GJ.0F@$2X@_!>L< M'F>D);&9'+\'2+ ?: M);>LA7,7U@J/ALKHIP/ASREP1O@5A Q 1FH8@F@YQ9N^>&&\,,)B, +-?\Z_ M/8]C,$^*M?@B O^Z^R6,7)@C)< CN' QL=$_D4?D+NVRNXNGYX[N3QGJ,S6: M.W\^>BDT\$QS$D\1'N!F9GQFA Z77GJ X#_/5^LB*"CFWAJM%D1]I?^D7I2[ M.,27B6?>9 ;DD@-_/[,"+L!VS^*-Y($9$PJ96F%-$#\W#((WS+ MZ7.1J2(0G9+H(:R!)-"#' )%0C/B\@S1,\X]QNF&4[:4$A./0)9^.44E$/G7,'2% M[W,/G:T1Q?KPZ_>[J2F5[YB"G1I0CM)MP)ALC>9W9;86?=$8P;(/3\R7(G@3 M^>HKV;]\8T-.5Z*OYS.;+6/Z3?&:[V3S)"M,D^TGKGC&S?>[\WG#[S*-@"# M9_H(0DCA_(EJ^.*>R^^S!= +J"G_OI77OEP7%M-66BNBEZ]C;^K^4$.YB,4D MH5C:_ 4OD6R*/&>[4&2[(\(4SF#P3N- 3W2CBMK2)"_!+[G;2]:5 U1X\P98 ME.V!K#9.GHEO2Z-DN?- S1 2S""QQ6QER'-( @#QS<$-=FG@)]^*/'BZ M?IEF.7AQ;L/'@H/2W'&# ;MXY#FSO?^+V[]=?>W*MOA&P[^@*"-D, #,)M/K M:7R )):@SS]^BQ#)C"#TO(HCA/W/?T8C$D-"9*.+9HN2>+L7(U(U CX"&A+# M2GC!B/J$9!^GV.?+O,08M)Y'DDG I2]/@:30 "MG^2*TO.T!,O!',$#/843R M+84$O=*==C!(<;;W2TSO:=Y)$ ;=J:N9*^'8^PB2!)!"^8KKP$.U#&[Y. MU[_SKP_3]:^XT1L :^!_$0VC]L%4]U48D1X_L42*^$%5"UV3%GK0NNYQF7&5Y3>44K3[.\@.C-#,;\.L0#-!I M&Y?\RCZFN='9DDF47G#=5TB[S8'-IOZ1:5N)HL0$9S>J)D#&YG)/G>[\1?5Q.97Z3EBR2B"?Z#09)GE[D1H(V(3"G MJ8:SM.+,\"$!9VKD)KE+0(=;2M0AA(174D=F?3XFT8*4L'E@"F=[)#0]("#R MZQ>9IL2@'F=)F\0">O;H%LCDW:3$ER&F+'Z3\D>6NA*!Q6+7L?!QR@L<\80< M/$[(,T@4KS^-.F7\J %-\0&"$?.GR%0E M,Z23+M$]W\5>DL!ZPOAQG1\QV3>',3\20Z)E2O1'X!/[.RERLUZ3 @EQ&2X1 M'I"$80>_E37"MR)D"^HTR3="49'O36_,]G#F4SUF;LA#OCUQ/N\YW..GGTID[SXZB\S3?D=@8QN^$AZ[7S8]A%Y+R@0B_@-W.1/SLJSGTWWG\@3KE%_ MFME>4N47=%MA(:'_92%M/XVGGY"WYY^"N"R0+W^;<)WEZL)HJ=-,I,O)WY:I M6"*8I>TSD:AJ1-?#:2]=4.%>9BR].[/B71\8R\G;:P0OPQA1" DQ9T"+>3^!R7 B"M>) M>_+FKC<1SNFM5W/1O<<(4;QL\GR\Q\/CS\)=PE(UY*WG*=$S?D>R@1[>M>/!WC!]<6; MJ[.>VU0RZ>E2%+ M,#U80?-JR6G0N1,5Q;?$"IN2LV!%/R*,^034OPR>Z Y] 0HPE'Z:2WZ,P6BC MH>N0@$<(T*C8F"6!S6@<1IGU!!IT-I 3"LGL]RS!C^;^9C>3N'6>TEML>:,Q M6,E1OF'[]E0?/7.3!38F,P,Z3SDD:VD>L@6?(O2)YS_(@O5@;'ID/0$;G 1@ MVY-UTH8FR RG$?RF.^Q2(J97]QHF^ ?^7;+@2?'95>O?;VA#@(F75 M-L"!-[6SG8Q[0]@6=H5F*6="/!GU0Q\02T[^4/24UO]W'&A$(Q#T-!+U:E&R MB <0#A+!IVX2/<45PXA!;Q2'BE(PJ&(2M4FR\[X&HM-\+!\I+)4%R*(FI?[T M]##F-(W!F>M17SY<-3MA]B:2E^4=_3L-2CF\1/>D 8+EF=9-" F!XNRWF4,T M>^N;D!]- W!RZ2;#!RU$UZP5Q^&+6V:O6_:2G[#1V'S?QC8VT='-C?;' M5/M=3+7?15DQ?4$^/<3^,,0XB1F?S2>JBO1+'OTC[.H M7A[H)NY)D-+=%[B)9JOD^V DZ8&NK3RRSC& MI\4O9[F)>NH%=#;TIK/\8;F^7>)#4*V0?3W3'"=2ICWR2H7YF_.O3^"KSXN? M&]J)(JE+OY).Y*6?KWS4B:0LOV/5DU9_KDE&+6.2E1/)8G)0[]-\PXJ3'R]: MF"_&J\H6UBJ[UCK1I;"](5;-5+QV6;"1O;D_@ [*]WXED:[L8,UI1TJ,\CYX M00MUCA9KI*-0J;30Y$J:M.6J-9/M(^>WIRA, [>;\\=Q,!X,SCY:L;0!CI-S MLLDFLK]RLOGR2E=?6,ZI]2*0<9]M*"%KR?C1^P]B9)4Q.*#_M0F#%WD*(/HX M%M],NC)?#O7^FC280/^U68'1\NK*%RC?N''(+R15XAGY<[59/Z#=&%V^EU- MK6.F2[&G5*.4)"RA%]T]8(E,D]*8V=QFZG2+JA'SA= MHT-K(8V0'__2Z0(YR48%N;+[A-#XE&#O/'#)/Y'VHORS]] MR^Z/2+6T*8MJ7B6/'E%F XC2.SW3ED19EQE!5$W632O6I^)@(\Y6*+%(M&76 MX'E/1)?PX?!$=(W2GS&42&ENQ5852:/3@X&),.=M1?(=T=B%DN<(VE[);X"@ M@?>*W>[O. J7@,?,CJC(RADCX#DF?^-A&$9)EYQ1*Y_YVYD)S@VNW6ISRDYR M4&!VT#.N((I6;:+(C77VL+-&CZ_'SGI#P 9#P!#5[>T MDSSC[3KFCL02C(O MY@^$[N! T5K$T"WN6W25910X&EXQL,G\*,#T[0-K(O-#=>IIO2YH[)((? MQG&6XOO'&C75>?&J;V'T-4S[R2#UBZ'=3T(DV3 &G: LIHZ*S2,-<( MQ;;#E&&8YI)A4GI.M^TRX5 E>FY3RVI*Y;M8^5?YD4ZQE!/K3W[:N$L=][U8 M7*T7@72#DX^Y8)K2Z6FV:)O< SM '*U34C7B2.WT=%N4;9L1'!V3,T936$KK M,G?#6!7(-8H]3U4-GF82>?F:G^("824'7Z[R4ZCG),6W;&5<4*OK&HRN#TJP M!B:'+2JFQ8@-SH&WOY6@4>#IG9XARNJB5=YJWZ\5*P=QV0/25)$GVJ*N;;U$<6>%/=RL6:*VP8T) J^) MEK(84>'.R:XA%NEE?] M06O0 AVOBX:QM:QR-X0].*W1\3N D]WI*8IHVSHC<#JHE/;E@'@,27.\&C0\ M(WL-ZP\L'*:PKMN%V$(L=:G3LPP)3/FZXL6;,:D%1OZQHFW=7L4V:),[/1L< M1T/:.IE\YV@[)M=@(2F85&C;)C&8NP3-+POS:9TW8>!\3&:53D\699GO1AP@ MA"IE!G\<0FH&(941"-6YL:!82U3[VT0Q1N!!T\>N24W.M_G"0IO=@L,6T35: MGK!SNYQ/7>OT5%'6MY9.'LMG#SUK%'P-Z-'!I!<5A96TM6,RV\L1?9+O2TZ; MTW84W&9G51Y7://??=0_+;'S6QA=%LQ<(G-D^U5AQ)CB\-B]NJX(#Q/,;9D? MKFY"(><5TAK; \[0=^>C(#D/W*F*J)ZHH5O 2$DTC:UW MZ[A3P!Z.UF[^UH2/7!9CL+D^O.]F*"2R+\E;AXJX$<\> M@MX+%=6'()4BR."'B9LX$I:@X,DCY3TR8_WC*KV-960-7D:VL8-A!?"R7#]0 M(-,SJ+^&H4MZ^%75(UJGI\NBL;TBX2X&>WA:>V"L?CSIX&FHHFJQ@J>C\C3" MX"FK..ABV@BNU8<*#ELTUZCZKSD#<\$LF8D+$F=T>K;)MP,.$"-KU/=JC%13 MV6176E0D[DKL'PVT3+L R=-L]$KJ5 4D@[BO$01PV*Y1G53GIX3ECZBUU+A ML _+IT7E4V.E\B?'TOY4?$4LO5>"V+!9*T%\4 =]E_>NR@[Z\@.^+/&D]@.^ M%?6Y*8'!;NFBJBV>M2PPTH#68NV8)T?X7A"^T:'BJ@@GV\VBI!JBLJ2J!,=X MW:X.RRO@M8?ZGN\E7MZVF[;L'H8^4#2FYHAY1A-RDPFS#L\&]Y<@H@(.W# E MNT/+,,*(XJ@B'YR0=1#R"*S=HE.K/Y-Y9HW>[2C?!L!Q:NU4/%L<=9PV*AFC M"0\ULAP>VK#-Q5W&QX_5_C%)'1%%$@V=GUP\0 AMV.%B.PB1.B(R*2+(#S?N M'PV%V16^.5;2!C/LZ/=X*QTG*9SIR0?%E+0,%W6+)PL<() J'2?9%DBD4[@H M2_SPX/XQ4>HKZ^+^\:0=RQ+/.VZZ]^V7,(K"%Z!#Y1T!HS 063F!QO'30/_; M5?AY+V_!K*^+.?V^5NZV FI) MG9YB&:(JU]7%IOG$-@ZYG1;8W1IR,D!.(F?PZ^K#Q5">68L]EJ]X@(&?KN % M3CCZV-XV(SL?QRJZ:\]&9AR^H@S^\+D:2P$!UD1;JG"G M$EM%--6Z>O0RM&ZT>%_E9M99J?:==$:\C\.6WH_MI']O@O0HJ%NW:P9.B#A E%7<' MWD6)R1)*#FH#X+VS\P=B>K?3I=[Y ?J2[%4UF2P01]D4#7/1:&K/"6.^V7 8 M,-]\LZ$JS&T2I)1$F@X<,C1^D\W88(%V?B) M68]E@_LWQ@J,6+^8U]DX#S_^EDT0I?JLX2DP_#]R+,LL+#6%+0.GFC_\> M'^_,&G@G+^?=$5CW#P=9!Z1-6&^^V$?+J;5OH\/UGHMGYX_HDNM/-;UX2*FS M?3,][&\C&!:*)EF9'S!+QB@2GFF1TW @_/$]]7J'(ZH3WO4@KVZ^+5.S8?"0 MA,YO=RBZC1X2E&"7%DZU_6K!F/N9#!JIR>=4,XLJPCWY@-A MC*.,O&?"RBEDY-^"E'2H\7F:#,,(V.]NYK;,IJ2]0]_E@ZM VFT'IW=ZN@C4 M+OZ_ =%S/*/I.W=/_*LX3JO/C50#MVQ1,2Q1-1=G1EV'77/F8R,W21US4Y1U M6526C3QG@4B[=I$B&%9-!3_CH=V76!(5+(*0KYV)4#%Y)^Q QL17#H;&_#;M-H"&S XTZ M\^=4DQ6'?D51,1@R(37RA3'R7/!%! >-O03Y++B8/,WI(^7%IBR] XY>!1<9 M/TM"6'$W0Y:RQI>P;AO*UNFO/'&./42MJS96/Z)(-K5HF[JH2JS4KZLS?8YY MM>\XZ2CU29@#.#_P'(\W-]XK SYMI?!C&#[\]E9.[W&"X$WN)8H"4JZCQ.6O M&9,KRZE&Y%0U95&U%SM-+6Q;[@:T'EOKBP[O%%LD5=L$%W/K.!!;#L$A[10_1AC%:301J-NU0!:LXK7!B"9'0 = M0>9E=JZJA7W8^/F3#Q=P)A*:,_N2,KFRC"J=GF& 36TL!N_X.11^W(JIXU8U MP%WM]$R;E/=8W*7D<#^F8U<+IY!WT<64$7\H!TI&[H7^F\>J;#8_PGP>N#6H M'NWPVH-OA:@6^(%<<+8[%%V/X.B'V'5\[Z)#U_3/"6D&6,3V2N'D$8J>O"![ MK[*T=4,YO*R8]8>79:D@.GWB*#?XIH\F*4D+!H,L0Q!GRCU/7(%B=@&^849[]1>M.=SX$7H,#QB$=-SOK0 MXYXG\Z'1$OGR =$X_#B,:2[4:81]1#+7SUX\-QD6@E:Z*\> -+L%]6$$:;+Z MEB;YLHH+L@Z#5-Z$C4L_R?")+'NJZEB2!:ZFX:J:;*K(LG5%0[JIRI9BN\:_ M%')\*[MI&,UV.IYPMQ]A]%L7#6#&I\A_09.88+H,8$!OF0OO$G"17+V?^]'G MWK(YK! 2:P^47E#5%.__1)YPC?K"M3>B %X)RM)PC<9&^V,J:!=30;LH"]K# M5+R(=.85^. "QN?UR0M E80I/,.E(_^C*.!7!X-FAN5-@&6MCR/R>;$G ][% M](2? %-'/VTT0Z*-88I4;\_T!ETD8*H^&L?XM/CES/7BL8\FIUY !TQO.LL? MEBL;(AMOU@@J$MG7,[$AYQ:)Z.1>8/[F_.L3^.KSXN>:?*(JVM*OI!-YZ>M/IS33)J&9,LGVBFS@>UT:!D4V%Q4.\_:DW<8T,_OH[+[(7+EG@1 M^VRJ96\651E&& O?X;IA+%R"OG=G.]""*HD;1%$.D2PW\,FF5*D7@^T@#S'8 MMX5&*1SPD9(U[%&%Y&EL$G5<.]NC(9?*,<0Q5"N&6ITVL-YSIY.^Q\\X2+]>,KQ(8Y@>CBY?'3\EY#F/8PS_?M2!AQA M+"),:AYBI*"\)(F6M9C(V_XB2MB19FI_E;C^PJAC>VP*KO)@-O%?L M=G_'4;@,<#))K+,463GCH#M T%4QQNO79DJG9\FL5 _@P&K,!M^?.E-94V>M M/MNS(6ZRPSW1-AM;;!W=8?R,06-6[X85-4KRJ)%@LB(J1ET=/YDY[/+!73L. MPFTMY.H@U&N.-S.#08ZTG9K%U9%F9(%G>WL7GC6H<777E E='85FW;%IAHZ^ MMS#CZ_)U3 [BL-MXF]_?OON/*M_J(HSI8=+Q?-Y5FSW-%JYME8J>K7$H"4=O M![^&H4M/K>/HV7-P_!#Z&_8[*ZUVI(.](>I+*BKQNGGMQM :?[!&#)'=?%W4 M3(ZA0\/0&D^O/@RI$@EUZ:+*0OU%#J)Z0;3&4ZL117*G9TJBSH(F.K*,HLS$ M=':56<2[+S1B:.:%\8E\YL4NION-R\2/-%;3%H-WF\L>WZQF,-*VQI!\%R,; M[SVKS.T]-'/!+0;ABM M35&I$T9FIZ=;HFDL'L3E,&HWC-;FG]0)(ZO3DRU%5'2NC@X.1VM32.H$DDV MI(JV2)WY 5>G&2)]3Q&R:Z8KC$^<_;^ MFC$79/5\CK,?%%=- BO4%!5YFZT$'F1@$4]KK- =X4D&/%FBOI49P?'$(I[6 MF*,[PI/2Z2FR('*#6V*4[0I0*!JIM;1EX82LBRK1=^BOR @&@$ ,C MR.8YZ?[A^]A)4M(!) K',-96M_)JH9S6:)<2]I(&\K?!5R\NFJ;<#JZ"! 5/ M7M_'I(!.$E?8N-"TVC8N>$""04"M,4QW *CZ=L(XH!@$U!K+= > ,CB@#AI0 M:RS3#R%J ]/4)-G!(M"!$50=P\$[PD=A$(4C(9SVN6ISF/2@3LIN%T"-8?SP MVT)Z39%3W.?+J#K7N$'EVIV>IHFYNL[W& MD7'/%TBH5A-5)1MSBYQZ!T,]!:,Y!UB3P;L:8JHVS4$;1DJ5-'F M!-F=5-U@Z]-(APX$^$)>4$L?/)#TL]O08)YM)(9\5QC2^:,O9MX# ]_5D<*+0*6[ZV+ M0H _5CBJE9V+98VW+F[*O*:P*[N\V1;*!P];&EJGIXJ:MO4"Q0,I#$)IDXJI M[T!I$2TZH,76.%8.$"N;U$6M3^T81.U8^M:92!Q*+$)ID_*IE?0.Z86VI,!$ MJ\.T3!NW]-!5G_HDN8DK).A5:'-4]G@3P3<]=S5+_RZ:>'M!"H2YG9Z[R[S4 M[#KP57%\^9I$" CK!2B:7"5X%(-8];PT@WE/LH &T-N5Y:P#55W"1 XA% *U->-X:08?::XQI MD_<&)P+)9^9AZM\.3SC8;C(< M7(*Q"EAUP[3OX\-4.GB!H>]>R5U:JGDL4!4".N'C,UPRG4STC3?6,);WO M\-<\D"]$=)8-0^[TI!-I,4&WUIJ,[Z&F!;$DCO]Y+Z,6_"L?P_\'![(2_RK% M_^+I8(Y_CO]5'D\-L-,^AOX/#N,=,=0)_F6+XY_C_UW@2;4CS_B@"'QP)"M% MT202H"R>A65: HYA+^3O] _L=A&,"CWAS ^,A33&KN % @S327UZ'(0H?@F'?5Q M=#N@2BF^39,X 6 "@7(%M4FXJJ2]K/V,-M?C"X.N/%Z[T[,M630L4U3MQ3IL MO.K%88J(W9R(V.]%6FH<;5TB8LL@(H8EFH8IFBH7D6,1$;E1T+T7CJEQO#6) M-.DH8!JBK$1$:E1&W@O:U#G@FH1$)^N(+DJ&M+2W'"-"0CW9SPD" MUQC^=;WGWL_PHWCM"$5/7I#MH"I+G2WZB1>X\->I8H+@[ S)](FG7@*O=][' MMD*P_3C$ G*<< 2CF5 ?-4S@?<0CA>%Y,/BG"/G"&$6)$ Z$9(AC#'A"J>L! M) B07)*Y27^C.\>(?#P SS9P/+@1P)%@TA$A/IF=LG]+OWQ$F@Z3*+K:GD:8 M>,W/^.S%*&TN!?P_D2="LC1PG4@. )-36![?I^\ M '1*F,(S7#J#/_ZT>L05P$=_4'4]TQ8TS D3\]$XQJ?%+V>N%X]]-#GU CH\ M>M-93IQ+,TT+%D7^?"8MLGDDWE)8]XYB_.1>D$OOJ\^+FFG*B*OO0K MZ41>^OFJ1RDGNF%7>M+JSS6YVAVKQB3+)Z:F\4%M-"C%J@:$/0WJ?4RMB?%O MF.9?QV7VPF4-![_M=2I0RBRP"&/A.UPWC(5+T&Z@U/$8E#I8V8(JB1M$Q0^1 M+#?PR:9480>#)0=ZTZQ*MMF@2,I&15'7SO9HR*5N*["'2!2.H2TP= QIU%L= M*62DV=[QGGK8RY%"NXXCA3MOQ), /4 M(WJ]"R/RAO,DB;Q^2B/EC^$=BL"%DM<6;9GN^2K2FE-E'ZJ[OOM1R_4W'MC] MH-<<8/I(9XW=#UKM] +/7Y\+L/Z#TS=[DJP5JN'WM^_^H^H&MM#.-B$]WGQ: M[E9 [K_3.*&[SVV.VQRZ ;EI=&:5=E_=Y>\\#B?P@$LT=O!^PM"1?M4 MD33:(U>7%MNE\+;H[<;GII$KHARN9B*2:&RLYQ!#)FN->)0+O3,U51M1:/"G$$'A\"-[7-:T2@3-J'69IH MFHO56#@$CQ""FV[/UHE!TOY+-D1;87HAYJBZKQF2).N#G$N]9GVP66;XQLFNA[C:/(*W'J=DM4E" MYS>N1WN/X=OU9+E=HM@?M4M:=/1Z,Y)EM>WHJA,.Z#\;FRZ'?WI]PV5H%*9! M'8MUDY<=""\X>/<&WE;7:'A;EV+YKM@7Y*/ P0)*A*_8R2OQR*+P;LV3@SG9 MN1F-JE9>G=N_OKKYMF3/RC M.F"\)0R7[5^O.:A(P9?OCF2[(LLVI-5.;S&UF"/J.!&E5$=4Q?P'K=-31-O4 M155:K,S!87MK.59[1Z:FF M:"A\F3U@S*W6=RL<"'V- U%$12D #4P^57\JG57<:#QJU@ VB%D M6-+P6;>/LLH0HS$.8EJ#;YOLRO;9 !^ST'AQ2LX=SITZ0W.SRI_Q8S@[N7J' M///_I%[L)?@!1\^>@S/#^QX[X5- GT)M\*K[<@JI M &XN3;CB:&02C5Q7<.YP[G#N<.YP[C!K!:V)(C)G!>F,64&M+IF^&9[6-J<^ MR%@\WRGAW.'A>8R/;]CB)G6)3EU;;9L#Z* M^C++RU\H^RS+JTJD+*\ERK8IFG)=M2V:+W-44PSU*&"XS+*OHRRO*M=0EI96]E>55]7K*\G+TM1%]RU3>_LKR MJD8-97DY\-@%7B7<;5+%<3NXF9V>:2BPUMK,K[5'D"BT_^J[AQ?[7V$]F*Q5 MWU6M3L\2)6J(T@KX3U0>)R<<.YP[G#N<.Y\[A<:?.@ US5I#)F!5T!/D>O <*#TIS[G#N<.X0\4'N/CW.'J!\C]I@ 55XBU0MBA4H"I[;(&B*YV>;1FB M*DNBJO$6*,<(PV6&_0<:5BRJ8I6W0.&(*A"UT(JB[B+%.ND'($JR+-I&7<<3 M.>P8A%VU_(F%/A0[*\JNZZ0%BJK8HJDLID?RNNR'@+U*T%OH!U [XHQ.3U-$ MTU2YOCMJ:DB;)Y-"U0,I1(2X*/]&\O<'&0G'8)-QF"#6^.LK/ I,5:%8:@V6>/H"YP[G M#N<.YP[G#JLVS,[-X8W[OA@J[_O"^[XP)C&[B%K4TO?%T,C&L&YHHFP=8NN7 MXX)9S8&*3[6M#<,@ZLFJK;<[1Q>3%CWG#N<.YP[G M#N<.YP[3L8IZC!J3+:.&-ZKA5^WEJB,H$L0;U?"X/N<.YPX;\1G62K0;5JL.7]D M893961B/8 >:MZGA$3[.'\#C!HSZ.A!K;UF1S M.U6!^FZ8 BZRNIY'49UU>14&;9]-;4R--+6Q1<6P1-6LN:G-5KQM03260WBI M!U%'0QQ3K[TA#D?C4:)QY\UT3(,VTU%ET5C2RX1#ED.V<@QF?XUX3'KV5S5E M4;47S_]^M#L Q^VAX+82;'?>Q,&&*L=K/0V M+TU #+M730 XL@] M?.0N4[7[:QYD2;4W#^*@/1305L'L F1K1ZKO*";% *H'>CFW*>:CHP?1S&]"S9:81) M-/\9G[UX;C(L&%ZZ*R>+-+L%]8$(:;+ZEA()' S@B.;Z(RGF=,"UX9@V97H7 MR+(.@]3G:5/^.8R*P8S1$^[VP2#XK8L&,/A3Y+^@24PX5N8 D+],T'=IL3CS M9:S:@,L4+#/.4&0"\7PTCO%I\^&R M)=9:OL+MQ5RSWJQRYE)S[;9H\O?P?@N_#:D ET7ARUNSN%44F9V_I\ON&'DN M_<4+!"<[BL^)U#MWG'24@C6(,^*X>. Y7L(ILT"9D&3.T-^<!U#O,7RK8I8O58K]T:6J%._8U%]EFV0W*#5;3X'C(.'Y*$R#.O1WDY<=""\X>/<&7EY8FE_%"TO7GA?\%3MY6K!, MTX*5;8[U'L7NR(J]:'./B;^6TNG9AB)JNEYC3_CFM_!J.@ER%#! I&<<)S!+\CU\ED2>DV WO^*X2O%7M2S4-9;%BB:EF75Q/Z4UO>S\!44N MK0SR+8P&V$O2#U@@MM3IF:H"@EG763"6#AEL5T.D/6A;IM$W.;"]HAWN9D!; M4/&VW.DMHFB3+5G.W(K,73C9O'OF*GME[D&N%KS$-N<.YP[G#N<.YPZSIL4F MU2>V,BW*#LK >\5N]W<V(.A>'7OZY6U&YH+^;F5/7B.%,23)%K4ENZ?MKSN[G9BU!V U^_(KL+6H M;/7:_+NCK2*\+Q=^"WU18KA! O*&N5C_M_VZXB#1Q2N(<^YP[G#N<.YP[C!K MU6P1/:C'JC'9LFJ..I'@'CO8@\$7H818"'!"4@624(A1XL6#B9"@5^'%2X8D MN83F%/1AV+3]12S0TEGYY>3^;A\!) 12$P '\<=;'[8VD,?#K)P[G#N<.YP[ MG#N<.YP['SS?L*Y8=[8K<8<\]UL8/:+7O\_L,_B ?ON%6&(7)4.L\G8%23\7 M%5,15;6&.MX<9$P=8UA3I'C6V2Z^SVS\Q[!6G)4<0KO3TT698^S@,+8FU+ _ MC*F2Q S&CB!#X:'.4$!KHW(\9LJYP[G3_#Y]:9EY#&=E<(GQ?!5<9+5OJ<;J MOUUE[O%_4B_V$OR HV?/P5DH_!X[X5- GT*CXI77(AGL:D,T#)F1"#A'(]<5 MG#N<.YP[G#N<.PQQ9T?.-AM6D,*8%513'@#+?OD-3@12E)]OR?.((N<.YP[G M3KNY4RT:OU#P=D7A*E@EKF@'EVM8*BHOZVJGI]FBK&G-1]HY?KAT<^YP[G#N M'!UWMMRGWLG*J+&S,A[!'O2W,((_ \%)HP@'SD1((GB8S_>A>8R/PZ[@X%=)8O6V%L/,%66R"%L6Y9$7:IAXXACCT'L58+>KMN MJ3(YGF22<_]SNX:;3CIB2+BL;^:GL$24/[[ZO9 MVBV JO:#SEA?3576.SU#E,'4K:&S)H,;3T?8>D155N[+4YQS$S=TWE MLETPU^2=5_B&/N<.YP[G#N<.YTZ;N%/)M%@X(MM49TU5MFKKK,FSCIKIK-G: MPW-[=>WKZ*RIRG:GIY%(6EW)1BR%:+>3L?:@JV9'?L.VFJHBU>;<'>UQVWWY M[QOS5.[T+.L =<%!HH?CT%#"JY:W;/G$T#.NZ9>O-A]HY M@+AX<^YP[G#N'!UWMMRHWLG2:#.T-![!+G3M[2];&T?B43[.'NJ*-]\%Y&: MHJA' <-EIOU"K[@/=+U4U1JZ7G)$'0BB=MX"3M5HUTM5$25]L=\UA]W!P*[2 M1I&YOSYBDLU.CU=$66+&VX'C+FJI2C, M=:6M:^MZJ9J=GB::EBW*6W6]Y.AK(_J6J;R%TM>[6VVM[#2"LDW72PX\=H%7 M"7>;E.?>#FYVIT=\"U5>;&C.VEI;4Z90AA)I2?"1_NT%+@Z2TR[A)D.PV7\W M3 9W!2C7ZH],FJRUP]3(+JZMB=;VH4N^%=4TZ);I]9WW-EI0])J\K+,&!],! M@&E- ;5=@$GA8&H/F'@. V#&&GYJ:FT-/WF^53,- M/QD\+\AB]**6CI^:UNG)EE1'RT]^*K5IE-4SA[.'LX>EFV7+4(2&YLN)DNFRU'G6+#:@[2] MX3\>G>7LX>SA[.'LX>SA[.'LV>;XA\U )U*-%!66-%%2MCD7PC'6.,:6Q:G7 M.'M;-8E<=/OL3D\Q%I/N.8K:C:*]@DB7& '1$:0GU-I*M+W1,Q[SA[.'LX>UMBS&Z>:#4M(8 M*UMU%&UO;(IORH%WJV%MAV[:)VFD^*_MBCKBTL[W[EA#D!< MOCE[.'LX>PZ2/=MM2^]D<=3861R/8$>Z]K:B[0TF\5@?9P]G#VV\=S?'+UP=G#V<.$=M_4RV9;N1O,*/IFUHG4!IXJVS>TJI&Y+8C*<@PO=R(^T'1R4?F>, _?0@%L) MMPNM"&N'JPS^GPG:EFM:#MAZ:G=8QKY:MQH*"5Y8MBK*:@TE.CATCP>ZRY3M M0O_-W1D)*NW[:B[I^,=1>_2HK03:3:KU;X=5K=.S+$FT3;OE)@(-,'^FX7+X MU_6>>S_#CV*X(Q0]>4'V7F4>(@X&DD=SU4P5$U"\,WC0)YZ2DVR>\SY@% *8 MQR$6D$/JE*!@0NJ4!F$"[R-=56!X'@S^*4*^,$81+7>:#'&, 54H=;V$%C@A M<\I*G024WK2PZ< +4.!X<&.

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ⅅ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ʅ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end XML 82 zlab-20240930_htm.xml IDEA: XBRL DOCUMENT 0001704292 2024-01-01 2024-09-30 0001704292 dei:AdrMember 2024-01-01 2024-09-30 0001704292 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001704292 us-gaap:CommonStockMember 2024-11-06 0001704292 dei:AdrMember 2024-11-06 0001704292 2024-09-30 0001704292 2023-12-31 0001704292 2024-07-01 2024-09-30 0001704292 2023-07-01 2023-09-30 0001704292 2023-01-01 2023-09-30 0001704292 us-gaap:CommonStockMember 2023-12-31 0001704292 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001704292 us-gaap:RetainedEarningsMember 2023-12-31 0001704292 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001704292 us-gaap:TreasuryStockCommonMember 2023-12-31 0001704292 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001704292 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001704292 2024-01-01 2024-03-31 0001704292 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001704292 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001704292 us-gaap:CommonStockMember 2024-03-31 0001704292 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001704292 us-gaap:RetainedEarningsMember 2024-03-31 0001704292 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001704292 us-gaap:TreasuryStockCommonMember 2024-03-31 0001704292 2024-03-31 0001704292 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001704292 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001704292 2024-04-01 2024-06-30 0001704292 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001704292 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001704292 us-gaap:CommonStockMember 2024-06-30 0001704292 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001704292 us-gaap:RetainedEarningsMember 2024-06-30 0001704292 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001704292 us-gaap:TreasuryStockCommonMember 2024-06-30 0001704292 2024-06-30 0001704292 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001704292 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001704292 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001704292 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001704292 us-gaap:CommonStockMember 2024-09-30 0001704292 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001704292 us-gaap:RetainedEarningsMember 2024-09-30 0001704292 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001704292 us-gaap:TreasuryStockCommonMember 2024-09-30 0001704292 us-gaap:CommonStockMember 2022-12-31 0001704292 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001704292 us-gaap:RetainedEarningsMember 2022-12-31 0001704292 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001704292 us-gaap:TreasuryStockCommonMember 2022-12-31 0001704292 2022-12-31 0001704292 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001704292 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001704292 2023-01-01 2023-03-31 0001704292 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0001704292 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001704292 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001704292 us-gaap:CommonStockMember 2023-03-31 0001704292 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001704292 us-gaap:RetainedEarningsMember 2023-03-31 0001704292 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001704292 us-gaap:TreasuryStockCommonMember 2023-03-31 0001704292 2023-03-31 0001704292 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001704292 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001704292 2023-04-01 2023-06-30 0001704292 us-gaap:TreasuryStockCommonMember 2023-04-01 2023-06-30 0001704292 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001704292 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001704292 us-gaap:CommonStockMember 2023-06-30 0001704292 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001704292 us-gaap:RetainedEarningsMember 2023-06-30 0001704292 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001704292 us-gaap:TreasuryStockCommonMember 2023-06-30 0001704292 2023-06-30 0001704292 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001704292 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001704292 us-gaap:TreasuryStockCommonMember 2023-07-01 2023-09-30 0001704292 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001704292 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001704292 us-gaap:CommonStockMember 2023-09-30 0001704292 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001704292 us-gaap:RetainedEarningsMember 2023-09-30 0001704292 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001704292 us-gaap:TreasuryStockCommonMember 2023-09-30 0001704292 2023-09-30 0001704292 us-gaap:FairValueInputsLevel1Member 2024-09-30 0001704292 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001704292 currency:USD 2024-09-30 0001704292 currency:USD 2023-12-31 0001704292 currency:CNY 2024-09-30 0001704292 currency:CNY 2023-12-31 0001704292 currency:HKD 2024-09-30 0001704292 currency:HKD 2023-12-31 0001704292 currency:AUD 2024-09-30 0001704292 currency:AUD 2023-12-31 0001704292 currency:TWD 2024-09-30 0001704292 currency:TWD 2023-12-31 0001704292 us-gaap:OfficeEquipmentMember 2024-09-30 0001704292 us-gaap:OfficeEquipmentMember 2023-12-31 0001704292 zlab:ElectronicEquipmentMember 2024-09-30 0001704292 zlab:ElectronicEquipmentMember 2023-12-31 0001704292 us-gaap:VehiclesMember 2024-09-30 0001704292 us-gaap:VehiclesMember 2023-12-31 0001704292 zlab:LaboratoryEquipmentMember 2024-09-30 0001704292 zlab:LaboratoryEquipmentMember 2023-12-31 0001704292 zlab:ManufacturingEquipmentMember 2024-09-30 0001704292 zlab:ManufacturingEquipmentMember 2023-12-31 0001704292 us-gaap:LeaseholdImprovementsMember 2024-09-30 0001704292 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001704292 us-gaap:ConstructionInProgressMember 2024-09-30 0001704292 us-gaap:ConstructionInProgressMember 2023-12-31 0001704292 zlab:CommercialProductsIntangibleAssetMember 2024-09-30 0001704292 zlab:CommercialProductsIntangibleAssetMember 2023-12-31 0001704292 us-gaap:ComputerSoftwareIntangibleAssetMember 2024-09-30 0001704292 us-gaap:ComputerSoftwareIntangibleAssetMember 2023-12-31 0001704292 zlab:RegulatoryMilestoneFeesMember 2024-09-30 0001704292 zlab:CommercialDevelopmentCostMember 2024-09-30 0001704292 srt:MinimumMember us-gaap:ComputerSoftwareIntangibleAssetMember 2024-09-30 0001704292 srt:MaximumMember us-gaap:ComputerSoftwareIntangibleAssetMember 2024-09-30 0001704292 zlab:ZejulaMember 2024-07-01 2024-09-30 0001704292 zlab:ZejulaMember 2023-07-01 2023-09-30 0001704292 zlab:ZejulaMember 2024-01-01 2024-09-30 0001704292 zlab:ZejulaMember 2023-01-01 2023-09-30 0001704292 zlab:OptuneMember 2024-07-01 2024-09-30 0001704292 zlab:OptuneMember 2023-07-01 2023-09-30 0001704292 zlab:OptuneMember 2024-01-01 2024-09-30 0001704292 zlab:OptuneMember 2023-01-01 2023-09-30 0001704292 zlab:QinlockMember 2024-07-01 2024-09-30 0001704292 zlab:QinlockMember 2023-07-01 2023-09-30 0001704292 zlab:QinlockMember 2024-01-01 2024-09-30 0001704292 zlab:QinlockMember 2023-01-01 2023-09-30 0001704292 zlab:NuzyraMember 2024-07-01 2024-09-30 0001704292 zlab:NuzyraMember 2023-07-01 2023-09-30 0001704292 zlab:NuzyraMember 2024-01-01 2024-09-30 0001704292 zlab:NuzyraMember 2023-01-01 2023-09-30 0001704292 zlab:VyvgartMember 2024-07-01 2024-09-30 0001704292 zlab:VyvgartMember 2023-07-01 2023-09-30 0001704292 zlab:VyvgartMember 2024-01-01 2024-09-30 0001704292 zlab:VyvgartMember 2023-01-01 2023-09-30 0001704292 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001704292 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001704292 us-gaap:RestrictedStockMember 2024-01-01 2024-09-30 0001704292 us-gaap:RestrictedStockMember 2023-01-01 2023-09-30 0001704292 zlab:BankOfChinaWorkingCapitalLoanFacilityMember us-gaap:LoansPayableMember 2024-09-30 0001704292 zlab:SPDBankWorkingCapitalLoanFacilityMember us-gaap:LoansPayableMember 2024-09-30 0001704292 zlab:ChinaMerchantBankWorkingCapitalLoanFacilityMember us-gaap:LoansPayableMember 2024-09-30 0001704292 us-gaap:StandbyLettersOfCreditMember zlab:BankOfChinaWorkingCapitalLoanFacilityMember 2024-02-05 0001704292 us-gaap:StandbyLettersOfCreditMember zlab:BankOfChinaWorkingCapitalLoanFacilityMember 2024-02-05 2024-02-05 0001704292 zlab:BankOfChinaWorkingCapitalLoanFacilityMember 2024-03-31 0001704292 us-gaap:StandbyLettersOfCreditMember zlab:BankOfChinaWorkingCapitalLoanFacilityMember 2024-02-06 0001704292 us-gaap:StandbyLettersOfCreditMember zlab:BankOfChinaWorkingCapitalLoanFacilityMember 2024-06-20 0001704292 zlab:BankOfChinaWorkingCapitalLoanFacilityMember us-gaap:LoansPayableMember zlab:ZaiLabShanghaiCo.Ltd.Member 2024-09-30 0001704292 zlab:BankOfChinaWorkingCapitalLoanFacilityMember us-gaap:LoansPayableMember zlab:ZaiLabShanghaiCo.Ltd.Member 2024-01-01 2024-09-30 0001704292 zlab:ShanghaiPudongDevelopmentBankCo.Ltd.Member 2024-02-06 0001704292 zlab:SPDBankWorkingCapitalLoanFacilityMember us-gaap:LoansPayableMember zlab:ZaiLabShanghaiCo.Ltd.Member 2024-09-30 0001704292 zlab:SPDBankWorkingCapitalLoanFacilityMember us-gaap:LoansPayableMember zlab:ZaiLabShanghaiCo.Ltd.Member 2024-01-01 2024-09-30 0001704292 zlab:NingboBankWorkingCapitalLoanFacilityMember us-gaap:LoansPayableMember zlab:ZaiLabSuzhouCompanyLimitedMember 2024-02-06 0001704292 zlab:NingboBankWorkingCapitalLoanFacilityMember us-gaap:LoansPayableMember 2024-02-06 0001704292 zlab:ChinaMerchantsBankCo.Ltd.Member 2024-07-05 0001704292 zlab:ChinaMerchantBankWorkingCapitalLoanFacilityMember us-gaap:LoansPayableMember zlab:ZaiLabShanghaiCo.Ltd.Member 2024-07-05 0001704292 zlab:ChinaMerchantBankWorkingCapitalLoanFacilityMember us-gaap:LoansPayableMember zlab:ZaiLabShanghaiCo.Ltd.Member 2024-07-05 2024-07-05 0001704292 zlab:ChinaMerchantBankWorkingCapitalLoanFacilityMember us-gaap:LoansPayableMember zlab:ZaiLabShanghaiCo.Ltd.Member 2024-09-30 0001704292 zlab:ChinaMerchantBankWorkingCapitalLoanFacilityMember us-gaap:LoansPayableMember zlab:ZaiLabShanghaiCo.Ltd.Member 2024-01-01 2024-09-30 0001704292 us-gaap:RestrictedStockMember 2024-01-01 2024-09-30 0001704292 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001704292 zlab:April2023AndLaterMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001704292 zlab:PriorToApril2023Member us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001704292 zlab:April2023AndLaterMember us-gaap:EmployeeStockOptionMember zlab:ShareBasedPaymentArrangementTrancheFourMember 2024-01-01 2024-09-30 0001704292 zlab:April2023AndLaterMember us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2024-01-01 2024-09-30 0001704292 zlab:April2023AndLaterMember us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-01-01 2024-09-30 0001704292 zlab:April2023AndLaterMember us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-01-01 2024-09-30 0001704292 zlab:PriorToApril2023Member us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-01-01 2024-09-30 0001704292 zlab:PriorToApril2023Member us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2024-01-01 2024-09-30 0001704292 zlab:PriorToApril2023Member us-gaap:EmployeeStockOptionMember zlab:ShareBasedPaymentArrangementTrancheFiveMember 2024-01-01 2024-09-30 0001704292 zlab:PriorToApril2023Member us-gaap:EmployeeStockOptionMember zlab:ShareBasedPaymentArrangementTrancheFourMember 2024-01-01 2024-09-30 0001704292 zlab:PriorToApril2023Member us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-01-01 2024-09-30 0001704292 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-07-01 2024-09-30 0001704292 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-01 2023-09-30 0001704292 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-09-30 0001704292 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-09-30 0001704292 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001704292 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001704292 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0001704292 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001704292 us-gaap:RestrictedStockMember 2024-09-30 0001704292 zlab:InnovivaInc.Member zlab:SULDURMember 2024-04-01 2024-06-30 0001704292 zlab:InnovivaInc.Member zlab:SULDURMember 2024-09-30 0001704292 zlab:BMSMember zlab:RepotrectinibMember 2024-04-01 2024-06-30 0001704292 zlab:BMSMember zlab:RepotrectinibMember 2024-09-30 0001704292 zlab:BMSMember zlab:XanomelineTrospiumChlorideMember 2024-07-01 2024-09-30 0001704292 zlab:BMSMember zlab:XanomelineTrospiumChlorideMember 2024-09-30 0001704292 zlab:OtherCounterpartiesMember 2024-07-01 2024-09-30 0001704292 country:CN 2024-01-01 2024-09-30 0001704292 country:CN 2024-07-01 2024-09-30 0001704292 country:CN 2023-07-01 2023-09-30 0001704292 country:CN 2023-01-01 2023-09-30 0001704292 country:CN 2023-12-31 0001704292 country:CN 2024-09-30 0001704292 zlab:PropertyAndEquipmentAndCommercialManufacturingDevelopmentActivitiesMember 2024-09-30 shares iso4217:USD iso4217:USD shares pure iso4217:CNY 0001704292 --12-31 2024 Q3 false 0 P3Y 10-Q true 2024-09-30 false 001-38205 ZAI LAB LIMITED E9 98-1144595 4560 Jinke Road Bldg. 1, Fourth Floor, Pudong Shanghai CN 201210 86 21 6163 2588 American Depositary Shares, each representing 10 Ordinary Shares, par value $0.000006 per share ZLAB NASDAQ Ordinary Shares, par value $0.000006 per share 9688 Yes Yes Large Accelerated Filer false false false 996087670 762979490 616086000 790151000 100000000 0 0 16300000 14000 17000 49970000 59199000 19278000 6134000 39548000 44827000 35667000 22995000 860549000 939606000 1118000 1113000 3153000 9220000 32000 111000 50765000 53734000 12833000 14844000 3012000 3069000 51669000 13389000 975000 1209000 1240000 0 985346000 1036295000 120652000 112991000 6585000 7104000 112994000 0 46084000 82972000 286315000 203067000 24924000 28738000 6113000 8047000 325000 325000 317677000 240177000 0.000006 0.000006 5000000000 5000000000 989268370 977151270 984356170 972239070 6000 6000 3031628000 2975302000 -2371399000 -2195980000 28270000 37626000 4912200 4912200 20836000 20836000 667669000 796118000 985346000 1036295000 101847000 69228000 289102000 200889000 418000 0 816000 0 102265000 69228000 289918000 200889000 36569000 25479000 105336000 70579000 348000 0 433000 0 65982000 58767000 182252000 183920000 67219000 68552000 216123000 198982000 0 0 0 10000000 -67853000 -83570000 -214226000 -242592000 9029000 9172000 28017000 29493000 745000 0 1350000 0 14457000 4852000 8281000 -26315000 3441000 394000 3859000 223000 -41671000 -69152000 -175419000 -239191000 0 0 0 0 -41671000 -69152000 -175419000 -239191000 -0.04 -0.04 -0.07 -0.07 -0.18 -0.18 -0.25 -0.25 981687390 981687390 968767730 968767730 976941030 976941030 965060570 965060570 -41671000 -69152000 -175419000 -239191000 0 0 0 0 -14503000 -4228000 -9356000 22267000 -56174000 -73380000 -184775000 -216924000 977151270 6000 2975302000 -2195980000 37626000 4912200 -20836000 796118000 1046440 0 0 0 17980000 17980000 -53471000 -53471000 1542000 1542000 978197710 6000 2993282000 -2249451000 39168000 4912200 -20836000 762169000 8087630 0 0 0 25000 0 44000 44000 18638000 18638000 -80277000 -80277000 3605000 3605000 986310340 6000 3011964000 -2329728000 42773000 4912200 -20836000 704179000 393850 0 0 0 2564180 0 2869000 2869000 16795000 16795000 -41671000 -41671000 -14503000 -14503000 989268370 6000 3031628000 -2371399000 28270000 4912200 -20836000 667669000 962455850 6000 2893120000 -1861360000 25685000 2236280 -11856000 1045595000 732040 0 0 0 4009460 0 1673000 1673000 1272330 5130000 5130000 16661000 16661000 -49144000 -49144000 -8413000 -8413000 967197350 6000 2911454000 -1910504000 17272000 3508610 -16986000 1001242000 6117040 0 0 0 41000 0 88000 88000 1280500 3540000 3540000 20511000 20511000 -120895000 -120895000 34908000 34908000 973355390 6000 2932053000 -2031399000 52180000 4789110 -20526000 932314000 394890 0 0 0 180000 0 317000 317000 104020 264000 264000 21992000 21992000 -69152000 -69152000 -4228000 -4228000 973930280 6000 2954362000 -2100551000 47952000 4893130 -20790000 880979000 -175419000 -239191000 -3000 1000 814000 746000 8824000 6570000 -2518000 -2547000 53413000 59164000 -6067000 -1965000 -451000 -139000 0 408000 6104000 6630000 0 10000000 700000 0 8281000 -26315000 -9712000 2823000 12901000 15563000 -4403000 14408000 10767000 -5126000 -234000 -140000 1223000 0 6545000 -9494000 -36854000 227000 -6853000 -5794000 -1548000 9619000 0 325000 -159100000 -183261000 0 134000000 16300000 102400000 3057000 6990000 29000 122000 40711000 658000 0 10000000 0 3893000 -27439000 -25233000 111738000 0 282000 0 700000 0 1321000 1899000 0 8725000 112077000 -6826000 402000 -3355000 -74060000 -218675000 791264000 1009273000 717204000 790598000 2612000 2625000 11358000 98000 0 31000 3945000 3296000 1593000 0 1169000 0 Organization and Principal Activities <div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Zai Lab Limited was incorporated on March 28, 2013 in the Cayman Islands as an exempted company with limited liability under the Companies Act of the Cayman Islands (as amended). Zai Lab Limited and its subsidiaries (collectively referred to as the “Company”) are focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. </span></div>The Company’s principal operations and geographic markets are in Greater China. The Company has a substantial presence in Greater China and the United States. Basis of Presentation and Consolidation and Significant Accounting Policies <div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a) Basis of Presentation</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), and applicable rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”), regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Annual Report”). The December 31, 2023 condensed consolidated balance sheet data included in this report were derived from the audited financial statements in the 2023 Annual Report. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments that are necessary to present fairly the results for the interim periods presented. Interim results are not necessarily indicative of the results for the year ending December 31, 2024.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b) Principles of Consolidation </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The unaudited condensed consolidated financial statements include the accounts of Zai Lab Limited and its subsidiaries, which are wholly owned. All intercompany transactions and balances are eliminated upon consolidation. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c) Use of Estimates </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Areas where management uses subjective judgment include, but are not limited to, accrual of rebates, recognition of research and development expenses, fair value of share-based compensation expenses, and recoverability of deferred tax assets. These estimates, judgments, and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. Actual results could differ from these estimates. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d) Fair Value Measurements </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Equity investments with readily determinable fair value are measured using level 1 inputs and were $3.2 million and $9.2 million as of September 30, 2024 and December 31, 2023, respectively. The unrealized losses from fair value changes are recognized in other income, net in the unaudited condensed consolidated statements of operations. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Financial instruments of the Company primarily include cash and cash equivalents, current restricted cash, short-term investments, accounts receivable, notes receivable, prepayments and other current assets, non-current restricted cash, </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">accounts payable, short-term debt, and other current liabilities. As of September 30, 2024 and December 31, 2023, the carrying values of cash and cash equivalents, current restricted cash, short-term investments, accounts receivable, prepayments and other current assets, accounts payable, short-term debt, and other current liabilities approximated their fair value due to the short-term maturity of these instruments, and the carrying value of notes receivable and non-current restricted cash approximated their fair value based on the assessment of the ability to recover these amounts.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(e) Recent Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures (Topic 280). This ASU requires all public entities, including public entities with a single reportable segment, to disclose the title and position of the Chief Operating Decision Maker (“CODM”) and the significant segment expenses and any additional measures of a segment’s profit or loss used by the CODM to allocate resources and assess performance. This ASU is effective on a retrospective basis for fiscal years beginning after December 15, 2023 and for interim periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this ASU and expects to adopt it for the year ending December 31, 2024.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (Topic 740). This ASU requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as additional information on income taxes paid. This ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted. This ASU will result in additional disclosure in the consolidated financial statements, once adopted. The Company is currently evaluating the impact of this ASU and expects to adopt it for the year ending December 31, 2025.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company did not adopt any new accounting standards in the nine months ended September 30, 2024 that had a material impact on the consolidated financial statements. For additional information on the Company’s significant accounting policies, refer to the notes to the consolidated financial statements in the 2023 Annual Report</span>. Basis of Presentation<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), and applicable rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”), regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Annual Report”). The December 31, 2023 condensed consolidated balance sheet data included in this report were derived from the audited financial statements in the 2023 Annual Report. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments that are necessary to present fairly the results for the interim periods presented. Interim results are not necessarily indicative of the results for the year ending December 31, 2024.</span></div> Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of Zai Lab Limited and its subsidiaries, which are wholly owned. All intercompany transactions and balances are eliminated upon consolidation. Use of Estimates The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Areas where management uses subjective judgment include, but are not limited to, accrual of rebates, recognition of research and development expenses, fair value of share-based compensation expenses, and recoverability of deferred tax assets. These estimates, judgments, and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. Actual results could differ from these estimates. Fair Value Measurements <div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Equity investments with readily determinable fair value are measured using level 1 inputs and were $3.2 million and $9.2 million as of September 30, 2024 and December 31, 2023, respectively. The unrealized losses from fair value changes are recognized in other income, net in the unaudited condensed consolidated statements of operations. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Financial instruments of the Company primarily include cash and cash equivalents, current restricted cash, short-term investments, accounts receivable, notes receivable, prepayments and other current assets, non-current restricted cash, </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">accounts payable, short-term debt, and other current liabilities. As of September 30, 2024 and December 31, 2023, the carrying values of cash and cash equivalents, current restricted cash, short-term investments, accounts receivable, prepayments and other current assets, accounts payable, short-term debt, and other current liabilities approximated their fair value due to the short-term maturity of these instruments, and the carrying value of notes receivable and non-current restricted cash approximated their fair value based on the assessment of the ability to recover these amounts.</span></div> 3200000 9200000 Recent Accounting Pronouncements<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures (Topic 280). This ASU requires all public entities, including public entities with a single reportable segment, to disclose the title and position of the Chief Operating Decision Maker (“CODM”) and the significant segment expenses and any additional measures of a segment’s profit or loss used by the CODM to allocate resources and assess performance. This ASU is effective on a retrospective basis for fiscal years beginning after December 15, 2023 and for interim periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this ASU and expects to adopt it for the year ending December 31, 2024.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (Topic 740). This ASU requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as additional information on income taxes paid. This ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted. This ASU will result in additional disclosure in the consolidated financial statements, once adopted. The Company is currently evaluating the impact of this ASU and expects to adopt it for the year ending December 31, 2025.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company did not adopt any new accounting standards in the nine months ended September 30, 2024 that had a material impact on the consolidated financial statements. For additional information on the Company’s significant accounting policies, refer to the notes to the consolidated financial statements in the 2023 Annual Report</span>. Cash and Cash Equivalents <div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s cash and cash equivalents ($ in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:63.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.201%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614,937 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789,051 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents (i)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,149 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616,086 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790,151 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominated in:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575,116 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762,436 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renminbi (“RMB”) (ii)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,093 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hong Kong dollar (“HK$”)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian dollar (“A$”)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">580 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taiwan dollar (“TW$”)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616,086 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790,151 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17.57pt">Cash equivalents represent short-term and highly liquid investments in a money market fund. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</span>Certain cash and bank balances denominated in RMB were deposited with banks in mainland China. The conversion of these RMB-denominated balances into foreign currencies is subject to the rules and regulations of foreign exchange control promulgated by the Chinese government. <div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s cash and cash equivalents ($ in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:63.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.201%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614,937 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789,051 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents (i)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,149 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616,086 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790,151 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominated in:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575,116 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762,436 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renminbi (“RMB”) (ii)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,093 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hong Kong dollar (“HK$”)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian dollar (“A$”)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">580 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taiwan dollar (“TW$”)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616,086 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790,151 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17.57pt">Cash equivalents represent short-term and highly liquid investments in a money market fund. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</span>Certain cash and bank balances denominated in RMB were deposited with banks in mainland China. The conversion of these RMB-denominated balances into foreign currencies is subject to the rules and regulations of foreign exchange control promulgated by the Chinese government. 614937000 789051000 1149000 1100000 616086000 790151000 575116000 762436000 40092000 25093000 53000 1974000 580000 587000 245000 61000 616086000 790151000 Inventories, Net <div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s inventories, net ($ in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:65.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.290%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,460 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,702 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,397 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,655 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,470 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,548 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,827 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The Company writes down inventory for any excess or obsolete inventories or when the Company believes that the net realizable value of inventories is less than the carrying value. The Company recorded write-downs in inventory, which were included in cost of product revenue, of an insignificant amount and $0.8 million in the three and nine months ended September 30, 2024, respectively, and $0.1 million and $0.7 million in the three and nine months ended September 30, 2023, respectively. <div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s inventories, net ($ in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:65.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.290%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,460 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,702 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,397 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,655 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,470 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,548 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,827 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 22460000 22702000 15397000 17655000 1691000 4470000 39548000 44827000 800000 100000 700000 Property and Equipment, Net <div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of the Company’s property and equipment, net ($ in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,059 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,047 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Electronic equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,527 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,161 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vehicle</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">201 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">199 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,793 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,140 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Manufacturing equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,944 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,680 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,544 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,371 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26,050 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24,272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">87,118 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">83,870 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(36,353)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(30,136)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Property and equipment, net</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">50,765 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">53,734 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>Depreciation expense was $2.1 million and $6.6 million in the three and nine months ended September 30, 2024, respectively, and $1.8 million and $6.1 million in the three and nine months ended September 30, 2023, respectively. <div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of the Company’s property and equipment, net ($ in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,059 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,047 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Electronic equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,527 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,161 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vehicle</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">201 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">199 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,793 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,140 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Manufacturing equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,944 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,680 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,544 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,371 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26,050 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24,272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">87,118 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">83,870 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(36,353)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(30,136)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Property and equipment, net</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">50,765 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">53,734 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1059000 1047000 9527000 9161000 201000 199000 20793000 20140000 17944000 17680000 11544000 11371000 26050000 24272000 87118000 83870000 36353000 30136000 50765000 53734000 2100000 6600000 1800000 6100000 Intangible Assets, Net <div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of the Company’s intangible assets, net ($ in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.415%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.417%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial products (i)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,050 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,881)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,169 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,351 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,165 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,215 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,715)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,340 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56,265</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,596)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51,669</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,691</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,302)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,389</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) The increase in the net carrying value is primarily driven by $33.0 million of regulatory milestone fees for repotrectinib and SUL-DUR (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and $6.0 million of commercial development costs. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Intangible assets for commercial products include capitalized post-approval milestone fees and commercial manufacturing development costs. The Company is amortizing commercial products as cost of product revenue over the estimated remaining useful life of the related products. Externally purchased software is amortized over <span style="-sec-ix-hidden:f-554">three</span> to five years on a straight-line basis. </span></div>Amortization expense was $0.7 million and $2.3 million in the three and nine months ended September 30, 2024, respectively, and $0.2 million and $0.5 million in the three and nine months ended September 30, 2023, respectively. <div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of the Company’s intangible assets, net ($ in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.415%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.417%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial products (i)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,050 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,881)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,169 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,351 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,165 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,215 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,715)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,340 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56,265</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,596)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51,669</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,691</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,302)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,389</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) The increase in the net carrying value is primarily driven by $33.0 million of regulatory milestone fees for repotrectinib and SUL-DUR (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13</span>) and $6.0 million of commercial development costs. 52050000 1881000 50169000 11351000 186000 11165000 4215000 2715000 1500000 4340000 2116000 2224000 56265000 4596000 51669000 15691000 2302000 13389000 33000000 6000000 P5Y 700000 2300000 200000 500000 Revenues <div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenue, Net </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company’s product revenue is derived from the sales of its commercial products primarily in mainland China. The table below presents the Company’s gross and net product revenue ($ in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.326%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Product revenue - gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">107,678 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">74,018 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">307,401 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">220,240 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Rebates and sales returns</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(5,831)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(4,790)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(18,299)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(19,351)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Product revenue - net</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101,847 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">69,228 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">289,102 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">200,889 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Sales rebates are offered to distributors in mainland China, and the amounts are recorded as a reduction of product revenue. Estimated rebates are determined based on contracted rates, sales volumes, and level of distributor inventories. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s net revenue by product ($ in thousands): </span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:27.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ZEJULA</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">48,227 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41,593 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">138,727 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">127,230 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">OPTUNE</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,562 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32,779 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,596 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">QINLOCK</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,643 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,702 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21,774 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,535 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">NUZYRA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,483 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32,205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,588 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">VYVGART </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">27,265 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,888 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">63,617 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,940 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Product revenue - net</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101,847 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">69,228 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">289,102 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">200,889 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Collaboration revenue was $0.4 million and $0.8 million in the three and nine months ended September 30, 2024, respectively, and related to promotional activities in mainland China. We had no such collaboration revenue in the prior year periods.</span></div> The table below presents the Company’s gross and net product revenue ($ in thousands):<div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.326%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Product revenue - gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">107,678 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">74,018 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">307,401 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">220,240 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Rebates and sales returns</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(5,831)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(4,790)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(18,299)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(19,351)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Product revenue - net</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101,847 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">69,228 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">289,102 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">200,889 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 107678000 74018000 307401000 220240000 5831000 4790000 18299000 19351000 101847000 69228000 289102000 200889000 <div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s net revenue by product ($ in thousands): </span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:27.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ZEJULA</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">48,227 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41,593 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">138,727 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">127,230 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">OPTUNE</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,562 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32,779 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,596 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">QINLOCK</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,643 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,702 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21,774 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,535 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">NUZYRA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,483 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32,205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,588 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">VYVGART </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">27,265 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,888 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">63,617 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,940 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Product revenue - net</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101,847 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">69,228 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">289,102 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">200,889 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 48227000 41593000 138727000 127230000 7715000 11562000 32779000 38596000 8643000 5702000 21774000 14535000 9997000 5483000 32205000 15588000 27265000 4888000 63617000 4940000 101847000 69228000 289102000 200889000 400000 800000 0 0 Income Tax <div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No provision for income taxes has been required to be accrued because the Company is in a cumulative loss position for the periods presented. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company recorded a full valuation allowance against deferred tax assets of all its consolidated entities because all entities were in a cumulative loss position as of September 30, 2024 and December 31, 2023. No unrecognized tax benefits and related interest and penalties were recorded in the periods presented.</span></div> 0 0 0 0 0 0 0 0 0 0 Loss Per Share <div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The following table presents the computation of the basic and diluted net loss per share ($ in thousands, except share and per share data):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.751%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(41,671)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(69,152)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(175,419)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(239,191)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average number of ordinary shares - basic and diluted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">981,687,390 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">968,767,730 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">976,941,030 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">965,060,570 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss per share - basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.04)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.07)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.18)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.25)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As a result of the Company’s net loss in the three and nine months ended September 30, 2024 and 2023, share options and non-vested restricted shares outstanding in the respective periods were excluded from the calculation of diluted loss per share as their inclusion would have been anti-dilutive.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Share options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">105,188,950 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">107,249,960 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non-vested restricted shares</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32,875,090 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32,359,260 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The following table presents the computation of the basic and diluted net loss per share ($ in thousands, except share and per share data):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.751%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(41,671)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(69,152)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(175,419)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(239,191)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average number of ordinary shares - basic and diluted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">981,687,390 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">968,767,730 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">976,941,030 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">965,060,570 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss per share - basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.04)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.07)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.18)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.25)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -41671000 -69152000 -175419000 -239191000 981687390 981687390 968767730 968767730 976941030 976941030 965060570 965060570 -0.04 -0.04 -0.07 -0.07 -0.18 -0.18 -0.25 -0.25 <div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As a result of the Company’s net loss in the three and nine months ended September 30, 2024 and 2023, share options and non-vested restricted shares outstanding in the respective periods were excluded from the calculation of diluted loss per share as their inclusion would have been anti-dilutive.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Share options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">105,188,950 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">107,249,960 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non-vested restricted shares</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32,875,090 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32,359,260 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 105188950 107249960 32875090 32359260 Borrowings<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company has debt arrangements with the Bank of China, SPD Bank, CMB, and Ningbo Bank to support its working capital needs in mainland China. The following table presents the Company’s short-term debt as of September 30, 2024 ($ in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Weighted average <br/>interest rate per annum</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Bank of China Working Capital Loans</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.86 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">70,925 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">SPD Bank Working Capital Loans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">China Merchant Bank Working Capital Loans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">27,798 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Total short-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.01 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">112,994 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Bank of China Working Capital Loan Facility</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">On February 5, 2024, the Company entered into an uncommitted facility letter with the Bank of China (Hong Kong) Limited (the “BOC HK”) pursuant to which the BOC HK will provide standby letters of credit for loans of up to $100.0 million for a term of one year. In connection with this agreement, the Company paid a one-time, non-refundable fee of $0.7 million in the first quarter of 2024. In accordance with this agreement, the Company also maintained restricted deposits of $100.0 million, which are presented as restricted cash-current on the unaudited condensed consolidated balance sheet, to secure the standby letters of credit. On February 6, 2024 and June 20, 2024, upon the Company’s application, the BOC HK provided standby letters of credit in favor of the Bank of China Pudong Development Zone Branch (the “BOC Pudong Branch”) for $50.0 million and $23.0 million, respectively, which are or may become payable by the Company’s wholly-owned subsidiary, Zai Lab (Shanghai) Co., Ltd. (“Zai Lab Shanghai”). Zai Lab Shanghai entered into working capital loans with the BOC Pudong Branch under this facility in the first half of 2024, and the aggregate principal amount outstanding was RMB497.0 million (approximately $70.9 million) as of September 30, 2024. Each working capital loan has a one-year term and is subject to a floating interest rate, which is subject to adjustment every six months.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">SPD Bank Working Capital Loan Facility</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">On February 6, 2024, the Company entered into a maximum-amount guarantee contract with the Shanghai Pudong Development Bank Co., Ltd. Zhangjiang Hi-Tech Park Sub-branch (the “SPD Bank”) pursuant to which the Company will guarantee working capital loans of up to RMB300.0 million (approximately $42.0 million) from SPD Bank to Zai Lab Shanghai over a three-year period. Zai Lab Shanghai entered into working capital loan contracts with SPD Bank under this debt facility in the first quarter of 2024, and the aggregate principal amount outstanding was RMB100.0 million (approximately $14.3 million) as of September 30, 2024. Each working capital loan has a one-year term and is subject to a fixed interest rate.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Ningbo Bank Working Capital Loan Facility</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">On February 6, 2024, the Company’s wholly-owned subsidiary, Zai Lab (Suzhou) Co., Ltd. (“Zai Lab Suzhou”), entered into a maximum credit contract with Bank of Ningbo Co., Ltd. Suzhou Sub-branch (“Ningbo Bank”) as well as an Electronic Commercial Draft Discounting Master Agreement and Online Working Capital Loan Master Agreement (collectively, the “Ningbo Bank Agreements”). The Ningbo Bank Agreements permit Zai Lab Suzhou to utilize, including through discounting or working capital loan agreements and subject to the terms and conditions in related master agreements, up to RMB230.3 million (approximately $32.4 million), of which the Company is authorized to utilize up to RMB160.0 million (approximately $22.5 million). In connection with the arrangements described in the Ningbo Bank Agreements, Zai Lab Suzhou agreed to pledge interests in certain real property it owns in Suzhou. As of September 30, 2024, Zai Lab Suzhou has not entered into any discounting arrangements or working capital loans under this Ningbo Bank working capital loan facility.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">China Merchants Bank Working Capital Loan Facility</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">On July 5, 2024, the Company issued a maximum-amount irrevocable letter of guarantee to China Merchants Bank Co., Ltd., Shanghai Branch (“CMB”) pursuant to which the Company will guarantee working capital loans of up to RMB250.0 million (approximately $34.4 million) from CMB to the Company’s wholly-owned subsidiary, Zai Lab Shanghai, and Zai Lab Shanghai entered into a Credit Agreement with CMB with respect to the RMB250.0 million facility. The credit facility will be available for one year. As of September 30, 2024, Zai Lab Shanghai has an aggregate principal amount outstanding of RMB194.8 million (approximately $27.8 million) under this debt facility. Each working capital loan has a one-year term and is subject to a floating interest rate, which is subject to adjustment every three months.</span></div> The following table presents the Company’s short-term debt as of September 30, 2024 ($ in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Weighted average <br/>interest rate per annum</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Bank of China Working Capital Loans</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.86 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">70,925 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">SPD Bank Working Capital Loans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">China Merchant Bank Working Capital Loans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">27,798 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Total short-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.01 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">112,994 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 0.0286 70925000 0.0345 14271000 0.0315 27798000 0.0301 112994000 100000000 P1Y 700000 100000000 50000000 23000000 497000000 70900000 P1Y P6M 300000000 42000000 P3Y 100000000 14300000 P1Y 230300000 32400000 160000000 22500000 250000000 34400000 250000000 P1Y 194800000 27800000 P1Y P3M Other Current Liabilities <div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s other current liabilities ($ in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued payroll</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24,077 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">33,711 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued professional service fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,986 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,520 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Payables for purchase of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,612 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,474 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued rebate to distributors</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16,926 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tax payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,756 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16,988 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other (i)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,853 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,353 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">46,084 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">82,972 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17.57pt">Other primarily includes accrued travel and business-related expenses.</span></div> <div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s other current liabilities ($ in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued payroll</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24,077 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">33,711 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued professional service fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,986 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,520 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Payables for purchase of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,612 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,474 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued rebate to distributors</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16,926 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tax payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,756 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16,988 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other (i)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,853 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,353 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">46,084 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">82,972 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17.57pt">Other primarily includes accrued travel and business-related expenses.</span></div> 24077000 33711000 3986000 7520000 2612000 2474000 8800000 16926000 3756000 16988000 2853000 5353000 46084000 82972000 Share-Based Compensation<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">During the nine months ended September 30, 2024, the Company granted share options to purchase up to 20,747,480 ordinary shares and restricted shares representing 17,293,410 ordinary shares under its equity incentive plans. The share options granted have a contractual term of ten years. Share options granted since April 2023 generally vest ratably over a four-year period, and share options granted prior to April 2023 generally vest ratably over a five-year period, with 25% or 20% of the awards vesting on each anniversary of the grant date, respectively, subject to continued employment/service with the Company on the vesting date. The restricted shares granted generally vest ratably over a specified period on the anniversary of the grant date, subject to continued employment/service with the Company on the vesting date. For a description of the Company’s equity incentive plans and more details on the terms of the share-based awards, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Note 15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> of the 2023 Annual Report</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The following table presents the share-based compensation expense that has been reported in the Company’s unaudited condensed consolidated statements of operations and comprehensive loss as follows ($ in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.751%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,404 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,041 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,861 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,880 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,391 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,951 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,552 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,795 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,992 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,413 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,164 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>As of September 30, 2024, there was unrecognized share-based compensation expense related to unvested share options and unvested restricted shares of $80.4 million and $83.3 million, respectively, which the Company expects to recognize over a weighted-average period of 2.83 years and 2.68 years, respectively. 20747480 17293410 P10Y P4Y P5Y 0.25 0.25 0.25 0.25 0.20 0.20 0.20 0.20 0.20 <div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The following table presents the share-based compensation expense that has been reported in the Company’s unaudited condensed consolidated statements of operations and comprehensive loss as follows ($ in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.751%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,404 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,041 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,861 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,880 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,391 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,951 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,552 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,795 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,992 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,413 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,164 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 10404000 14041000 31861000 35880000 6391000 7951000 21552000 23284000 16795000 21992000 53413000 59164000 80400000 83300000 P2Y9M29D P2Y8M4D License and Collaboration Agreements<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company has entered into various license and collaboration agreements with third parties to develop and commercialize product candidates. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Significant License and Collaboration Arrangements</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">For a description of the material terms of the Company’s significant license and collaboration agreements, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Note 16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> of the 2023 Annual Report. During the nine months ended September 30, 2024, the Company did not enter into any new significant license or collaboration agreements. The following includes a description of milestone fees incurred in the nine months ended September 30, 2024 under the Company’s significant license and collaboration agreements. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">License and Collaboration Agreement with Innoviva (SUL-DUR)</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Under the terms of the Company’s license and collaboration agreement with Entasis Therapeutics Holdings Inc., a wholly owned subsidiary of Innoviva, Inc. (“Innoviva”), the Company recorded an $8.0 million regulatory milestone in the second quarter of 2024, which was capitalized as an intangible asset. As of September 30, 2024, the Company may be required to pay an additional aggregate amount of up to $80.6 million in development, regulatory, and sales-based milestones as well as certain royalties at tiered percentage rates ranging from high single digits to low-teens on annual net sales of the licensed products in the licensed territory. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">License Agreement with BMS (Repotrectinib)</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Under the terms of the Company’s license agreement with Turning Point Therapeutics, Inc., a company later acquired by Bristol Myers Squibb (“BMS”), the Company recorded $25.0 million for regulatory milestones in the second </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">quarter of 2024, which was capitalized as an intangible asset. As of September 30, 2024, the Company may be required to pay an additional aggregate amount of up to $116.0 million in development, regulatory, and sales-based milestones as well as certain royalties at tiered percentage rates ranging from mid- to high-teens on annual net sales of the licensed products in the licensed territory. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">License Agreement with BMS (Xanomeline and Trospium Chloride)</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Under the terms of the Company’s license agreement with Karuna Therapeutics, Inc. (a company later acquired by BMS), the Company recorded a $10.0 million development milestone into research and development expenses in the third quarter of 2024. As of September 30, 2024, the Company may be required to pay an additional aggregate amount of up to $132.0 million in development, regulatory, and sales-based milestones as well as certain royalties at tiered percentage rates ranging from low- to high-teens on annual net sales of the licensed products in Greater China.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other License and Collaboration Arrangements That Are Not Individually Significant</span></div>The Company recorded an upfront payment of $12.0 million into research and development expenses in the third quarter of 2024 for a license and collaboration agreement that is not individually significant. 8000000.0 80600000 25000000.0 116000000.0 10000000.0 132000000.0 12000000.0 Other Income, Net <div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s other income, net ($ in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.751%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government grants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,861 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on equity investments with readily determinable fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(920)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(661)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,067)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,965)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Others miscellaneous gain</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,740 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,441 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,859 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s other income, net ($ in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.751%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government grants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,861 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on equity investments with readily determinable fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(920)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(661)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,067)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,965)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Others miscellaneous gain</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,740 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,441 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,859 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 3861000 671000 7186000 754000 -920000 -661000 -6067000 -1965000 500000 384000 2740000 1434000 3441000 394000 3859000 223000 Restricted Net Assets <div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company’s ability to pay dividends may depend on the Company receiving distributions of funds from its Chinese subsidiaries. Relevant Chinese laws and regulations permit payments of dividends by the Company’s Chinese subsidiaries only out of its retained earnings, if any, as determined in accordance with Chinese accounting standards and regulations. The results of operations reflected in the unaudited condensed consolidated financial statements prepared in accordance with U.S. GAAP differ from those reflected in the statutory financial statements of the Company’s Chinese subsidiaries. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In accordance with the Company Law of the People’s Republic of China, a domestic enterprise is required to provide statutory reserves of at least 10% of its annual after-tax profit until such reserve has reached 50% of its respective registered capital based on the enterprise’s Chinese statutory accounts. A domestic enterprise may provide discretionary surplus reserve, at the discretion of the Board of Directors, from the profits determined in accordance with the enterprise’s Chinese statutory accounts. The aforementioned reserves can only be used for specific purposes and are not distributable as cash dividends. The Company’s Chinese subsidiaries were established as domestic enterprises and therefore are subject to the above-mentioned restrictions on distributable profits. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">No appropriation to statutory reserves was made in the three and nine months ended September 30, 2024 and 2023 because the Chinese subsidiaries had substantial losses during such periods. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As a result of these Chinese laws and regulations, subject to the limits discussed above that require annual appropriations of 10% of after-tax profit to be set aside, prior to payment of dividends, as a general reserve fund, the Company’s Chinese subsidiaries are restricted in their ability to transfer out a portion of their net assets. </span></div>Foreign exchange and other regulation in mainland China may further restrict the Company’s subsidiaries in mainland China from transferring out funds in the form of dividends, loans, and advances. As of September 30, 2024 and December 31, 2023, amounts restricted included the paid-in capital of the Company’s subsidiaries in mainland China and were $506.0 million. 0 0 0 0 506000000.0 506000000.0 Commitments and Contingencies <div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a) Purchase Commitments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As of September 30, 2024, the Company’s commitments related to purchase of property and equipment and the commercial manufacturing development activities that are contracted but not yet reflected in the unaudited condensed consolidated financial statements were $8.6 million and were expected to be incurred within one year.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b) Legal Proceedings</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company is not currently a party to any material legal proceedings. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c) Indemnifications</span></div>In the normal course of business, the Company enters into agreements that indemnify others for certain liabilities that may arise in connection with a transaction or certain events and activities. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. 8600000 false false false false